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CHAPTER I 
 
INTRODUCTION 
 
Overview of Monoamine Systems 
Catecholamine synthesis and discovery 
As the brain‘s endogenous chemical messengers, neurotransmitters provide the 
foundation for the sophisticated system of communication in the nervous system that 
enables us not only to eat and breathe, but also to feel and think.  The first 
neurotransmitter discovered was acetylcholine in 1921 by the German Otto Loewi 
(Bennett 2000).  Since this original discovery, the list of neurotransmitters has expanded 
tremendously and subsequent studies designed to understand the intricacies of their 
function in the brain grow exponentially by the day.  Neurotransmitters that contain a 
single amino group connected by a two carbon chain to an aromatic ring are classified as 
monoamine neurotransmitters.  Of particular interest here are those monoamines that 
contain a catechol group, the catecholamines such as norepinephrine (NE), also known as 
noradrenaline, and dopamine (DA).  NE and DA are generated from the same synthetic 
pathway in the brain, NE by a three step process and DA by a simple two step process 
(Figure 1).  This pathway begins with tyrosine which is converted in the initial rate 
limiting step by the enzyme tyrosine hydroxylase (TH) into 3,4-dihydroxyphenylalanine.  
3,4-dihydroxyphenylalanine is then utilized to generate DA by aromatic amino acid 
decarboxylase (AADC), which is then accumulated within the vesicle and ready for 
synaptic signaling in dopaminergic neurons or, in noradrenergic neurons, where DA β 
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Figure 1. Noradrenergic synapse. In the presynaptic terminal of a noradrenergic neuron, 
conversion of tyrosine into Dopa via tyrosine hydroxylase, the rate limiting enzyme in 
catecholamine synthesis, initiates the production of NE.  Following Dopa production, 
aromatic-L-amino acid decarboxylase is responsible for the production of DA which is 
then loaded via the vesicular monoamine transporter type 2 (VMAT2) into vesicles.  At 
this point, in dopaminergic neurons, vesicles are ready for neurotransmitter release.  In 
the noradrenergic neuron, however, once inside the vesicle, DA is converted by 
dopamine β hydroxylase into NE for subsequent release.  Importantly, after the arrival of 
an action potential and corresponding calcium influx, fusion of the NE-loaded vesicles 
allows for NE to fill the synaptic space.  In the synapse, the NE transporter is absolutely 
critical for clearing synaptic NE and thereby determining the duration and intensity of 
noradrenergic signaling.  Following reuptake through the transporter, NE is then either 
reloaded into synaptic vesicles or is broken down by monoamine oxidase within the 
mitochondria.  Adapted from Dr. Randy Blakely at Vanderbilt University.  
 
 
 
hydroxylase (DBH) is responsible for the conversion of this DA into NE.   
Today, while the importance of these two monoamine neurotransmitters as 
chemical messengers within the brain is widely accepted, years of research provided the 
foundation for this easily accepted notion.  Indeed it was not until almost 30 years after 
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the initial discovery of the first neurotransmitter that the Swedish scientist Ulf Svante von 
Euler revealed NE as the neurotransmitter utilized by neurons in the sympathetic nervous 
system (Ordway et al. 2007).  Soon to follow, Peter Wilhelm Joseph Holtz expanded the 
role of NE from the peripheral nervous system (PNS) to the central nervous system 
(CNS) by his discovery of its presence within the brain.  Unlike NE, the discovery of DA 
in the brain predates its recognition as a neurotransmitter by some time.  As an 
intermediary in the synthesis of NE, initially researchers believed DA was simply this 
and not a neurotransmitter in its own right.  It was not until 1958 that seminal work, by 
Avid Carlsson and colleagues, recognized that DA itself was a vital neurotransmitter for 
movement (Carlsson et al. 1958).  Since these initial discoveries years of research have 
been dedicated to understanding the role these monoamines play in the brain and 
ultimately behavior.  In this thesis, through my studies and discussion of the NE 
transporter (NET) trafficking and function, I hope to provide new insights about the role 
and regulation of these monoamine neurotransmitters in the brain.  As represented 
schematically in Figure 1, NET is a protein critical for clearing NE and sometimes DA 
from the synapse, and thus NET is essential for controlling both the duration and 
intensity of noradrenergic and at times dopaminergic signaling in the brain.  Given this 
significant contribution to monoamine homeostasis, discussion and study of the 
transporter will afford not only perspective of how aberrant regulation of monoamine 
neurotransmitters may ultimately contribute to mental health disorders but also promises 
to reveal novel therapeutics for treating such disorders.   
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Monoamine function 
Groundbreaking research over the last several decades has illuminated 
fundamental insight into the precise role NE and DA play in brain function.  In particular, 
the development of sophisticated transgenic mouse models has afforded us the unique 
opportunity to study the physiological and behavioral consequences of preventing 
catecholamine production in vivo.  In the 1990‘s Richard Palmiter and colleagues 
generated a series of knockout (KO) mice targeting key enzymes in the catecholamine 
synthetic pathway such as TH and DBH (Thomas et al. 1995; Zhou et al. 1995; Zhou et 
al. 1995).  KO of TH, which catalyzes the initial rate limiting step in the synthesis of both 
DA and NE, enabled researchers to examine in vivo the physiological effects of 
abolishing catecholamine production altogether.  Interestingly, TH knockout proved to be 
embryonic lethal further emphasizing the importance of these catecholamines (Thomas et 
al. 1995).  Additional studies from the same group demonstrate that DBH, the enzyme 
required for the conversion of DA into NE, KO also disrupts appropriate embryonic 
development in mice, and in fact 88% of DBH KO mice do not survive (Thomas et al. 
1995; Thomas et al. 1997; Thomas et al. 1997).  Those DBH KO mice that do survive are 
believed to do so only through the maternal transfer of the minimal levels of NE required, 
and of these survivors 60% die within 5 weeks of life.  In addition, DBH KO mice have 
significantly reduced body mass, experience hypothermia more easily than wild type 
controls, and fail to piloerect or constrict peripheral vasculature (Thomas et al. 1995; 
Thomas et al. 1997; Thomas et al. 1997).  While these studies firmly establish a vital role 
for NE in fetal development, study of DBH KO mice supplemented with NE to bypass 
fetal requirements allowed for more sophisticated investigation into the role of NE in 
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behavior.  Indeed, such DBH KO mice show decreased maternal care, normal learning, 
but decreased memory, and disturbed motor function (Thomas et al. 1997; Thomas et al. 
1997; Thomas et al. 1998; Weinshenker et al. 2002).  Interestingly, although the 
condition is incredibly rare, humans with severe DBH deficiency have been found (Man 
in 't Veld et al. 1987; Usera et al. 2004; Senard et al. 2006).  Despite the existence of such 
a condition, detailed study of these individuals is still lacking, and thus it remains to be 
seen if phenotypes of the DBH KO mice are consistent with the human condition.  
Although, consistent with the notion that these catecholamines are critical for normal 
fetal development, mothers of DBH deficient patients have a history of spontaneous 
abortions and still births (Vincent et al. 2002). 
 
Monoamine projections 
Whereas KO animal studies emphasize the importance of catecholamines, years 
of research on the neurons that synthesize, store, and release NE and DA provide an 
excellent foundation for understanding the role of these neurotransmitters in mediating 
specific behaviors.  Figure 2 provides a schematic representation of the most highly 
studied and well characterized noradrenergic and dopaminergic nuclei in the brain as well 
as representations of their neuronal projections throughout the brain.  The widespread 
projections of these monoaminergic neurons in the CNS insinuate an essential role for 
these neuromodulators in numerous brain functions.   
In comparison to the noradrenergic system, the DA system is significantly more 
restricted with respect to its distribution within the brain.  The four major dopaminergic 
projections include the tuberoinfundibular pathway (not pictured in Figure 2), the 
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Figure 2. Monoamine projections in the central nervous system. Schematic illustration of 
dopaminergic (top) and noradrenergic (bottom) projections. DA neurons in the 
nigrostriatal pathway project to the striatum from the substantia nigra.  DA neurons from 
the ventral tegmental area that project to the nucleus accumbens and the prefrontal cortex, 
constitute the mesolimbic and mesocortical pathways, respectively.    The 
tuberoinfundibular pathway is not depicted.  NE neurons in the locus coeruleus project to 
a vast array of regions within the CNS.   Given the widespread distribution of these 
projections, noradrenergic function modulates a variety of brain functions ranging from 
memory and mood to feeding behavior and attention.  Other noradrenergic nuclei are not 
depicted such as the lateral tegmental nucleus which has more limited projections to 
regions such as the amygdala and spinal cord.  Adapted from Neuroscience Exploring the 
Brain Third Edition by Mark F. Bear, Barry W. Connors, and Michael A. Paradiso. 
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nigrostriatal pathway, the mesocortical pathway, and the mesolimbic pathway.  Globally, 
proper dopaminergic tone in the brain is important for motor function, cognition, mood, 
motivation, and reward.  Given the focus of this thesis on NET, however, and its capacity 
to dramatically influence noradrenergic and at times dopaminergic activity in the brain, 
our discussion of DA and dopaminergic projections will be limited to those regions of the 
brain which can be influenced by NET activity.  Two particular regions of DA release 
impacted by NET function are the prefrontal cortex (PFC), which is part of the 
mesocortical pathway, and the nucleus accumbens (NAcc) shell, a component of the 
mesolimbic DA pathway (Gresch et al. 1995; Yamamoto et al. 1998; Moron et al. 2002; 
Miner et al. 2003).  Significantly low levels of the dopamine transporter (DAT) within 
the cortex, necessitate the need for other means of DA clearance (Sesack et al. 1998).  
Indeed, the primary mechanisms for clearing synaptic DA in the PFC is through 
enzymatic degradation by catechol-O-methyl transferase (COMT) and reuptake by NET 
(Axelrod et al. 1958; Moron et al. 2002).  Thus, NET function can significantly impact 
DA levels in this mesocortical pathway that modulates brain functions such as cognition, 
motivation, and reward.  Although reuptake of DA through NET is less substantial in the 
NAcc shell, NET can play a minor role in DA clearance here and thus has the potential to 
impact mesolimbic pathway functions such as reward and pleasure.  Importantly, deficits 
in the mesocortical pathway are associated with cognitive disorders such as schizophrenia 
and attention-deficit hyperactivity disorder (ADHD), whereas deficits in both the 
mesocortical and mesolimbic pathways have been linked to substance abuse disorders.  
Thus, abnormal NET function or regulation in these DA rich areas of the brain has the 
potential to contribute to such DA related disorders. 
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Unlike like the relatively restricted projections of the dopaminergic system, NE 
neurons innervate virtually all areas of the brain including the spinal cord.  Indeed, single 
noradrenergic neurons have been shown to innervate regions as disparate as the cortex 
and the spinal cord (Room et al. 1981).  The noradrenergic system is subdivided into two 
major divisions, the lateral tegmental (LT) system (not pictured in Figure 2) and the locus 
coeruleus (LC).  The LT system contains cell groups, defined by Moore and Card, A1-
A3, A5, A7 whereas the LC is comprised of cell groups A4 and A6 (Moore et al. 1979).  
The LT system, which is substantially less well studied than the LC, projects primarily to 
the spinal cord, brainstem, hypothalamus, and the basal forebrain.  As reflected in these 
projections, the LT noradrenergic system plays an important role in the regulation of food 
intake, stress, anxiety, and mediating the body‘s fight or flight system through 
modulation of the PNS.   
 
The locus coeruleus 
Although the LT system remains relatively uncharacterized, the LC is one of the 
most heavily studied neuronal groups to date.  Indeed, the first documented description of 
the LC by Reil in 1809 significantly predates the discovery of NE itself (Reil 1809).  The 
early identification of this noradrenergic nucleus in large part is due to its unique blue 
black color in postmortem brain tissue.  In fact, the distinct color of this nucleus 
prompted Wenzel in 1812 to coin the term ‗locus coeruleus‘ which means ‗the blue 
spot‘(Wenzel 1812).  Approximately, 55,000 to 65,000 cells comprise the LC in humans 
which can be divided into four distinct sub-zones according to the region of brain (i.e. 
hippocampus, cortex, hypothalamus, or spinal cord/cerebellum) innervated by projecting 
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neurons along the dorsal-ventral and anterior-posterior axes (Iversen et al. 1983; Pearson 
et al. 1983; Baker et al. 1989; Chan-Palay et al. 1989).  Whereas NE neurons from the LC 
can be somewhat subdivided based on projections to these four different regions, this is 
certainly not an inclusive list of all the diverse regions of the brain that LC activity may 
influence.  Indeed, the projections of LC neurons innervate essentially all of the regions 
of the brain, and even single neurons within the LC can project to areas as distinct as the 
PFC and brainstem.   
Given the expansive reach of LC projections, this noradrenergic nucleus has been 
implicated in a variety of brain functions such as sleep, arousal, stress, attention, memory, 
etc.  Indeed, extensive research of LC activity has yielded significant insight into the role 
of NE in the nervous system.  Current conceptualizations of LC function indicate that the 
LC, which receives information from numerous brain regions and subsequently projects 
to a wide array of regions, may provide a site where converging streams of information 
are prioritized (Simpson 2007).  Consistent with this hypothesis, LC activity is responsive 
to both alterations in organism homeostasis as well as changes in environmental stimuli.  
For example, LC firing correlates extremely well with the sleep wake cycle, and thus this 
nucleus and NE play a critical role in regulating sleep (Aston-Jones et al. 1981).  Years of 
research on this aspect of noradrenergic function is summarized elegantly in a 2007 
review by Gary Aston-Jones (Aston-Jones 2007).  In addition to evidence for the 
involvement of LC activity in the regulation of sleep, increases in LC activity, NE 
release, and NE turnover are observed in response to stress.  Indeed, the amount of NE 
release correlates well with the degree of stress or arousal experienced, particularly 
within the PFC  (Nakane et al. 1994; Finlay et al. 1995; Ramos et al. 2007).  Similarly, 
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NE release in the PFC and hippocampus is important for the maintenance of attention and 
ultimately for memory (Abercrombie et al. 1988; Aston-Jones et al. 1999; Usher et al. 
1999; Southwick et al. 2002; Aston-Jones et al. 2005).  Interestingly, although NE release 
is important for attention, arousal, and memory, conditions of too little or excessive stress 
and subsequent too little or excessive NE release are believed to disrupt these PFC related 
functions.  Indeed, current models of NE function in the brain support an inverted-U 
relationship between LC activity/NE release/stress and performance on tasks that require  
 
 
 
 
Figure 3. Optimal NE release and performance on cognitive tasks. Schematic illustration 
of inverted-U relationship between NE release and performance on cognitive tasks.  LC 
activity and subsequent NE release in the PFC correlates well with arousal state and 
stress levels in an individual.  Importantly, too much or too little stress/arousal negatively 
impacts performance on PFC related tasks.  Correspondingly, excessive or too little NE 
release in the prefrontal cortex is also associated with poor performance on these 
cognitive tasks.  Thus, an inverted-U relationship is said to exist between NE release in 
the PFC and cognitive function, where moderate levels of NE release result in optimal 
performance. 
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attention and memory (Aston-Jones et al. 2005; Arnsten 2007; Aston-Jones 2007; Ramos 
et al. 2007).  For example, hypoactive LC firing is associated with little NE release, 
drowsiness, and inattention which ultimately reflects in poor performance on attention 
related tasks.  On the other hand, moderate levels of LC activity and NE release are 
believed to support optimal attention and performance, while excessive LC firing is 
associated with distractibility and poor performance.  Interestingly, such hyperactive 
modes of LC function are hypothesized to play a role in disorders like ADHD, whereas 
hypoactive modes have been implicated in the negative symptoms associated with 
schizophrenia such as poor attention and deficits in working memory.  Research to date, 
suggests that this inverted-U relationship between NE release and performance is 
partially mediated by the differential affinity of α1 versus α2 adrenergic receptors for NE 
and the differential effects of their distinct signaling pathways on PFC function.  Detailed 
studies supporting this theory are summarized nicely in two reviews by Amy Arnsten 
(Arnsten 2007; Ramos et al. 2007).       
Cumulatively, noradrenergic and dopaminergic signaling, in both the CNS and 
PNS, impacts a vast array of brain and body functions.  As exemplified by TH and DBH 
KO studies, these neurotransmitters are not only important for appropriate adult brain 
function they are also crucial for fetal development.  In addition, studies of the neurons 
that synthesize and release these monoamines reveal unique insight about their role in a 
plethora of brain functions ranging from motivation and reward to cognition, food intake, 
attention, stress, arousal, motor control, etc.  Indeed, imbalances in monoamine 
homeostasis are believed to underlie diseases related to abnormalities in these functions 
such as substance abuse disorders, depression, schizophrenia, ADHD, Parkinson‘s 
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disease, anorexia, etc.  Thus, proper maintenance of monoaminergic tone within the brain 
is absolutely imperative for appropriate DA and NE signaling and subsequent brain 
function.  Here, monoaminergic tone is defined by the signaling of these monoamines at 
the synapse and thus is determined by three important signaling components: the amount 
of neurotransmitter released into the synapse, the time neurotransmitter is available for 
signaling within the synapse, and finally the affinity/sensitivity of neurotransmitter 
receptors in the synapse.  Monoamine transporters, such as NET, can impact all three 
aspects of monoaminergic tone defined here.  First, transporters directly determine, 
through their reuptake of monoamines in the synapse, the time these neurotransmitters 
remain available within the synapse for signaling.  In addition, reuptake of monoamines 
through transporters is crucial for neurotransmitter recycling and thus transporter function 
can significantly impact the amount of neurotransmitter released from the synapse.  
Finally, synaptic receptor availability and sensitivity is altered by the duration and 
concentration of neurotransmitter at the synapse, and thus this aspect of synaptic 
signaling may be influenced indirectly by transporter function also.  The remainder of 
this thesis will focus on understanding the intricacies of monoamine transporter function, 
with particular focus on NET, and its capacity to impact brain monoamine homeostasis 
and thus brain function and behavior.   
 
Monoamine Transporter Structure and Function 
The first descriptions of neurotransmitter re-uptake were provided by Julius 
Axelrod in 1959 and 1961 (Axelrod et al. 1969; Axelrod 1971).  His studies demonstrated 
the selective accumulation of radiolabeled epinephrine and NE in organs innervated by 
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the sympathetic nervous system such as the spleen and heart.  These studies were 
extended by Iverson in 1963 who further demonstrated the capacity of [
3
H] NE uptake in 
the heart, and finally by Coyle and Snyder in 1969 who showed, for the first time, re-
uptake of neurotransmitter in brain tissue (Iversen 1963; Coyle et al. 1969).  Since these 
original descriptions of neurotransmitter reuptake, the identification of specific 
transporters responsible for the reuptake of particular neurotransmitters has opened an 
entire field of fruitful research on these proteins and their role in synaptic signaling.   
The monoamine transporters—DAT, NET, and the serotonin (5-HT) transporter 
(SERT)—belong to the SLC6 gene family of Na+/Cl- dependent transporters and are 
critical for regulating extracellular levels of neurotransmitters.  These transporters rely 
mainly on the co-transport of Na
+ 
down its electrochemical gradient to facilitate the 
uptake of biogenic amines from the inter- and extrasynaptic space.  This transporter 
mediated re-uptake controls both the duration and the intensity of monoamine signaling 
at the synapse and is hypothesized to occur via an alternating access mechanism (Axelrod 
1965; Jardetzky 1966; Forrest et al. 2008).  This model of transporter function suggests 
that substrate and Na
+
 binding trigger conformational changes that shift the transporter 
from an ―outward-facing‖ conformation, in which the substrate is exposed extracellularly, 
to an ―inward-facing‖ conformation where the substrate is exposed to the intracellular 
milieu (Jardetzky 1966; Erreger et al. 2008; Forrest et al. 2008; Shi et al. 2008).  In 
addition to the classical alternating access model of transporter function, studies on 
monoamine transporters also revealed the existence of channels in transporters as an 
important aspect of transporter function (Galli et al. 1995; Galli et al. 1996; Galli et al. 
1998; DeFelice et al. 2007).  Indeed, bursts of NE release have been demonstrated to be 
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associated with discrete channel opening events (Galli et al. 1995; Galli et al. 1996; Galli 
et al. 1998).  Collectively, both alternating access and channel like activity enables 
monoamine transporters to accumulate neurotransmitters back into the intracellular 
compartment after vesicular release in order to ensure both appropriate regulation and 
maintenance of synaptic signaling. 
 
Monoamine transporter structure 
Topological predictions and experimental data to date indicate that the 
monoamine transporters have 12 transmembrane domains (TMD) with intracellular 
amino and carboxy termini (Figure 4), and these predictions have been confirmed by the 
crystal structure of the bacterial leucine transporter (LeuT), a bacterial homolog of the 
neurotransmitter transporters (Pacholczyk et al. 1991; Bruss et al. 1995; Hersch et al. 
1997; Chen et al. 1998; Androutsellis-Theotokis et al. 2002; Yamashita et al. 2005).   
Subsequent structural studies of the LeuT structure have yielded additional insight into 
important structural domains of the monoamine transporters.  For example, sites critical 
for substrate binding, 
 
Figure 4. Monoamine transporter 
topology. Illustration of monoamine 
transporter topology.  The monoamine 
transporters are predicted to have twelve 
transmembrane segments with 
cytoplasmic N and C termini.  These 
predictions have been experimentally 
confirmed by various studies and in 
particular via the crystal structure of the 
close leucine transporter homolog.  
Adapted from (Torres et al., 2003). 
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ion dependence, and even antidepressant binding have now been identified (Henry et al. 
2007; Torres et al. 2007).  In addition, support for the existence of these transporters as 
functional dimers or multimers has also come from these types of structural studies.  
Another important structural domain of the transporters is the large extracellular domain, 
located between TMD3 and TMD4, that is post-translationally modified in order to 
ensure appropriate targeting of the transporters to the surface (Li et al. 2004).  Finally, 
numerous putative phosphorylation sites and binding domains have also been identified 
within the intracellular domains of the various monoamine transporters, and these 
domains are considered vital for transporter regulation (Blakely et al. 1998; Granas et al. 
2003; Sung et al. 2003; Khoshbouei et al. 2004; Fog et al. 2006; Blakely et al. 2007).  
Initially, research on monoamine transporters focused primarily on understanding 
the intricacies of transporter function.  A milestone in monoamine transporter research, 
the cloning of the human NET, propelled the field further by allowing for not only more 
detailed studies of transporter function but also for studies on transporter regulation 
(Pacholczyk et al. 1991).  Today, evidence clearly supports the notion that NET and the 
other monoamine transporters are not merely stagnant regulators of synaptic monoamine 
levels, but rather are dynamically modulated proteins that contribute to synaptic 
plasticity.  This dynamic regulation of NET will be the subject of the remainder of the 
thesis.  First, however, to provide a foundation for these discussions, it is important to 
take an in-depth look at the transporter and its role in maintaining monoamine 
homeostasis in the brain. 
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NET localization   
As described previously, NET is the primary mechanism by which NE is cleared 
from the synapse.  As such, the transporter is specifically localized to noradrenergic 
neurons within the CNS.  In the periphery, however, NET expression is not limited to 
sympathetic neurons, but it is also found in the lungs, placenta, and adrenal medulla 
(Ramamoorthy et al. 1994; Westwood et al. 1996; Schroeter et al. 2000).  At the level of 
a single neuron, NET expression is observed as punctuate not only at the periphery of the 
synapse (as pictured in Figure 1), but also as punctuate along the axons, somata, and 
dendrites (Lorang et al. 1994; Miner et al. 2003; Matthies et al. 2009).  In addition, 
intracellular compartments contain NET and thus suggest the potential for redistribution 
of NET from intracellular pools to the surface or vice versa in response to stimuli 
(Matthies et al. 2009).  Importantly, while NET expression is limited to noradrenergic 
neurons in the CNS, the ability of this transporter to reuptake other neurotransmitters 
besides NE, adds additional weight to its importance in the maintenance of monoamine 
homeostasis.  In particular, NET reuptake of DA, in regions of low DAT expression such 
as the cortex or even in regions with substantial DAT expression such as NAcc shell, can 
significantly influence dopaminergic tone in the brain (Gresch et al. 1995; Yamamoto et 
al. 1998; Moron et al. 2002; Miner et al. 2003; Liprando et al. 2004). 
 
NET KO mice 
The significance of NET function for maintenance of brain monoamine 
homeostasis cannot be fully appreciated without discussion of NET KO models.  In 2000, 
Xu et al. published the first description of NET KO mice (Xu et al. 2000).  As 
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anticipated, clearance of NE in these KO mice was at least 6-fold slower in comparison to 
WT controls.  Indeed, defective clearance is seen in the other monoamine transporter KO 
mice, thus these deficits further substantiate the claim that transporters are critical for 
both temporal and spatial control of synaptic signaling (Jones et al. 1998).  Interestingly, 
in addition to abnormal NE clearance and elevated extracellular levels of NE, NET KO 
mice also display a 55% to 70% reduction in NE tissue content in NE enriched regions of 
the brain.  Once NE is taken up by the transporter it can either be degraded enzymatically  
or be taken up into vesicles by the vesicular monoamine transporter 2 (VMAT2).  In fact, 
70% of NE recaptured by NET is recycled rather than degraded (Schomig et al. 1989; Xu 
et al. 2000).  Thus, the significant reduction in NE tissue content observed in NET KO 
mice, despite compensatory increases in TH, is reflected in the inability of neurons to 
recycle NE into vesicles for subsequent release.  Not surprisingly then, even synaptic NE 
release is diminished by 60% in these KO mice.  In addition to disruptions in 
noradrenergic homeostasis, NET KO mice display a plethora of interesting phenotypes.  
For example, NET KO mice are smaller, exhibit reduced body temperatures, and behave 
similarly to normal mice treated with antidepressants in various behavioral paradigms.  
Interestingly, perhaps in part due to the ability of NET to reuptake DA, DA related 
functions are also disrupted in NET KO mice.  For instance, NET KO mice display 
disrupted DA clearance in the cortex and DA receptor ‗supersensitivity‘ which is 
believed to underlie their increased responsiveness to drugs of abuse such as 
amphetamine (AMPH) and cocaine (Xu et al. 2000; Moron et al. 2002; Keller et al. 
2006).  Altogether, the striking behavioral and physiological phenotypes of NET KO 
mice further emphasize the vital role NET plays in maintaining monoaminergic tone 
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within the brain, and in addition lend gravity to the notion that disruptions in NET 
function may contribute to abnormalities in brain function and behavior. 
 
Monoamine transporters as pharmacological targets   
 Not only is NET of substantial interest given its ability to significantly influence 
monoaminergic signaling, but the transporter is also the target of therapeutics and drugs 
of abuse.  A vast array of drugs utilized to treat a number of different brain-related 
disorders target the monoamine transporters.  Among the first to be identified as 
therapeutically useful were the tricyclic antidepressants which typically block both SERT 
and NET (Owens et al. 1997; Richelson 2003).  Since then, both 5-HT selective and NE 
selective reuptake inhibitors (SSRI and SNRI respectively) have been developed for the 
treatment of depression.  Interestingly, while the majority of treatments for ADHD have 
focused on manipulation of the dopaminergic system and DAT itself, atomoxetine, a 
NET specific inhibitor, has become recognized as another effective strategy for treating 
this disorder in some individuals (Corman et al. 2004).  Not surprisingly, perhaps, given 
both the ability of NET to impact cortical DA levels, and the importance of cortical NE 
itself in the regulation of attention.  Along with this rationale, clinical trials with NET 
specific inhibitors are ongoing in populations of schizophrenic patients with the hopes of 
alleviating negative symptoms of the disorder such as deficits in the attention and 
working memory (clinicaltrials.gov).  Although pharmacological targeting of NET and 
other monoamine transporters can be useful in the treatment of various disorders, these 
transporters are also the targets of psychostimulant drugs of abuse such as cocaine and 
AMPH.  Indeed, drugs such as AMPH not only inhibit monoamine reuptake and thereby 
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disrupt brain monoamine homeostasis, but they can also hijack the sophisticated signaling 
pathways that dynamically regulate these transporters to exacerbate their effects.    
 In summary, as exemplified by monoamine transporter knockout studies and by 
study of the drugs that target them, appropriate transporter function is absolutely critical 
for maintaining monoamine homeostasis in the brain.  Furthermore, this maintenance 
ensures proper brain function, and thus disruptions in NET function ultimately have the 
potential to impact behavior.  In addition, years of research on these transporters has 
revealed that they are more than mere stagnant monitors of synaptic monoamine levels, 
but rather through their own dynamic regulation they are important components of 
synaptic plasticity.  This dynamic regulation will be the focus of the remainder of the 
thesis. 
Monoamine Transporter Regulation 
Amphetamine regulation of monoamine transporters 
Although early research on monoamine transporters laid an excellent foundation 
for a detailed understanding of how transporters facilitate the reuptake of 
neurotransmitter, recent studies over the last decade have focused more intensely on the 
dynamic regulation of these transporters.  Importantly, transporter regulation manifests 
through two distinct mechanisms.  First, uptake or the activity of the transporter can be 
manipulated (i.e. slowed, accelerated, reversed, or inhibited entirely), or secondly, the 
availability of the transporter on the surface can be altered.  An excellent example of 
monoamine transporter regulation that encompasses both mechanisms is the regulation of 
the transporters by AMPH.  Indeed, the AMPH regulation of monoamine transporters has 
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been studied in depth and thus serves as an excellent case study for monoamine 
transporter regulation.      
AMPH and its derivatives are regularly used in the treatment of a wide array of 
disorders such as ADHD, obesity, traumatic brain injury, and narcolepsy (Prinzmetal 
1935; Olfson et al. 2002; Knutson et al. 2004; Martinsson et al. 2004; Sulzer et al. 2005; 
Fleckenstein et al. 2007).  Despite the important medicinal role for AMPH, it is more 
widely known for its psychostimulant and addictive properties as a drug of abuse.  The 
primary molecular targets of AMPH are both the VMATs and plasma membrane 
monoamine transporters, DAT, NET, and SERT.  The rewarding and addicting properties 
of AMPH rely on its ability to act as a substrate for these transporters and ultimately 
increase extracellular levels of monoamines.  AMPH achieves this elevation in 
extracellular levels of neurotransmitter by inducing synaptic vesicle depletion, which 
increases intracellular monoamine levels, and also by promoting reverse transport of 
monoamines (efflux) through plasma membrane monoamine transporters (Burn et al. 
1958; Carlsson et al. 1962; Kirshner 1962; Ritz et al. 1987; Sulzer et al. 1995; Fon et al. 
1997; Jones et al. 1998).  Here, the focus will remain on two important aspects of 
AMPH-induced regulation of the plasma membrane monoamine transporters—
transporter mediated monoamine efflux (reverse transporter activity) and transporter 
trafficking (changes in transporter surface availability).    
The molecular mechanism underlying AMPH action remained a mystery until the 
late 1950‘s when the work of Burn and Rand revealed that AMPH acts by ―releasing a 
noradrenaline-like substance‖ (Burn et al. 1958).  Thus the foundation of the field was 
established, and since then numerous studies have focused intently on discovering the 
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detailed mechanism behind AMPH‘s ability to induce monoamine release into the 
extracellular milieu.  Investigations following the work of Burn and Rand implicated both 
vesicular and plasma membrane monoamine transporters as important conduits for 
monoamine release.  This discussion, however, will focus on efforts surrounding the 
plasma membrane monoamine transporters.  The reader is directed to a substantial review 
for a thorough discussion of VMAT contribution to AMPH-mediated monoamine release 
(Sulzer et al. 2005).   
Early evidence demonstrated that AMPH-like drugs act as substrates for 
monoamine transporters and that AMPH-induced monoamine release could be blocked 
by uptake inhibitors such as cocaine and nomifensine (Heikkila et al. 1975; Raiteri et al. 
1979; Parker et al. 1988; Seiden et al. 1993; Sulzer et al. 1995; Jones et al. 1998; Schenk 
2002).  In tandem with these studies, Fischer and Cho proposed the facilitated exchange 
diffusion model as a model for AMPH-induced monoamine release via DAT (Fischer et 
al. 1979; Burnette et al. 1996).  Fischer and Cho hypothesized that AMPH is transported 
as a substrate into the cell via DAT which subsequently results in the counter transport of 
DA extracellularly.  Given that AMPH serves as a substrate for DAT, its transport into 
the cell increases the number of transporters in the inward facing conformation, and thus 
increases the probability that intracellular DA will bind to DAT and induce reverse 
transport.  Evidence in support of this model of AMPH-induced efflux demonstrates that 
AMPH accumulation in rat synaptosomes is saturable, temperature-dependent, and 
ouabain-sensitive, implicating an active transport mechanism for AMPH (Zaczek et al. 
1991).  Additional evidence for an active transport mechanism has been supported by 
several electrophysiology studies illustrating AMPH‘s ability to generate DA-like 
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transporter associated currents (Sonders et al. 1997; Sitte et al. 1998; Khoshbouei et al. 
2003; Kahlig et al. 2004).  
  Since the introduction of facilitated exchange diffusion in 1979, new 
experimental results have emerged that challenge this model.  For example, direct 
intracellular injections of AMPH into the giant DA neuron of Planorbis corneus, the 
pond snail, induce reverse transport despite the fact that AMPH has not been taken up via 
the transporter (Sulzer et al. 1995).  Furthermore, AMPH increases intracellular Na
+
 
concentration and an increase in intracellular Na
+
 is sufficient to drive DA efflux even in 
the absence of extracellular AMPH (Khoshbouei et al. 2003).  In fact, numerous studies 
to date on AMPH-induced changes in uptake, charge transfer, and efflux all support the 
notion that the influx of extracellular sodium ions via the transporter triggers reverse 
transport (Pifl et al. 1995; Pifl et al. 1997; Sitte et al. 1998; Pifl et al. 1999; Schenk 2002; 
Pifl et al. 2004).  Other experiments, utilizing concatemers of SERT (AMPH sensitive) 
and GAT (AMPH insensitive) reveal that AMPH-induced efflux also depends upon the 
oligomeric nature of the monoamine transporters (Seidel et al. 2005).  Finally, additional 
studies have revealed that AMPH can cause DAT-mediated DA efflux by a process that 
results in rapid bursts of DA efflux through a channel-like mode of DAT, a process that is 
independent from the slow exchange-like mechanism (Kahlig et al. 2005).  This was 
demonstrated in outside-out patches from both heterologous cells stably expressing DAT 
and from dopaminergic neurons.  Interestingly, this channel-like mode of DA release is 
approximately equivalent to a quantum of DA release from synaptic vesicle fusion.  
Therefore, this channel-like burst mode may actually influence the synaptic action and 
psychostimulant properties of AMPH.  These studies suggest that although facilitated 
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exchange diffusion may contribute to AMPH-mediated monoamine release, it cannot 
account for all experimental observations to date (Figure 5).  
   
 
 
Figure 5. Transporter-mediated monoamine efflux. Schematic representation of 
transporter mediated monoamine efflux. Transporters in the inward facing conformation 
are capable of mediating monoamine efflux by binding substrate and co-transported ions. 
Transporter reversal can be enhanced under certain conditions such as in the presence of 
AMPH or increased intracellular Na+. In addition to the slow exchange-like mechanism 
of efflux, AMPH can also induce efflux through a channel-like mode of the transporter. 
 
 
 While the model of AMPH-induced efflux evolved to include not only facilitated 
exchange diffusion but also channel-like modes of the transporter, its development is 
incomplete without considering regulation by second messenger systems.  As mentioned 
previously, numerous putative phosphorylation sites for various protein kinases have 
been identified within the intracellular regions of the monoamine transporters.  In fact, 
several studies have demonstrated that DAT function is heavily regulated by a plethora of 
protein kinases (Melikian et al. 1999; Carvelli et al. 2002; Granas et al. 2003; Loder et al. 
2003).  As evidence emerged that AMPH is capable of increasing protein kinase C (PKC) 
activity in vivo, the possibility that kinase regulation may impact AMPH‘s ability to 
25 
 
induce transporter-mediated monoamine efflux became enticing (Giambalvo 1992).  
Soon thereafter, strong evidence for the involvement of PKC in AMPH-induced DAT-
mediated DA efflux appeared in experiments that utilized specific PKC inhibitors to 
prevent AMPH-stimulated DA release altogether (Kantor et al. 1998; Cowell et al. 2000).  
A similar role for PKC was also established for AMPH regulation of NET efflux in 
undifferentiated PC12 cells (Kantor et al. 2001).  Not surprisingly, these experiments also 
revealed a requirement for intracellular Ca
2+
 in AMPH-induced NET efflux, along with 
the necessity for PKC activity.  In addition to a role for intracellular Ca
2+
, the effects of 
repeated AMPH exposure on NET were shown to depend on N-type and L-type Ca
2+
 
channel activity (Kantor et al. 2004).  These studies were further extended by research 
that demonstrated the ability of intracellular Ca
2+
 to regulate both AMPH-induced DAT 
currents and efflux (Gnegy et al. 2004).  Finally, recent studies investigating PKC‘s 
involvement in AMPH mediated DA release have provided evidence for the importance 
of an actual physical association of PKCβII with DAT in the rat striatum (Johnson et al. 
2005).   
Considering the wealth of data supporting a role for PKC in AMPH stimulated 
neurotransmitter release, the finding that PKC activation leads to N-terminal 
phosphorylation of DAT in the rat striatum is not surprising (Foster et al. 2002).  
Nevertheless, a DAT mutant lacking the first 22 amino acids of the N-terminus, which 
eliminates 
32
P incorporation in response to PKC, shows no significant deficits in uptake, 
inhibitor binding, internalization, or oligomerization (Granas et al. 2003).  Given the 
substantial evidence for PKC involvement in AMPH-induced transporter efflux, Galli 
and coworkers chose to investigate the role of the N-terminus in regulating DAT-
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mediated DA efflux by using the 22 amino acid deletion mutant.  The study revealed an 
80% reduction in AMPH-induced DA efflux in the mutant DAT (Khoshbouei et al. 
2004).  Additionally, they demonstrated that mutation of 5 N-terminal serine residues to 
alanine residues (S/A) produced an identical phenotype to that of the 22 amino acid 
deletion DAT mutant.  Furthermore, mutation of the same five residues to aspartate (S/D) 
restored AMPH-induced DA efflux to normal levels.  From this study, the authors 
proposed a novel model for AMPH-induced regulation of DAT efflux that implies a role 
for N-terminal phosphorylation in shifting DAT from a ―reluctant‖ to a more ―willing‖ 
state for efflux.   
Although an abundance of evidence insinuates a role for phosphorylation via PKC 
in AMPH-induced DAT efflux, additional data implicates the involvement of other 
kinases in this complex process (Pierce et al. 1997; Kantor et al. 1999).  In fact, recent 
data indicates that Ca
2+
/calmodulin-dependent protein kinase α (CaMKIIα) is a key 
component of AMPH-induced regulation of DAT efflux (Fog et al. 2006).  In this study, 
the researchers clearly demonstrated that inactivation or inhibition of CaMKIIα 
dramatically reduced AMPH-induced DA efflux.  Furthermore, a physical association 
between CaMKIIα and the DAT C-terminus was observed, and subsequent disruption of 
this association was sufficient to diminish AMPH-stimulated DA release.  Thus, research 
clearly indicates a role for both PKC and CaMKIIα signaling in AMPH-induced DAT 
mediated DA efflux.  Whether or not these two signaling pathways contribute to efflux in 
parallel or sequentially, however, has yet to be determined. Interestingly, recent research 
focused on the role of CaMKII in AMPH-mediated DA efflux has identified syntaxin1A 
(SYN1A) as an important link between CaMKII signaling and transporter reversal (Binda 
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et al. 2008).  SYN1A is a SNARE (soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor) that is critical for synaptic vesicle release.  In addition to its role in 
vesicular fusion, SYN1A also interacts with and regulates numerous transmembrane 
proteins including ion channels and importantly, neurotransmitter transporters.  In fact, 
DAT/SYN1A and NET/SYN1A associations have been shown to increase in response to 
AMPH, and evidence now indicates that this enhancement in SYN1A association is vital 
for AMPH-mediated DA efflux (Dipace et al. 2007; Binda et al. 2008).  Interestingly, 
SYN1A interaction with NET and DAT has also been shown to influence transporter 
channel-like activity, a mode of the transporter that is important for AMPH-induced 
efflux (Sung et al. 2003; Carvelli et al. 2008).  By utilizing pharmacological and peptide 
inhibitors of CaMKII, experiments have clearly established that the increase in 
SYN1A/DAT association in response to AMPH requires CaMKII activity.  From these 
findings, a model for AMPH-induced DA efflux can be formulated, whereby the binding  
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of CaMKIIα to the C-terminus of DAT facilitates the phosphorylation of the N-terminus 
and the binding of SYN1A, promoting the shift of DAT towards a ‗willing‘ state for 
AMPH-induced DA efflux (Figure 6).   
Unlike AMPH-induced neurotransmitter efflux, a phenomenon recognized in the 
late 1950‘s, another aspect of AMPH regulation of monoamine transporters did not 
emerge from the literature until the late 1990‘s.  Fleckenstein and coworkers 
hypothesized that AMPH not only induces transporter efflux, but also may regulate 
transporter surface expression levels based on their observation that in rats a single high 
dose injection of AMPH results in a decrease in DAT function one hour later 
(Fleckenstein et al. 1997).  Since then, AMPH-induced regulation of DAT trafficking has 
been confirmed by numerous studies, and the investigation into the mechanisms 
underlying this phenomenon has become an area of intense research (Saunders et al. 
2000; Kahlig et al. 2003; Kahlig et al. 2004; Kahlig et al. 2006).   
The first comprehensive demonstration of AMPH-induced trafficking of DAT in 
heterologous systems surfaced a few years after Fleckenstein‘s original proposal.  In this 
study, acute treatment with the DAT substrates AMPH and DA not only reduced [
3
H]DA 
uptake and AMPH-induced currents, but also clearly decreased DAT cell surface 
expression (Saunders et al. 2000).  By utilizing a dominant negative mutant of dynamin I 
(K44A) to prevent substrate-induced trafficking, the authors also provided evidence to 
suggest that AMPH-stimulated DAT endocytosis occurs via a dynamin dependent 
pathway.  Following these experiments, a series of investigations verified these results in 
other heterologous systems (Xenopus oocytes), rat synaptosomal preparations, and 
finally, indirectly, in vivo via high speed chronoamperometry (Gulley et al. 2002; Chi et 
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al. 2003; Kahlig et al. 2004; Owens et al. 2005; Williams et al. 2007).  Interestingly, 
application of DAT inhibitors such as cocaine, mazindol, and nomifensine is sufficient to 
prevent the AMPH-induced DAT trafficking, implying that transport of AMPH into the 
cell may be an important component of this regulation.  To address this hypothesis, a 
mutant DAT (Y335A) capable of substrate binding but impaired in substrate transport, 
was exposed to AMPH and analyzed for redistribution from the cell surface to the 
cytosol.  Interestingly, extracellular AMPH application did not induce internalization of 
the uptake-impaired DAT, but when applied directly into the intracellular milieu, AMPH 
was sufficient for inducing trafficking of the mutant (Kahlig et al. 2006).  From this, the 
researchers concluded that whereas the DAT transport cycle is unnecessary for AMPH-
induced DAT trafficking, an increase in intracellular AMPH is an essential component of 
this regulation. An important caveat to consider in these studies is the timing of 
transporter cell surface redistribution in response to AMPH application. Indeed, recent 
studies point out that AMPH-induced trafficking of DAT is dependent upon the time of 
AMPH exposure.  For example, a rapid enhancement of DAT surface expression occurs 
within seconds of AMPH application and diminishes by 2.5 minutes implying that 
AMPH‘s regulation of transporter trafficking differs with respect to acute versus long 
lasting effects (Johnson et al. 2005).   
As AMPH-induced DAT trafficking became well established, researchers shifted 
their focus towards identifying underlying key components of the phenomenon.  
Considering the wealth of evidence supporting a role for AMPH-induced PKC activation 
in transporter efflux, the idea that PKC activity may also be involved with transporter 
trafficking seemed plausible.  In fact, numerous studies had already demonstrated that 
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PKC activation leads to the rapid redistribution of DAT from the cell surface in both 
heterologous and neuronal systems (Pristupa et al. 1998; Daniels et al. 1999; Granas et al. 
2003; Loder et al. 2003; Sorkina et al. 2003)  However, recent results show that while 
AMPH application induces N-terminal phosphorylation of DAT via PKC, prevention of 
this phosphorylation by mutation does not deter AMPH-induced DAT trafficking (Granas 
et al. 2003; Cervinski et al. 2005).  Furthermore, more recent studies have demonstrated 
that residues required for PKC-induced internalization are not critical for AMPH-
triggered DAT sequestration, and PKC inhibition also failed to inhibit AMPH-induced 
DAT redistribution (Boudanova et al. 2008; Boudanova et al. 2008).  Therefore, while 
experiments to date clearly implicate a role for PKC in AMPH-induced regulation of 
DAT efflux, at this time it does not appear to be involved in AMPH-induced transporter 
trafficking from the surface.  Interestingly, new work from Vaughan and co-workers 
indicates that PKC induced DAT regulation may differ depending on the membrane 
localization of the transporter (Foster et al. 2008).  In this study the authors, demonstrate 
that PKC-stimulated phosphorylation of DAT occurs to a significantly higher level in 
lipid raft populations of DAT compared to non-lipid raft populations.  In fact, the PKC-
triggered DAT internalization happens primarily from non-raft population.  Thus, PKC 
regulation of DAT depends heavily upon the discrete membrane localization of the 
transporter.  Given AMPH‘s dual effect on transporters, one can imagine a scenario 
where non-raft populations are primarily responsible for AMPH-induced DAT 
internalization whereas raft populations may primarily constitute transporters-mediating 
monoamine efflux.  Whether membrane localization is important or not for AMPH-
induced efflux and trafficking has yet to be determined, but it will be an interesting 
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question for future studies.  In addition to PKC, other kinases have also been implicated 
in AMPH-induced DAT trafficking.  For example, AMPH application results in a time-
dependent increase in CaMKII activity which is required for DAT trafficking (Wei et al. 
2007). Importantly, this CaMKII activation inhibits an important kinase in the insulin 
signaling pathway, Akt. This study suggests that insulin signaling is involved in DAT 
trafficking and as a consequence may impact DA homeostasis. Thus, the current model of 
AMPH-induced DAT internalization proposes an intersection of AMPH-stimulated 
signaling and the insulin signaling pathway. 
 Whereas evidence for AMPH-induced internalization of DAT has accumulated 
since the 1990‘s, experiments supporting a similar phenomenon with respect to NET did 
not appear until the 2000‘s (Zhu et al. 2000; Dipace et al. 2007).  The first studies, from 
Ordway and colleagues, which investigated the effects of chronic AMPH exposure on 
NET revealed that long term AMPH exposure reduces NET expression in both a time and 
concentration dependent manner (Zhu et al. 2000).  Furthermore, a study from 2007 
demonstrated that, like DAT, acute AMPH application stimulated a slow, significant 
reduction in surface levels of NET in a catecholaminergic cell line (Dipace et al. 2007).  
Although these results come as no surprise, the study also revealed novel aspects of 
AMPH-induced regulation of the transporter.  First, the authors clearly demonstrated that 
this process is Ca
2+
 dependent by utilizing BAPTA-AM and Cd
2+
 to diminish 
intracellular Ca
2+
 levels and prevent AMPH-stimulated NET internalization.  
Furthermore, inhibition of CaMKII via KN93 also prevented AMPH-induced NET 
trafficking, implying that this process for NET is both Ca
2+
 and CaMKII dependent just 
as it is for DAT.  Finally, the study of an N-terminal deletion mutant (hNET∆28-47) also 
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indicated that AMPH-stimulated regulation of NET internalization may be mediated 
through the N-terminus (Dipace et al. 2007).  Interestingly, whether a similar region is 
critical for AMPH-induced DAT internalization has yet to be determined. In comparison 
to the wealth of research dedicated to determining how AMPH regulates both trafficking 
and efflux of DAT, knowledge related to AMPH-induced regulation of NET is rather 
limited.  Despite this gap in the field, much research has been done on β-PMA induced 
downregulation of NET and evidence supports a role for lipid rafts in NET internalization 
(Jayanthi et al. 2004; Jayanthi et al. 2006).  Perhaps, similar mechanisms will be 
elucidated for AMPH-mediated NET trafficking which would suggest a divergence in the 
regulation of NET compared to DAT given the clathrin dependence of AMPH-induced 
DAT trafficking.  Thus, much research is still needed in the field of AMPH-induced NET 
internalization and efflux as many important questions remain unanswered, such as which 
compartment does the transporter travel through during AMPH-stimulated trafficking and 
what intracellular signals and modifications of NET are required for this trafficking 
phenomenon? Furthermore, does the insulin signaling pathway play any role in the ability 
of AMPH to induce NET mediated NE efflux and NET trafficking? 
Since the first clues behind AMPH‘s mechanism of action began to emerge as 
early as the late 1950‘s, this field of research has seen an exponential amount of growth.  
After almost 50 years of investigation, the original model for AMPH-induced monoamine 
efflux has evolved from its simplest form of facilitated exchange diffusion to a 
multifaceted mechanism that requires not only exchange diffusion and channel-like 
modes of release but also regulation by second messenger systems.  Perhaps, even more 
remarkable than the transformation of the efflux field, is the discovery of a second 
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mechanism of action for AMPH altogether—transporter trafficking.  Despite the 
advancements over the last few years, both the broad implications and the intricate details 
of AMPH‘s actions continue to elude us.  For instance, how does AMPH‘s ability to 
dynamically regulate monoamine transporter membrane expression contribute to its 
psychostimulant and addictive properties?  Which intracellular signaling pathways are 
critical for AMPH-induced regulation of transporter efflux and trafficking, and how do 
they differ?  Research aimed at addressing these types of questions promises to bring us 
one step closer to comprehending the basis of not only AMPH abuse and addiction but 
also its role as a treatment for various pathological conditions.  As our understanding of 
AMPH action continues to progress, so too will our comprehension of monoaminergic 
regulation in general. For example, recent work involving a DAT coding variant 
associated with ADHD that effluxes DA, as if it were exposed continuously to AMPH, 
has been shown to have aberrant regulation under normal conditions that closely parallels 
regulation of wild-type DAT by AMPH (Mazei-Robison et al. 2008).  Thus, uncovering 
the secrets of AMPH-mediated monoamine transporter regulation promises to enhance 
our capacity to generate novel therapeutic strategies for treating drug abuse as well as 
disorders associated with monoaminergic dysfunction in general such as depression and 
ADHD. 
 
 Insulin/Akt regulation of monoamine transporters 
The complexity with which AMPH regulates both monoamine transporter 
function and transporter surface expression offers critical insight into the dynamic nature 
of transporter regulation.  Here, however, a less well characterized mechanism of 
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monoamine transporter regulation is of particular interest, the regulation of these 
transporters by the insulin signaling pathway.  Unlike in the periphery where insulin 
signaling is primarily important for the regulation of glucose levels, within the CNS it has 
been demonstrated to influence a broad array of functions (Figure 7) such as 
neurodevelopment, cell survival, neurogenesis, receptor trafficking, neurotransmitter 
release, and neurotransmitter reuptake (Woods et al. 1996; Bruning et al. 2000; 
Schulingkamp et al. 2000; van der Heide et al. 2006).  Given its diversity in function, it is 
not surprising then that insulin signaling is hypothesized to impact numerous brain 
functions such as learning, memory, regulation of food intake etc. and that disruptions in 
insulin signaling perhaps contribute to brain related disorders.  Importantly, while the 
source of CNS insulin is still debated, the majority of evidence supports the active 
transport of insulin past the blood brain barrier from the periphery (Schwartz et al. 1992; 
Banks 2004).  Indeed, peripheral manipulations of insulin are mirrored by alterations in 
CNS insulin (Schwartz et al. 1990).  Thus, the exponential growth in the number of 
individuals afflicted with peripheral insulin related disorders such as obesity and diabetes 
further necessitates a full appreciation of the role of insulin signaling pathways in the 
brain  
The notion that insulin signaling may be involved in the regulation of monoamine 
homeostasis began with studies that revealed striking alterations in the dopaminergic 
system of rodents rendered diabetic through streptozotocin (STZ) treatment, which 
results in necrosis of insulin producing pancreatic β cells (Chu et al. 1986; Karkanias et 
al. 1997; Saitoh et al. 1998).  Although these initial studies provided preliminary 
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evidence that insulin is capable of altering monoaminergic signaling in the brain, 
subsequent studies demonstrated specifically the ability of insulin to regulate DAT and 
thus dopaminergic signaling.  For example, tyrosine kinase inhibitors, which block the 
kinase activity of the insulin and insulin-like growth factor receptors were shown to 
reduce DA clearance due to a decrease in the surface expression levels of DAT (Doolen 
et al. 2001). Concurrently, other investigators expanded these results by illustrating that 
inhibition of downstream components of the insulin signaling pathway, such as 
phosphatidylinositol 3- kinase (PI3K) and Akt, also dramatically reduce DA clearance 
and surface expression of DAT (Carvelli et al. 2002; Garcia et al. 2005).  Furthermore, 
surface levels and function of DAT are significantly diminished in both STZ models of 
diabetes and diet-induced obese states of insulin resistant rats ((Williams et al. 2007) and 
unpublished data).  Thus, basal insulin signaling is critical for appropriate dopaminergic 
tone via its maintenance of DAT at the cell surface.  Given the importance of insulin 
signaling for maintaining DAT at the plasma membrane, researchers quickly realized the 
ability of insulin signaling to impact AMPH action in the brain.  For example, the 
reinforcing properties of AMPH are tremendously diminished in the STZ model of 
diabetes, as demonstrated by the AMPH self-administration paradigm (Galici et al. 2003).  
Additionally, selective inhibition of PI3K via LY294002 results in a dramatic reduction 
in AMPH‘s ability to elicit DAT-mediated DA efflux in heterologous cells, dopaminergic 
neurons, and in vivo within the striatum of rats as measured by both in vivo voltammetry 
and functional magnetic resonance imaging (Williams et al. 2007; Lute et al. 2008).  
These data suggest that kinases linked to both glucose homeostasis and food intake 
regulation are also capable of regulating the reward pathways in the brain that are 
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targeted by psychostimulants such as AMPH.  Although studies continue to elucidate 
new aspects of the insulin regulation of DAT, similar in-depth research on the role of 
insulin in the regulation of noradrenergic homeostasis is clearly lacking. 
In addition to disruptions in the dopaminergic system, early studies on diabetic 
rodents also revealed abnormalities in noradrenergic tone (Ganguly et al. 1986; Lucas et 
al. 1989; Lackovic et al. 1990; Shimizu 1991).  Differences in the types of animals 
studied and the regions of the nervous system examined, however, failed to offer a 
consensus on whether deficits in insulin signaling stimulate or depress noradrenergic 
function.  Despite these discrepancies in diabetic models, initial studies on insulin 
regulation of NET function were more consistent.  For example, insulin inhibits NE 
uptake in whole brain neuronal cultures, dissociated brain cells, and whole brain 
synaptosomes (Boyd et al. 1985; Boyd et al. 1986; Masters et al. 1987; Raizada et al. 
1988).  Furthermore, Figlewicz et al. demonstrated the ability of nanomolar 
concentrations of acute insulin to decrease NE uptake from both hypothalamic and 
hippocampal slices (Figlewicz et al. 1993).  Subsequently, these studies were extended to 
demonstrate that insulin also inhibits NE uptake in PC12 cells which endogenously 
synthesize NE and express NET (Figlewicz et al. 1993).  Since these original studies in 
the late 1980‘s and early 1990‘s insulin regulation of noradrenergic signaling and NET 
function has remained a relatively untouched area of research.  Indeed, only a single 
additional study on the topic was published in 2001, which in SK-N-SH cells 
demonstrated that insulin increases NE uptake in contrast to earlier studies in PC12 cells 
(Apparsundaram et al. 2001).  Thus, in this thesis, I explore the nature of insulin‘s 
regulation of NET with particular interest in how disruptions in this regulation have the 
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potential to impact monoamine homeostasis, behavior, and perhaps ultimately mental 
health. 
Monoamine Dysfunction and Disease 
 The notion that monoamine dysfunction in the nervous system may contribute to 
various neurological and psychiatric disorders has persisted nearly since their discovery 
as neurotransmitters in the brain.  Indeed, drugs that alter the monoaminergic systems 
have been utilized for the treatment of mental health disorders for over 50 years now.  In 
particular, the ability of the NE and DA systems to modulate attention, arousal, mood, 
food intake, reward, and memory has implicated them in mood disorders associated with 
deficits in these realms such as ADHD, schizophrenia, depression, anorexia, and 
substance abuse disorders.  In addition to mood disorders, these monoamines are also 
implicated in different neurological disorders such as Parkinson‘s disease and 
Alzheimer‘s disease.  Indeed, for the noradrenergic system in particular, a substantial loss 
of LC neurons is well documented in both of these devastating diseases (Chan-Palay et 
al. 1989).  For now, however, the focus will remain on evidence supporting a link 
between noradrenergic dysfunction and mood disorders with specific attention paid to 
those disorders in which disrupted insulin/Akt signaling has been preliminarily 
implicated, depression and schizophrenia.  Whereas the NE system received significant 
attention in early studies of mood disorders, in the last decade the plausibility of 
noradrenergic signaling involvement in such disorders has largely been ignored while 
hypotheses abound for the other monoamines such as DA and 5-HT.  Thus, it is 
absolutely imperative to remind ourselves of the plentiful evidence supporting a link 
between anomalous NE signaling and disease.   
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NE and Depression 
First and foremost, in the case of depression, LC activity and thus NE release in 
the brain is heavily affiliated with behaviors that are disturbed in depression such as 
sleep, attention, memory, and stress.  Furthermore, antidepressants that target NET and 
SERT, and thereby increase synaptic levels of NE and 5-HT in the brain, are still the 
primary treatment for the disorder.  Although SSRIs are more heavily used and 
researched in comparison to NSRIs, studies evaluating SSRIs relative to NSRIs suggest 
that the two classes of drugs are of similar efficacy (i.e. individuals treated with either of 
these on average show approximately a 50% improvement  in symptoms) (Anderson 
1998; Anderson 2000).  In addition to the effectiveness of targeting the noradrenergic 
system in depressed individuals, numerous studies investigating the levels of NE and its 
metabolites in depressed patients have revealed striking alterations in the system (Roy et 
al. 1985; Roy et al. 1988; Kelly et al. 1998; Ressler et al. 1999).  For example, a recent 
positron emission tomography (PET) study, revealed alterations in NE specifically within 
the PFC of patients with major depression (Fu et al. 2001).  However, a consensus from 
these types of studies on whether depressed patients are afflicted with excessive NE or 
too little NE is lacking.  Indeed depending on the individual study and the type of 
depressed individuals chosen for the study, the results can vary significantly.  This, 
perhaps, is not surprising considering the studies of LC activity, which demonstrate that 
non-moderate NE release regardless of whether it is too little or too much can have 
similar adverse consequences for behavior.  Thus, it is easy to imagine that individuals 
with either too little or excessive NE may manifest similar depression related symptoms.  
Or, perhaps, diminished NE levels may be characteristic of a particular subtype of 
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depression in comparison to another subtype defined by excessive levels of the 
monoamine, or even subtypes may exist where abnormalities in NE fail to contribute at 
all.  In addition to these issues, measurements of NE levels from humans are also 
particularly susceptible to changes in movement, exercise, stress, methodological 
differences, etc.  Thus additional research utilizing more advanced and reliable measures 
of NE as well as enhancements in research design (i.e. careful selection of research 
subjects for specific symptoms or subtypes of depression) is necessary to understand 
more clearly the abnormalities seen in the noradrenergic system during depression.  In 
addition to exploring alterations in NE itself, other studies have focused on other 
noradrenergic signaling components for connections to depression, such as α2 adrenergic 
receptors and TH.  Indeed, higher densities of α2 receptors have been demonstrated in the 
frontal cortex, hippocampus, temporal cortex, hypothalamus, and LC of depressed suicide 
victims in several reports (Meana et al. 1987; Meana et al. 1992; Gonzalez et al. 1994; 
Ordway et al. 1994; Callado et al. 1998).   Some studies have even shown evidence for 
altered α2 affinity and density on the platelets of depressed patients (Piletz et al. 1990).  
In the case of TH, studies are less consistent and some have shown increases in TH levels 
in the LC of depressed individuals while others have shown support for decreased TH 
(Biegon et al. 1992; Zhu et al. 1999).  Finally, catecholamine depletion studies in humans 
have also been preformed to provide evidence for a link between NE and depression.  In 
unaffected individuals catecholamine depletion will not precipitate depressive symptoms; 
however, similar treatment in subjects with a history of depression instigates expression 
of depressive symptoms (Salomon et al. 1997; Charney 1998; Berman et al. 1999).  
Altogether, while the precise nature of the noradrenergic system‘s contribution to 
44 
 
depression remains elusive divergent human studies of individuals with depression 
consistently supports the idea that noradrenergic dysfunction may contribute to aspects of 
this disorder. 
 
NE and Schizophrenia 
In the schizophrenia research field predominant hypotheses classically focus on 
dopaminergic dysfunction as a key component of the disorder, primarily due to the 
efficacy of D2 dopamine receptor (D2DR) antagonists in the treatment of the disorder.  
While other neurotransmitters, such as glutamate and 5-HT, are just beginning to receive 
attention in the field, investigation of noradrenergic contribution to the disorder is 
minimal to non-existent.  The role of NE, however, should not be overlooked, given early 
findings in the 1980‘s of elevated NE in the CSF and altered DBH activity in patients 
with schizophrenia (Farley et al. 1978; Breier et al. 1990; Maas et al. 1993; van Kammen 
et al. 1994).  Indeed, numerous studies have examined NE and its metabolites in the CSF 
of patients, and most often elevations in NE are seen in association with both negative 
and positive symptoms of the disorder.  Since these original observations, however, the 
reliability of such measurements has been brought into question, and consequently 
interest in NE as part of schizophrenia pathology has remained relatively shelved.  In 
addition to the well known positive symptoms of schizophrenia, the disorder is also 
characterized by a subset of negative symptoms which include deficits in cognition (i.e. 
attention and working memory).  As described previously, noradrenergic activity within 
the PFC is an essential component of cognitive function.  Thus more recent research has 
focused on the role of NE in the manifestation of negative symptoms associated with the 
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disorder.  For example, significant reductions in PFC NE have been seen in cognitively 
impaired schizophrenics relative to schizophrenics with low levels of cognitive deficits 
(Bridge et al. 1985; Bridge et al. 1987).  Consistently, enhanced NE turnover (i.e. reduced 
levels of NE and increased MHPG) in the NAcc has been associated with cognitive 
impairments in schizophrenics.  Despite growing interest, especially within the realm of 
the disorder‘s cognitive deficits, research on noradrenergic function in schizophrenia is 
still insufficient.  This point is further emphasized by the little recognized fact that all 
effective antipsychotics, typical or atypical, have been shown to block the noradrenergic 
α1 receptor as well as D2DRs (Cohen et al. 1986; Baldessarini et al. 1992).  It remains to 
be determined, however, whether this additional α1 receptor blockade is important for the 
efficacy of these drugs.  In summary, substantial research is needed to fully appreciate 
and understand the contribution of the noradrenergic system to schizophrenia in general 
and more specifically to particular symptoms of the disorder.   
 
NET Dysfunction and Disease 
Through its re-uptake of synaptic NE and other monoamines such as DA, NET is 
pivotal for maintaining the integrity of monoaminergic signaling in the brain and 
periphery (Iversen 1971; Pacholczyk et al. 1991; Xu et al. 2000; Moron et al. 2002).  
Thus, disruption of NET function has the potential to impact both autonomic function and 
mental health.  Indeed, studies supporting a direct link between transporter dysfunction 
and disease continue to accumulate.  The first of such studies revealed a pivotal role for 
aberrant NET function in the autonomic nervous system disorder, orthostatic intolerance 
(OI), a disease characterized by the inability of an individual‘s body to withstand the 
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physiological stressors associated with postural changes (i.e. moving from a sitting 
position to standing upright) (Shannon et al. 2000; Robertson et al. 2001; Hahn et al. 
2003). From this work, a single nucleotide polymorphism (SNP), alanine457proline 
(A457P), was identified in the transporter from a family of patients with OI.  
Interestingly, A457P NET cannot appropriately express at the surface, and in addition the 
mutant transporter acts in a dominant negative manner to further prevent the surface 
expression of wild-type NET resulting in severely deficient NE reuptake.  Thus, 
individuals with this particular allele experience dizziness, tachycardia, and fainting upon 
standing because of an inability to control synaptic levels of NE in the periphery.   
Since this original description of a direct role for anomalous NET function in 
disease, substantial effort has been invested in identifying other NET SNPs which may 
contribute to both autonomic and central nervous system disorders.  For example, as 
emphasized by the role of NET in OI, NE plays a critical role in the peripheral nervous 
system in the regulation of heart rate and blood pressure.  Not surprisingly then, several 
NET SNPs have been identified and associated with hypertension, and researchers 
continue to search for additional associations with other peripheral disorders such as 
myocardial ischemia, cardiomyopathy, etc. (Halushka et al. 1999; Rumantir et al. 2000; 
Ono et al. 2003; Hahn et al. 2005; Nonen et al. 2008).  As for monoamine related mood 
disorders, NET SNPs have not only been identified but they have also been functionally 
characterized (Hahn et al. 2005; Kim et al. 2006; Haenisch et al. 2008; Hahn et al. 2009).  
In the case of ADHD, for example, a SNP associated with the disorder was found within 
the promoter of the NET gene where it creates a novel repressor site and thus results in 
altered transcription of the transporter (Kim et al. 2006).  NET SNPs not associated with 
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particular disorders have also been identified and functionally characterized (Hahn et al. 
2005).  For some of these, subsequent to their functional investigations, association of the 
mutant transporters with particular disorders was soon to follow.  For example, the NET 
SNP F528C was first shown to have increased plasma membrane expression and function 
as well as deficits in antidepressant binding and PKC induced trafficking, before its 
association with major depression was described (Hahn et al. 2005; Haenisch et al. 2008).  
On the other hand, the list of newly identified, non-functionally characterized NET SNPs, 
that are associated with disorders such as depression, ADHD, OI, and hypertension 
continues to grow exponentially (Hahn et al. 2008; Kim et al. 2008; Nonen et al. 2008).  
Whereas the identification of NET SNPs offers new insight into the connection between 
monoamines and nervous system related disorders, it is important to remind ourselves 
that transporter function is sophistically regulated by a battery of other proteins and 
complex signaling pathways.  Thus, expanding research beyond the transporter itself, in 
an effort to encompass important regulators of these dynamically modulated proteins, 
promises to offer new and exciting insight into how aberrant monoamine transporter 
regulation may also contribute to disease states. 
 
Specific Aims 
Monoamine homeostasis in the nervous system supports a variety of vital 
functions ranging from mood, memory, and reward to sleep, heart rate, and food intake.  
As an integral component of this delicate system, transporters play the key role of 
monitoring monoamine synaptic availability.  Therefore, understanding the intricacies of 
how these transporters are regulated and function is absolutely imperative.  Indeed, 
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examples of aberrant transporter function linked to specific diseases emphasize this need.  
Here, of particular interest, is the role of insulin signaling in the regulation of NET.  
Today, as sedentary lifestyles and access to high fat, high sugar, food abounds, the 
number of individuals afflicted with disorders characterized by aberrant insulin signaling 
grow exponentially.  Thus, it is critical to understand how these changes impact 
transporter function and ultimately the brain and behavior.  As such, the specific aims of 
this project were to: 
 
I. Determine the role of insulin signaling in the regulation of NET in both the 
central nervous system (CNS) and the peripheral nervous system (PNS). 
II. Identify components of the insulin signaling pathway that are required for the 
regulation of NET. 
III. Study the physiological and behavioral consequences of manipulating this 
regulation in vivo.   
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CHAPTER II 
 
INSULIN REVEALS AKT SIGNALING AS A NOVEL REGULATOR OF 
NOREPINEPHRINE TRANSPORTER TRAFFICKING AND NOREPINEPHRINE 
HOMEOSTASIS* 
 
Abstract 
Noradrenergic signaling in the central nervous system plays an essential role in 
circuits involving attention, mood, memory, and stress as well as providing pivotal 
support for autonomic function in the peripheral nervous system. The high affinity 
norepinephrine (NE) transporter (NET) is the primary mechanism by which 
noradrenergic synaptic transmission is terminated. Data indicates that NET function is 
regulated by insulin, a hormone critical for the regulation of metabolism. Given the high 
co-morbidity of metabolic disorders such as diabetes and obesity with mental disorders 
such as depression and schizophrenia we sought to determine how insulin signaling 
regulates NET function and thus noradrenergic homeostasis. Here, we show that acute 
insulin treatment, through the downstream kinase protein kinase B (Akt), significantly 
decreases NET surface expression in mouse hippocampal slices and superior cervical 
ganglion neuron (SCGN) boutons (sites of synaptic NE release). In vivo manipulation of 
insulin/Akt signaling, with streptozotocin (STZ), a drug that induces a Type 1-like 
diabetic state in mice, also results in aberrant NET function and NE homeostasis. 
Notably, we also demonstrate that Akt inhibition or stimulation, independent of insulin, is 
* The work presented in this chapter is in press as Sabrina D. Robertson, Heinrich J.G. Matthies, Anthony 
W. Owens, Vidiya Sathananthan, Nicole S. Bibus Christianson, J. Philip Kennedy, Craig W. Lindsley, 
Lynette C. Daws, Aurelio Galli (J. Neuroscience) 2010 
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capable of altering NET surface availability. These data suggest that aberrant states of 
Akt signaling such as in diabetes and obesity have the potential to alter NET function and 
noradrenergic tone in the brain. Furthermore, they provide one potential molecular 
mechanism by which Akt, a candidate gene for mood disorders such as schizophrenia and 
depression, can impact brain monoamine homeostasis. 
 
Introduction 
Appropriate regulation of critical brain functions such as learning, memory, 
attention, sleep, mood, and stress depend on the fidelity of noradrenergic signaling in the 
nervous system. The norepinephrine transporter (NET) is fundamental for maintaining 
this fidelity by controlling both the duration and strength of NE signaling through its 
reuptake of synaptic NE (Iversen 1971; Pacholczyk et al. 1991; Bonisch et al. 2006). 
Indeed, disruption of NET function has been shown to directly impact both autonomic 
function and mental health (Ganguly et al. 1986; Klimek et al. 1997; Rumantir et al. 
2000; Shannon et al. 2000; Hahn et al. 2003; Hahn et al. 2005; Kim et al. 2006; Haenisch 
et al. 2008; Hahn et al. 2008; Hahn et al. 2009).   
Prior studies illustrate that NET function is dynamically regulated both by 
changes in transporter turnover rate and by trafficking of the transporter to and from the 
plasma membrane (Apparsundaram et al. 1998; Apparsundaram et al. 1998; Uchida et al. 
1998; Apparsundaram et al. 2001; Miner et al. 2003; Sung et al. 2003; Jayanthi et al. 
2004; Dipace et al. 2007). Importantly, previous studies implicate a clear role for insulin, 
a metabolic hormone, in the regulation of NET function. Indeed, insulin inhibits NE 
uptake in whole brain neuronal cultures, dissociated brain cells, and whole brain 
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synaptosomes (Boyd et al. 1985; Boyd et al. 1986; Masters et al. 1987; Raizada et al. 
1988). Furthermore, Figlewicz et al. demonstrated the ability of nanomolar 
concentrations of acute insulin to decrease NE uptake from both hypothalamic and 
hippocampal slices (Figlewicz et al. 1993). These studies were elegantly extended to 
demonstrate that insulin also inhibits NE uptake in PC12 cells which endogenously 
synthesize NE and express NET (Figlewicz et al. 1993). Conversely, more recent studies 
have shown in different preparations that insulin increases NE uptake (Apparsundaram et 
al. 2001). Our studies, both in vitro and in vivo, indicate that insulin plays an inhibitory 
role in the regulation of NET function by controlling its surface availability. Moreover, 
we reveal that protein kinase B (Akt), a multifunctional kinase downstream of numerous 
signaling pathways including insulin, is required for this insulin regulation. Importantly, 
we also show that Akt activity potently regulates NET surface levels independently of 
changes in insulin status.  
Diseases characterized by aberrant insulin and Akt signaling such as diabetes and 
obesity have a high co-morbidity with monoamine related mental disorders such as 
schizophrenia and depression (Mukherjee et al. 1989; Mukherjee et al. 1996; Lustman et 
al. 2005; Zhao et al. 2006). Our data reveal for the first time, Akt function as a potent 
regulator of NET activity/trafficking and thus provide an interesting and plausible link 
between metabolic dysfunction and mood disorders. Considering the identification of Akt 
as a candidate susceptibility gene in schizophrenia and perhaps depression (Hsiung et al. 
2003; Emamian et al. 2004; Karege et al. 2007; Arguello et al. 2008), these data also 
provide a plausible molecular mechanism linking anomalous Akt function to altered 
monoamine homeostasis which is characteristic of these disorders. 
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Results 
Acute insulin treatment decreases NET surface levels in the central and peripheral 
nervous systems as well as in heterologous preparations  
NET plays a pivotal role in controlling global noradrenergic tone and its aberrant 
regulation has the capacity to impact mental health (Ganguly et al. 1986; Klimek et al. 
1997; Rumantir et al. 2000; Shannon et al. 2000; Hahn et al. 2003; Hahn et al. 2005; Kim 
et al. 2006; Haenisch et al. 2008; Hahn et al. 2008; Hahn et al. 2009). Evidence indicates 
that insulin signaling regulates NE homeostasis (Shimizu 1991; Figlewicz et al. 1993; 
Figlewicz et al. 1996; Barber et al. 2003). Thus, understanding how insulin/Akt fine tunes 
NET trafficking and/or function may provide an interesting and plausible link between 
metabolic dysfunction and mental disorders such as depression and schizophrenia 
(Mukherjee et al. 1989; Mukherjee et al. 1996; Lustman et al. 2005; Zhao et al. 2006). 
Our goal is to determine the nature of insulin‘s regulation of NET in the central and 
peripheral nervous systems. Here, we provide evidence for the role of insulin in the down 
regulation of the transporter from the surface. Utilizing a new assay, slice biotinylation, 
we show for the first time that acute in vitro treatment of mouse hippocampal slices with 
1 nM insulin significantly diminishes surface levels of NET (Fig. 8A). Tyrosine 
hydroxylase (TH), a cytosolic protein, is detected primarily in the total fraction and 
comprises less than 1% of the surface fraction. Therefore, these data demonstrate that the 
biotinylated fraction represents cell surface proteins and speaks to the health of 
noradrenergic TH positive neurons in the assay. These results provide an ANOVA 
followed by Dunnett‘s test; N=3-8). molecular mechanism to describe the decreased NE 
uptake described by Figlewicz and collaborators (Figlewicz et al. 1993). In addition to
53 
 
 
 
 
 
 
 
Figure 8. Insulin stimulation decreases NET surface levels in mouse hippocampal slices, 
SCGN boutons, and hNET cells. A, (Left) Mouse hippocampal slices treated with either 1 
nM insulin or vehicle (CTR) for 20 minutes. Shown are representative Western blots of 
NET surface and total levels, as well as surface Na
+
/K
+
 ATPase levels to serve as a 
loading control. (Center) Quantification of the insulin-induced decrease in NET surface 
expression is also shown. Data are normalized to total NET and expressed as a percent of 
control (mean ± s.e.m, **P<0.01 by Student‘s t-test; N=7-6). (Right) Representative 
Western blot of TH levels in the biotinylated and total fractions. B, (Left) Confocal 
images of NET distribution in SCGN boutons treated with vehicle (CTR), 1 nM, or 100 
nM insulin for 20 minutes. Insulin treatments induce an increase in intracellular NET 
accumulation. (Right) NET fluorescence intensity plots (see Materials and Methods) 
across SCGN boutons treated with vehicle (open squares) and 100 nM insulin (solid 
squares). The normalized NET intensity was plotted against the normalized distance as 
described in Material and Methods (mean ± s.e.m, P<0.0001 by Two-way ANOVA; 
N=18-8 boutons). Panel B special thank you to Heinrich Matthies. C, (Left) Acute 100 
nM insulin treatment for 20 minutes significantly increases NET and Rab11a 
colocalization in SCGN boutons with respect to vehicle (CTR). (Right) Quantification of 
NET and Rab11a colocalization using the ICQ analysis (see Materials and Methods). 
Insulin significantly increases NET colocalization with the strictly intracellular protein 
Rab11a (mean ± s.e.m, ***P<0.001 by Student‘s t-test; N=23). Panel C special thank you 
to Heinrich Matthies D, Insulin decreases NET surface levels in a time dependent manner 
in hNET cells. (Left) Shown are representative Western blots for surface and total NET 
in cells treated with vehicle (CTR) or insulin at varying time points. (Center) Western 
blot analysis showed that 1 µM of insulin exposure significantly decreases surface NET. 
Data are normalized to total NET and expressed as a percent of control (mean ± s.e.m, 
*P<0.05 by one-way ANOVA followed by Dunnett‘s test; N=4). (Right) The cytosolic 
kinases ERK1/2 are found in the total fraction but not in the surface fraction. E,  
Quantitation of Western blots from hNET cells exposed to 5 minutes of insulin at varying 
concentrations (mean ± s.e.m, *P<0.05 and **P<0.01 by one-way ANOVA followed by 
Dunnett‘s test; N=3-8). 
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revealing a role for insulin in the regulation of NET trafficking in slices from the central 
nervous system, we also sought to demonstrate the ability of insulin to regulate NET in 
the peripheral nervous system. 
Superior cervical ganglion neurons (SCGN) enable us to investigate the role of 
insulin in the peripheral nervous system. Importantly, due to the large diameter (2-4 
micron) of SCGN boutons, these cultures also provide us with the unique opportunity to 
study NET regulation at presynaptic sites of NE release (Matthies et al. 2009). Before 
exploring the role of insulin in the regulation of these noradrenergic neuronal cultures, we 
sought to demonstrate that these cells express the insulin receptor (IR). Not only is IRβ 
staining abundant throughout the SCGN (data not shown), the receptor is also specifically 
localized to single boutons (Appendix Fig. A1). After demonstrating the presence of IRs 
on noradrenergic SCGNs, we serum-starved the SCGN cultures for 1 hour and then 
treated them with vehicle, 1 nM, or 100 nM insulin for 20 minutes and discovered a 
dramatic increase in intra-bouton NET immunoreactivity (Fig. 8B). We quantified these 
observations using pixel intensity plots of a single confocal section (see Materials and 
Methods). Pixel intensity plots were obtained from a straight line drawn across the widest 
region of the approximately spherical bouton, starting at the brightest spot of 
fluorescence on one side of the bouton. The subsequent line spanned the entire diameter 
of the bouton, and was extended beyond the limits of the bouton to provide a background 
value. This line was then divided arbitrarily into 20 bins, and the NET fluorescence 
intensity of each bin was normalized to the fluorescence intensity of the brightest spot on 
the perimeter of the bouton (100%). The mean ± s.e.m. pixel intensity (normalized NET 
intensity) is plotted against each bin (normalized distance). Figure 8B shows that in 
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insulin-treated neurons, the NET intra-bouton fluorescence signal is significantly higher 
than in vehicle-treated neurons as shown by a shift in the curve upward. This 
demonstrates that NET is accumulated intracellularly upon 100 nM insulin treatment. Our 
result that 100 nM insulin treatment significantly increases intracellular NET 
accumulation is further substantiated by co-staining for the recycling endosome marker 
Rab11a. Rab11a is a GTPase that plays an important role in the trafficking of numerous 
proteins including NET via ―slow‖ recycling endosomes (Matthies et al. 2010). 
Importantly, we show that 100 nM insulin exposure significantly enhances NET 
colocalization with the strictly intracellular protein Rab11a (Fig. 8C). This increase in 
colocalization was quantified by utilizing the intensity correlation analysis/intensity 
correlation quotient (ICA/ICQ) method (Li et al. 2004). We calculated the ICQ of NET 
and Rab11a in boutons and found a significant increase upon 100 nM insulin treatment 
(Fig. 8C). 
Our results, for the first time, demonstrate the ability of insulin to induce NET 
trafficking, in both the central and peripheral nervous systems. Furthermore, this 
regulation is seen not only at the level of hippocampal slices but also at the level of a 
single bouton. In order to dissect this insulin-induced regulation further, we chose to 
study it in a more malleable system, Chinese hamster ovary (CHO) cells with stably 
transfected HA-tagged human NET (hNET cells). Here we validate this model by 
demonstrating that insulin-induced trafficking of NET away from the cell surface is both 
time and dose-dependent in hNET cells. Incubation of hNET cells for 5 minutes with 1 
µM insulin results in a significant reduction of NET in the biotinylated fraction (Fig. 8D). 
Additionally, 5 minutes of insulin exposure at varying doses results in significant 
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decreases in surface NET (Fig. 8E). In addition, to insulin‘s ability to modulate NET 
surface availability in these cells, uptake assays also support an insulin mediated decrease 
in NET function. Consistent with previous results, our data reveal a significant decrease 
in [
3
H] DA uptake after exposure to 10 nM insulin (Vehicle 1.162 ± 0.020 and Insulin 
0.986 ± 0.020 pmol*well
-1
*min
-1; mean ± s.e.m., **P<0.01 by Student‘s t-test; N=4-3). 
The time and dose dependent changes in NET surface levels and function in response to 
insulin in hNET cells illustrates the utility of this system for studying the intricacies of 
regulation of this transporter by insulin. In particular, we sought to uncover specifically 
which components of the insulin signaling pathway are essential for insulin-induced NET 
regulation. 
 
Insulin requires Akt to induce changes in NET surface expression  
 Insulin receptors are tyrosine kinase receptors which upon activation recruit both 
phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) to the membrane for 
subsequent activation. Akt, in particular, is a multifunctional kinase that is involved with 
diverse pathways in cell growth, survival, metabolism etc. Indeed aberrant Akt function 
has been implicated in a vast array of disorders such as diabetes, obesity, cancer, 
autoimmune disease, as well as mental disorders such as depression and schizophrenia 
(Hsiung et al. 2003; Emamian et al. 2004; Dummler et al. 2007; Karege et al. 2007; 
Manning et al. 2007; Krishnan et al. 2008). While genetic evidence for the involvement 
of Akt in mental disorders grows, how Akt dysregulation impacts these diseases at the 
molecular level is still unclear. Importantly, it has been shown that Akt is critical for the 
regulation of other transporters such as the glucose and dopamine transporter by insulin 
58 
       
(Carvelli et al. 2002; Garcia et al. 2005; He et al. 2007; Zaid et al. 2008). Here, we 
investigate whether Akt plays a critical role in the insulin regulation of NET by utilizing 
the isoform specific Akt1, Akt2, or Akt1/2 inhibitors (DeFeo-Jones et al. 2005; Lindsley 
et al. 2005; She et al. 2008). These inhibitors are allosteric inhibitors that require the 
pleckstrin homology (PH) domain of Akt to inhibit phosphorylation and activation of the 
kinase. Although they require this domain for inhibition, binding of the inhibitors to Akt 
requires the whole protein since in vitro assays show the PH domain alone is insufficient 
for binding. Furthermore, the inhibitors reversibly inhibit both the activation and activity 
of Akt and are highly specific for Akt compared to other similar kinases such as PKA, 
PKC, and SGK. In our studies, 5 µM application of the dual Akt1/2 inhibitor to hNET 
cells 30 minutes prior to and during insulin exposure prevents insulin stimulated 
trafficking of NET away from the surface (Fig. 9A). In addition to pharmacological 
blockade, we also utilize a ―kinase-dead‖ dominant negative mutant (K179R) construct of 
Akt (Akt-KD) to show that Akt activity is required for insulin induced regulation of the 
transporter (Garcia et al. 2005). Consistent with our previous results, transient 
transfection of hNET cells with the Akt- KD construct 48 hours prior to insulin 
application abolishes insulin stimulated trafficking of NET away from the plasma 
membrane (Fig. 9B). While both genetic and pharmacological inhibition of Akt prevents 
insulin induced regulation of the transporter in hNET cells, we sought to extend these 
observations to a more physiologically system.  
 Given the abundance of NET expression in mouse hippocampal slices, we chose 
this experimental system to investigate the role of Akt in the insulin regulation of NET. 
While all three isoforms of Akt are expressed within the brain, the distribution and
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Figure 9. In hNET cells, Akt inhibition and Akt-KD overexpression prevents insulin 
induced NET trafficking. A, (Left) Representative Western blot of NET from hNET cells 
incubated in medium containing 0.1% DMSO or the dual Akt 1/2 inhibitor (5 µM) 
dissolved in DMSO 30 min prior to and during either vehicle (CTR) or insulin treatment 
(5 min). The absence of cytosolic ERK1/2 bands in the biotinylated fraction supports the 
integrity of the biotinylation assay. (Right) Quantitation of Western blots represented by 
the left panel. Data are normalized to total NET and expressed as a percent of control 
(mean ± s.e.m, **P<0.01 by one-way ANOVA followed by Dunnett‘s test; N=4-5). B, 48 
hours prior to treatment with vehicle (CTR) or insulin (5 min), hNET cells are transfected 
with either Akt-KD, a kinase dead dominant negative form of Akt or pcDNA3.1 (vector). 
(Left) A representative Western blot shows that overexpression of Akt-KD inhibits the 
insulin induced reduction of surface NET compared to vector transfected control. 
Overexpression of Akt-KD was confirmed by probing for total levels of Akt. The 
cytosolic kinases ERK1/2 are found in the total fraction but not in the surface fraction. 
(Right) Quantitation of multiple Western blots represented by the left panel. Surface NET 
is normalized to total NET levels and expressed as a percent of control (mean ± s.e.m, 
**P<0.01 by one-way ANOVA followed by Dunnett‘s test; N=4-5). 
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differences in their expression across various regions of the brain is relatively 
uncharacterized (Easton et al. 2005). We anticipate that for Akt to regulate the transporter 
it should be localized in the same neuronal domain. Indeed, NET, Akt1, and Akt2 co-
staining of slices reveals that Akt1 and Akt2 are heavily expressed in NET positive 
hippocampal terminals (Fig. 10A). Thus, Akt is poised for regulating the transporter in 
hippocampal slices. Consistent with these findings, insulin-stimulated decreases in NET 
are abolished by pre-treatment with either the Akt1 or Akt2 inhibitor for 1 hour prior to 
and during insulin exposure (Fig. 10B). These data demonstrate that insulin-induced 
down-regulation of NET requires Akt activity. Interestingly, changes in the 
phosphorylation status of Akt at serine residue 473, which relates to Akt activation, 
correlate well with changes in NET surface levels (Fig. 10C). This correlation is seen 
consistently throughout our studies and led us to hypothesize that Akt alone, which can 
be stimulated by numerous pathways, is a pivotal regulator of the transporter. Before 
investigating the effects of altering Akt activity independent of insulin signaling, 
however, we sought to determine if in vivo manipulation of insulin and Akt signaling 
results in significant changes in NET regulation and consequential monoamine 
homeostasis. 
 
Hypoinsulinemic mice have reduced Akt phosphorylation, enhanced NE levels, and 
elevated NET surface expression/function  
To induce a hypoinsulinemic state, mice were injected with streptozotocin (STZ), 
a selectively toxic compound targeting the insulin producing pancreatic beta cells 
(Lenzen 2008).  These mice display hallmarks of hypoinsulinemia such as aberrant 
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Figure 10. Akt1 and Akt2 colocalize with NET at terminals in mouse hippocampal 
slices, and their inhibition precludes insulin stimulated decreases in surface NET. A, 
Confocal images of NET (green), Akt1 (red top panel), and Akt2 (red bottom panel) 
immunoreactivity in mouse hippocampal slices. The merge panels provide evidence of 
colocalization between NET and both isoforms of Akt. B, Mouse hippocampal slices 
were treated with vehicle or the specific isoform inhibitor for Akt1 or Akt2 (12 µM) for 
40 minutes prior to and during 1 nM insulin treatment for 20 minutes. (Left) Shown is a 
representative Western blot of surface and total levels of NET while surface Na
+
/K
+
 
ATPase levels serve as a loading control. TH is detected in the total fraction but absent in 
the surface fraction. (Right) Quantification of multiple Western blots represented by the 
left panel. Surface NET is normalized to total NET and expressed as a percent of control 
(mean ± s.e.m, **P<0.01 by one-way ANOVA followed by Dunnett‘s Test; N=10-7). C, 
(Left) Representative Western blot from the same mouse hippocampal slice samples used 
for quantitation in panel B probed for phosphorylated Akt at serine residue 473 
(pAkt473) and total levels of Akt. (Right) Quantification of pAkt473 levels in slices 
treated as in panel B. pAkt473 levels are expressed as a percent of control (mean ± s.e.m, 
*P<0.05, by one-way ANOVA followed by Dunnett‘s Test; N=8-9). 
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glucose regulation, hyperphagia, hypouria, etc (Hernandez et al. 1972; Bell et al. 1983). 
In our studies, mice received one 200 mg/kg i.p. injection of STZ, and 48 hours later 
blood glucose levels were measured to confirm drug efficacy. Control mice, which 
received vehicle injections, maintained normal glucose levels while STZ injected mice 
showed aberrantly elevated levels of blood glucose (Appendix Fig. A2). After 
measurement of blood glucose levels, mice were left untreated in the STZ-induced 
diabetic state for 7 to 10 days and were then sacrificed for biochemical studies. STZ mice 
display deficits in Akt phosphorylation at ser473 in the hippocampus, which is 
accompanied by an increase in NE tissue content in the region (Fig. 11A, B). Importantly, 
studies show that appropriate NET function is critical for regulating NE tissue content 
(Xu et al. 2000). Thus, given the deficits in Akt phosphorylation and the significant 
elevation of NE tissue content, we hypothesize that these mice will display significantly 
enhanced NET surface levels. Moreover, evidence from previous studies show that STZ 
rats have elevated steady state levels of NET mRNA in the locus coeruleus (Figlewicz et 
al. 1996). Importantly, hippocampal slice biotinylation reveals a significant increase in 
surface NET in mice with STZ-induced hypoinsulinemia (Fig. 11C). To determine if 
enhanced surface expression of NET in hippocampal slice preparations from STZ-treated 
mice results in increased NE clearance in hippocampus in vivo, we utilized high speed 
chronoamperometry (HSCA). Clearance rate of NE locally injected into the dentate gyrus 
was significantly increased in STZ treated mice, as indicated by the decreased time 
required for the NE signal to diminish in STZ mice as compared with saline treated mice 
(Fig. 11D, left panel). Consistently, the average clearance rate of NE over a range of 
concentrations, measured as described in Material and Methods, was significantly 
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Figure 11. STZ-induced hypoinsulinemia decreases hippocampal Akt phosphorylation 
while significantly increasing NET surface expression and function. Mice were injected 
with either vehicle (CTR) or 200mg/kg i.p. STZ to mimic a type I diabetic state as 
described in Materials and Methods. A, (Left) Representative Western blot of pAkt473 
and total Akt levels in mouse hippocampal slices from CTR or STZ mice. (Right) 
Quantitation of pAkt473 levels from CTR and STZ mouse hippocampal slices. Data are 
represented as percent of CTR (mean ± s.e.m, *P<0.05 by Student‘s t-test; N=14-11). B, 
Tissue content of norepinephrine as measured by HPLC from hippocampal homogenates 
in CTR versus STZ mice (mean ± s.e.m, *P<0.05 by Student‘s t-test; N=9-8). C, (Left) 
Shown is a representative Western blot of surface and total levels of NET from 
hippocampal slices of either CTR or STZ mice. Surface Na
+
/K
+
 ATPase levels serve as a 
loading control. (Center) Quantitation of Western blots represented by the left panel. 
Surface NET is normalized to total levels of NET and expressed as percent of CTR 
(mean ± s.e.m, *P<0.05 by Student‘s t-test; N=14-11). (Right) The absence of cytosolic 
TH bands in the biotinylated fraction supports the integrity of the hippocampal slice 
biotinylation assay. D, (Left) Oxidation currents (converted to µM concentration using a 
calibration factor determined in vitro) produced by pressure ejection of 0.8 to 60 pmol of 
NE into the dentate gyrus region of the hippocampus of anaesthetized CTR and STZ 
mice. Corresponding summary data for the rates (nM/s) (Right) and time (s) (Bottom) of 
NE clearance plotted as a function of increasing concentrations of NE (CTR n=8; STZ 
n=7; Rate: main effect treatment, p=0.0453; main effect NE concentration, p<0.0001; 
Time: main effect treatment, p=0.0255; main effect NE concentration, p<0.0001; by Two-
way ANOVA with Bonferroni post-hoc comparisons, *p<0.05) Panel D courtesy of 
Anthony Owens and Lynette Daws. 
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enhanced in STZ mice as compared to control animals, such that the apparent maximal 
velocity for NE clearance was increased approximately 2-fold compared to control mice 
(Fig. 11D, right panel). Similarly, the average time required for NE clearance (NE 
clearance time) over the same range of concentrations was significantly reduced in STZ 
treated mice (Fig. 11D, bottom panel). Thus, STZ mice display aberrant Akt regulation 
and increased NE tissue content in the hippocampus which corresponds with increased 
NET surface expression and function. Importantly, the STZ-induced diabetic mice 
display normal protein levels of other noradrenergic markers in the hippocampus such as 
TH (CTR N=9 100.0 ± 5.5; STZ N=11 94.5 ± 7.2; unpaired T-Test p=0.57) and 
dopamine beta hydroxylase (CTR N=7 100.0 ± 8.5; STZ N=9 101.7 ± 8.2; unpaired T-
Test p=0.89). These data indicate that changes in NE tissue content correlates with 
altered NET surface expression and function and are not due to changes in NE synthesis. 
In addition, to support our hypothesis that hypoinsulinemia induced by STZ underlies the 
alterations observed in NET expression and function, we sought to reverse these deficits 
in vitro and in vivo with acute insulin treatment. Again, STZ treated mice had 
significantly reduced levels of Akt ser473 phosphorylation (Fig. 12A) and enhanced 
surface expression of NET (Fig. 12B) in biotinylated hippocampal slices relative to 
control mice. However, 1nM insulin treatment for 20 minutes restores Akt 
phosphorylation levels and surface expression of the transporter to control levels (Fig. 
12A, B). Thus, acute in vitro insulin treatment is sufficient to rectify STZ-induced 
alterations in hippocampal preparations. To determine if a similar rescue is possible in 
vivo we again utilized HSCA.  As before, the average time required for NE clearance was 
significantly reduced, indicating enhanced NET function, in STZ treated, 
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hypoinsulinemic mice, relative to saline treated control mice (Fig. 12C, left panel). 
Similar to our in vitro paradigm, local infusion of insulin (10 μM / 100 nL to deliver 1 
pmol) was then utilized in the dentate gyrus of STZ mice in an attempt to rectify the 
changes observed in NET function. First, exogenous NE was locally applied (200 μM / 
10 nL to deliver 2 pmol) to achieve reproducible signals with amplitudes recorded at the 
carbon fiber electrode in the range of 1 μM. Insulin was then infused and two minutes 
later NE was applied again. Importantly, insulin itself did not produce any 
electrochemical signal. Exogenous insulin application 5 minutes before NE infusion, 
however, significantly increased the time required for NE to clear from the extracellular 
fluid in the dentate gyrus thus implying a significant reduction in NET function (Fig. 
12C, center and right panel). The ability of in vitro and in vivo insulin application to 
restore STZ-induced deficits further supports the notion that peripheral hypoinsulinemia 
underlies NET dysfunction in these mice.  Thus, our data from biotinylated hippocampal 
slices and in vivo HSCA in STZ-induced diabetic mice show for the first time, that in 
vivo manipulation of insulin levels in the periphery impacts both Akt 
signaling/phosphorylation and NET function in the brain with consequences for 
monoamine homeostasis.  
 
Akt signaling regulates NET surface availability in hNET cells, SCG neurons, and in 
cortical slices following in vivo antipsychotic treatment 
 We hypothesize that manipulation of Akt signaling either by pharmacological 
means or receptor stimulation, independently of insulin, alters the surface availability of 
NET. To investigate if Akt signaling is capable of regulating NET trafficking, we 
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exposed hNET cells to the Akt1/2 inhibitor (5 µM) for varying time periods (Fig. 13A). 
Inhibition of Akt significantly increased NET surface expression in a time-dependent 
manner. Importantly, this pharmacological manipulation of Akt is independent of insulin 
status. To determine if Akt regulates NET at sites of NE release, we extended these 
studies to boutons of SCGN cultures. Co-staining of SCGN cultures for NET, Akt1, and 
Akt2 indicates that Akt is indeed present in the bouton and poised for regulation of the 
transporter (Appendix Fig. A3). Given the close proximity of both Akt isoforms to NET 
in the SCGN boutons, we exposed SCGN cultures to vehicle, Akt1 inhibitor, or Akt2 
inhibitor for 1 hour to determine if both isoforms are capable of driving NET to the 
surface. In order to allow for Akt signaling inhibition by the Akt inhibitors the neurons 
were not serum starved. Here we show, at sites of synaptic NE release, that incubation of 
cultures with either the Akt1 or Akt2 isoform specific inhibitors results in a significant 
increase in NET immunoreactivity on the perimeter of the bouton (Fig. 13B). Thus, both 
Akt1 and Akt2 are capable of regulating NET surface availability in SCGN. Again, we 
quantified these observations using pixel intensity plots of a single confocal section (see 
Materials and Methods). Upon Akt inhibition, the Pixel intensity plots reveal a significant 
downward shift, indicating an increase in NET surface levels in response to Akt 
inhibition. Furthermore, the average NET intensity across inner bins (bins 3-17) reveals a 
significant decrease in NET immunoreactivity within the bouton in the presence of either 
Akt inhibitor (Fig. 13B, inset). These data demonstrate, for the first time, that Akt activity 
is a potent regulator of NET.   
Next, we determined if activation of Akt by signaling pathways distinct from 
insulin are capable of altering NET surface expression. Numerous studies have shown 
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Figure 13. Basal Akt inhibition significantly increases NET surface expression. A, hNET 
cells are treated with vehicle (CTR) or the dual Akt1/2 inhibitor (5 µM) for varying 
amounts of time. (Left) Shown is a representative Western blot of surface and total levels 
of NET after vehicle or Akt1/2 inhibitor treatment. Cytosolic ERK1/2 bands are not 
present in the surface fraction. (Right) Quantitation of the increase in NET surface 
expression induced by Akt inhibition is also shown. Surface NET is normalized to total 
levels of NET and expressed as percent of CTR (mean ± s.e.m, *P<0.05 by one-way 
ANOVA followed by Dunnett‘s Test; N=6-4). B, Mouse SCGNs were cultured and 
processed for immunocytochemistry as described in Material and Methods. (Top Left) 
Confocal images of NET immunoreactivity in SCGN cultures treated with vehicle or 12 
µM of either the Akt1 or Akt2 inhibitor for 1 hour. (Bottom) Analysis of intensity plots 
spanning SCGN boutons. The normalized NET intensity is plotted against the normalized 
distance as described in Material and Methods (mean ± s.e.m, P<0.0001 by Two-way 
ANOVA; N=14). (Dotted Inset) The average NET intensity across bins 3-18, which 
represent bins that are within the interior of the bouton, in CTR, Akt1 inhibition, or Akt2 
inhibition conditions (mean ± s.e.m, **P<0.01 by one-way ANOVA followed by 
Dunnett‘s Test; N=14). 
73 
       
 
74 
       
that antipsychotics, such as clozapine, influence the phosphorylation status and activity of 
Akt in the cortex (Emamian et al. 2004; Kang et al. 2004; Roh et al. 2007). Our evidence 
suggests that alterations in the phosphorylation status of Akt correlate well with changes 
in NET surface expression. Thus, we determined if in vivo i.p. injections of clozapine are 
capable of altering both the phosphorylation state of Akt at ser473 as well as surface 
levels of NET. Mice received 30 mg/kg i.p. single injections of clozapine and one hour 
after injection the mice were sacrificed and cortical slices were taken and biotinylated to 
examine both Akt phosphorylation and surface levels of NET. As expected, clozapine 
treatment significantly enhanced phosphorylation of Akt at ser473 in the cortex while 
total levels remained unaltered (Fig. 14A). Importantly, this increase in Akt 
phosphorylation is accompanied by a significant decrease in the levels of surface NET 
(Fig. 14B). Thus, activation of Akt through receptor signaling distinct from that of insulin 
alters the dynamics of NET surface expression.  
 
Discussion 
Through its re-uptake of synaptic NE and other monoamines such as DA, NET is 
pivotal for maintaining the integrity of monoaminergic signaling in the brain and 
periphery (Iversen 1971; Pacholczyk et al. 1991; Xu et al. 2000; Moron et al. 2002). NET 
function is intricately controlled not only through regulation of transporter activity but 
also through the dynamic trafficking of the transporter to and from the plasma membrane 
(Apparsundaram et al. 1998) (Apparsundaram et al. 2001; Sung et al. 2003; Wersinger et 
al. 2006; Dipace et al. 2007). Importantly, single nucleotide polymorphisms in NET that  
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impact surface availability have been shown to be directly linked to both central and 
peripheral nervous system disorders, such as depression, ADHD, orthostatic intolerance, 
and blood pressure abnormalities (Halushka et al. 1999; Hahn et al. 2003; Hahn et al. 
2005; Haenisch et al. 2008; Hahn et al. 2009). Thus, the ability of abnormal NET surface 
expression to impact mental health and autonomic function makes it imperative that we 
understand how dysregulation of signaling pathways linked to these disorders impacts 
NET function. Notably, aberrant Akt signaling has been implicated in diseases such as 
diabetes and obesity, which have a high co-morbidity with monoamine related mental 
disorders, as well as with the pathology of schizophrenia and depression (Mukherjee et 
al. 1989; Mukherjee et al. 1996; Hsiung et al. 2003; Emamian et al. 2004; Lustman et al. 
2005; Zhao et al. 2006; Karege et al. 2007; Krishnan et al. 2008). Here, our goal was to 
characterize how changes in Akt signaling, regulates NET function in the nervous 
system. 
We demonstrate for the first time, that insulin and Akt signaling are capable of 
fine tuning NET surface levels and function in both the central and peripheral nervous 
systems. We show that acute insulin treatment significantly decreases NET surface 
availability in mouse hippocampal slices, at sites of synaptic NE release (SCGN 
boutons), and in heterologous cells. Moreover, our studies demonstrate that Akt is 
required for insulin regulation of NET. Consistently, in vivo manipulation of insulin 
signaling in the periphery via STZ treatment, results in aberrant Akt signaling in the 
hippocampus, and this deficit correlates with enhanced NE levels, NET surface 
expression, and NE clearance. The aberrant NE levels and NET regulation in STZ-
induced diabetic mice provides a strong proof of principle, that metabolic dysfunction in 
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the periphery has the potential to impact NET function and monoamine homeostasis in 
the brain. These data provide one plausible avenue to explain the depressive-like 
behavioral deficits observed in diabetic rodents (Hilakivi-Clarke et al. 1990). STZ-
induced diabetic mice undergo physiological changes beyond hypoinsulinemia, and 
therefore we cannot exclude the possibility that these changes in NET expression are 
exclusively due to insulin deficits. Still, our in vitro data strongly indicate a direct role for 
insulin in regulating NET surface levels. Furthermore, the ability of acute insulin 
treatment in STZ hippocampal slices to restore NET surface levels and phosphorylation 
of Akt to control levels, as well as its ability to restore NET function in STZ animals in 
vivo supports our notion that hypoinsulinemia underlies these alterations. Altogether, 
these data provide convincing support for an inhibitory role of insulin/Akt signaling in 
the regulation of NET function, and importantly, this regulation of NET in the brain can 
be altered by abnormal insulin signaling in the periphery. 
Interestingly, this down regulation of NET in response to insulin is opposite to the 
effect of insulin signaling in the regulation of the dopamine transporter (DAT). For 
example, early studies showed that in vivo manipulation of insulin levels via STZ 
treatment and food deprivation results in decreased DAT mRNA and DAT-mediated DA 
uptake respectively (Figlewicz et al. 1996; Patterson et al. 1998). More recent studies 
confirm these original observations and substantial evidence supports the notion that 
insulin/PI3K/Akt signaling is critical for maintaining basal levels of DAT at the surface 
(Carvelli et al. 2002; Galici et al. 2003; Garcia et al. 2005; Owens et al. 2005; Zhen et al. 
2006; Wei et al. 2007; Williams et al. 2007; Lute et al. 2008; South et al. 2008). This 
ability of insulin to differentially regulate DAT and NET surface expression is intriguing 
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given the high homology of the two transporters, and thus speaks to the specificity of 
insulin signaling in the regulation of monoamine homeostasis.  
In addition, to describing the nature of insulin‘s regulation of NET we also 
establish a novel role for Akt in controlling NET surface availability. We show that Akt 
inhibition, independent of insulin, in heterologous cells and SCGN boutons results in 
enhanced NET surface expression. Indeed, overall, our studies show that NET surface 
expression correlates well with the phosphorylation status of Akt at ser473. Therefore, 
Akt is not only required for insulin regulation of the transporter, but manipulation of Akt 
alone impacts NET surface availability. Distinct signaling pathways such as receptor 
tyrosine kinase (RTK), integrin, and G-protein coupled receptor (GPCR) signaling 
converge on Akt. Thus, divergent signaling pathways have the potential to similarly 
impact NET function via Akt signaling as a final common pathway. Indeed, here we 
demonstrate that similar changes in NET surface availability can be induced by either 
stimulation of insulin signaling or manipulation of GPCR signaling with an antipsychotic. 
The ability of the atypical antipsychotic clozapine, which can target α2-adrenergic 
receptors present on presynaptic noradrenergic terminals, to enhance Akt phosphorylation 
at ser473 is well documented in the cortex (Ashby et al. 1996; Emamian et al. 2004; 
Kang et al. 2004; Karkoulias et al. 2006; Roh et al. 2007). We show that i.p. injection of 
clozapine not only increases Akt ser473 phosphorylation, but also, similar to acute insulin 
treatment, it stimulates a subsequent decrease in NET surface expression. These data 
substantiate the hypothesis that completely distinct signaling pathways which converge 
on Akt have the potential to similarly influence NET availability and function. In 
addition, the ability of clozapine to manipulate the surface availability of NET could be 
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important for its enhanced efficacy in the treatment of cognitive symptoms associated 
with schizophrenia (Woodward et al. 2005). Indeed, a number of clinical trials utilizing 
NET specific inhibitors are ongoing and promise to reveal if NET specific inhibition will 
prove effective in treating schizophrenia cognitive symptoms such as poor concentration 
and memory deficits (clinicaltrials.gov).  
The importance of the discovery of Akt as a potent regulator of NET is further 
emphasized when one considers the wealth of information supporting a role for Akt 
dysfunction in the development of mental disorders such as schizophrenia and 
depression. A link between Akt and schizophrenia was first described in (Emamian et al. 
2004). The authors revealed decreased levels of Akt protein in lymphocytes and post-
mortem brain tissue from schizophrenic patients along with evidence for a genetic 
association between schizophrenia and an Akt haplotype. Since these original studies 
numerous reports substantiate an association between Akt dysfunction and schizophrenia 
(Norton et al. 2007; Arguello et al. 2008; Dawn et al. 2008). In particular, human genetic 
and imaging studies corroborate a relationship between an Akt1 variant associated with 
schizophrenia and disruptions in DA-associated behaviors linked to the disorder (Tan et 
al. 2008). These studies indicate a possible link between Akt dysregulation, monoamine 
function, and predisposition to schizophrenia. Correspondingly, our studies provide one 
molecular mechanism by which Akt dysfunction has the potential to impact monoamine 
homeostasis, via its regulation of NET, a protein critical for controlling both global NE 
homeostasis and cortical DA homeostasis (Yamamoto et al. 1998; Moron et al. 2002). 
Thus, future studies investigating the impact of schizophrenia-linked Akt1 variants on the 
noradrenergic system (i.e. NET expression, NE homeostasis) and ultimately NE-related 
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behaviors will strengthen the growing link between aberrant Akt function, monoamine 
homeostasis, and schizophrenia. Interestingly, related studies from our laboratory in mice 
show that ablation of phosphorylation of Akt at Ser473 in neurons results in dramatically 
enhanced NET surface expression as well as behavioral and biochemical phenotypes that 
are hallmark characteristics of schizophrenia (Siuta and Robertson et al. in press at PLoS 
Biology).  
Whereas a role for abnormal Akt signaling in schizophrenia is well supported, 
studies supporting a role for Akt in depression are just beginning to appear. For example 
recent studies reveal deficits in Akt activity in the PFC post-mortem tissue of depressed 
individuals (Hsiung et al. 2003; Karege et al. 2007). Interestingly, social defeat induced 
depression in mice has also been shown to depend on a decrease in Akt activity 
(Krishnan et al. 2008). Thus impairments in Akt activity may sustain depression. In 
addition, chronic antidepressant treatment in both mice and humans results in enhanced 
levels of phosphorylated Akt (Krishnan et al. 2008) which our studies correlate with 
decreased surface NET. Interestingly, chronic antidepressant treatment has also been 
shown to result in a down regulation of NET (Kitayama et al. 2006; Song et al. 2008; 
Jeannotte et al. 2009; Jeannotte et al. 2009). Whether this antidepressant-stimulated 
decrease in surface NET is Akt dependent, however remains to be determined. Thus, 
increases in NET cell surface expression could underlie the etiology of depression. 
Indeed, one NET SNP F528C that is associated with major depression has enhanced 
membrane expression of the transporter along with deficits in trafficking of the 
transporter away from the plasma membrane (Hahn et al. 2005; Haenisch et al. 2008).  
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Given the widespread influence of NET on monoamine homeostasis in both the 
CNS and PNS, and the evidence supporting a link between NET dysfunction and disease, 
substantial effort must be invested into enhancing our understanding of NET trafficking 
and regulation. Here, we show that Akt signaling is key for fine tuning NET surface 
availability. As our picture of NET regulation becomes more complete, so too will our 
ability to create unique approaches for treating disorders such as, depression, 
schizophrenia, drug addiction, and ADHD. 
 
Materials and Methods 
Cell culture and transfection 
We gratefully acknowledge Dr. Randy Blakely for the gift of CHO cells stably 
transfected with HA tagged human NET (hNET cells). The cells were maintained in 
Ham‘s F12 Media/10% FBS/L-Glu/pen/strep. Cells were plated on poly-D-lysine 
(Chemicon/Millipore, Billerica, MA)-coated plates for each experiment and incubated for 
24 to 48 h before each experiment. Transient transfections with Akt-KD, a kinase dead 
(catalytically inactive) construct of Akt with the lysine at residue 179 replaced with an 
arginine (AKT-K179R) (Garcia et al., 2005), was graciously provided by Dr. R. Roth 
Stanford University (Stanford, CA). Transfections were performed with Fugene6 
according to manufacturer‘s instructions (Roche), and experiments on transfected 
cultures were performed 48 hours following transfection. Mouse superior cervical 
ganglion neurons (SCGNs) were cultured according to Savchenko et al. (Savchenko et al. 
2003; Matthies et al. 2009). Briefly, superior cervical ganglions were dissected from 1-3 
day old C57BL/6J mice and dissociated for 30 minutes in 3 mg/mL collagenase/0.5 
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mg/mL trypsin, followed by 10% FBS in DMEM. Cells were plated and incubated with 
3% fetal bovine serum in UltraCulture medium containing NGF for 2 hrs at 37° C to 
allow fibroblasts to adhere. Supernatant medium (containing SCG cells) was centrifuged, 
resuspended in medium supplemented with FBS, and cultured on poly-D-lysine- and 
collagen-coated glass-bottom plates for 14 days before experiments (treating with 1 μM 
5-fluoro-5-deoxyuridine after 24 hrs). 
 
Antibodies and other reagents 
Monoclonal anti-mNET (NET-05) and monoclonal anti-hNET (NET 17-1) from 
MAb Technologies, Stone Mountain, GA (Matthies et al. 2009)), monoclonal anti- 
Na+/K+ ATPase α subunit (Developmental Studies Hybridoma Bank, Iowa City, IA), 
anti-Tyrosine Hydroxylase (MAB5280, Millipore/Chemicon, Billerica, MA), anti-ERK ½ 
(V114A, Promega, Madison, WI), anti-Akt (9272, Cell Signaling, Danvers, MA), anti-
phospho-Akt (ser473) (4060, Cell Signaling) were used at dilutions of 1:200, 1:1000, 
1:50, 1:1000, 1:5000, 1:1000 and 1:1000, respectively, for immunoblotting. Detection 
was obtained with secondary antibodies from Santa Cruz Biotechnology (Santa Cruz, 
CA) and by enhanced chemiluminescence reaction (ECL Plus Western Blotting Detection 
System, RPN2133, GE Healthcare). Monoclonal anti-mNET (NET-05 MAb 
Technologies, Stone Mountain, GA (Matthies et al. 2009)), anti-Rab11a (Lapierre et al. 
2001), anti-Akt1 (2938, Cell Signaling), anti-Akt2 (D-17, sc-7127, Santa Cruz 
Biotechnology), anti-insulin Rβ (C-19, sc-711, Santa Cruz Biotechnology) were used at 
dilutions of 1:500, 1:110, 1:400, 1:100, and 1:50 for immunocytochemistry. Fluorescent 
secondary antibodies included highly cross-absorbed anti-mouse, goat, or rabbit IgG 
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(Molecular Probes/invitrogen, Carlsbad, CA). Insulin from bovine pancreas (I6634), 
clozapine (C6305), NE, and STZ (S0130) were obtained from Sigma (I6634 St. Louis, 
MO). Akt1/2, Akt1, and Akt2 inhibitors (Lindsley et al. 2005) were generously provided 
by Dr. C. Lindsley (Vanderbilt University, Nashville, TN).   
 
Cell and slice surface protein biotinylation 
Biotinylation experiments were performed on intact cells as described previously 
(Sung et al. 2003; Garcia et al. 2005; Dipace et al. 2007). Briefly, hNET cells were plated 
at a density of 1 x 106 per well in a six-well poly-(D-lysine) coated plate. Cells were 
serum starved for 30 minutes to 1 hour prior to treatment, and washed with cold PBS 
containing Ca
2+
/Mg
2+
. Then, cells were incubated with 1.0 mg/mL sulfosuccinimidyl-2-
(biotinamido)ethyl-1,3-dithiopropionate [NHS-SS-biotin] (Peirce/ThermoScientific, 
Rockford, IL) for 30 minutes, washed, quenched with 100 mM glycine, and extracted in 
lysis buffer (PBS Ca2+/Mg2+, 1% Triton 100-X, and 0.5 mM PMSF at 4°C). Lysates 
were centrifuged, total fractions reserved, and supernatants incubated with immobilized 
streptavidin beads (Pierce/ThermoScientific) for 1 hr at room temperature. Beads were 
washed three times in lysis buffer, and bound proteins eluted with 2X sample buffer 
containing 2-mercaptoethanol. Proteins were separated by SDS-PAGE and 
immunoblotted. For estimation of relative amounts of proteins, the exposed films of the 
immunoblots were scanned, and band intensities were measured with Scion Image (Scion 
Corporation, Frederick, MD). For brain slice preparation and biotinylation all procedures 
were performed according to Vanderbilt University Institutional Animal Care and Use 
Committee approved procedures. Brain slices were prepared from C57BL/6J 15 to 20-
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week-old male mice from Jackson Laboratories that were anesthetized with isoflurane 
and rapidly decapitated. Following, removal the brain was chilled in oxygenated 4°C 
sucrose solution (sucrose 210 mM; NaCl 20 mM; KCl 2.5 mM; MgCl2 1 mM; 
NaH2PO4•H2O 1.2 mM), and then while in sucrose solution 300 µm coronal slices were 
made using a vibratome. Slices were then collected in oxygenated artificial cerebral 
spinal fluid (ACSF) (NaCl 125 mM, KCl 2.5 mM,  NaH2PO4•H2O 1.2 mM, MgCl2 1 
mM, CaCl2•2H2O 2 mM). For in vitro drug treatments slices were then allowed to 
recover for 1 hour at 37°C in oxygenated ACSF and were then followed by drug 
treatment (i.e. insulin) and subsequent biotinylation. For in vivo treated animals (STZ or 
Clozapine experiments), slices were immediately washed twice with oxygenated 4°C 
ACSF following collection, and then incubated with 4°C ACSF solution containing 
1mg/mL of EZ-Link Sulfo-NHS-SS-Biotin (Pierce/ThermoScientific; Rockford, IL.) for 
45 min. After biotin incubation, the slices were rinsed twice quickly and for two 10min 
washes in oxygenated 4°C ACSF. The reaction was quenched by washing twice for 
20min each with oxygenated 4°C ACSF containing glycine. Following quenching, slices 
were frozen on dry ice and the hippocampus was cut out and frozen at -80°C until used. 
For each experiment, a minimum of 4 animals were used for the collection of slices per 
treatment group, and a single slice was utilized for each sample (represented in the text as 
―N‖). Single slices were lysed in 1% Triton buffer (25 mM Hepes, 150 mM NaCl, 2 mM 
Sodium orthovanadate, 2 mM NaF, plus a cocktail of protease inhibitors). Lysates were 
then centrifuged at 17,000g for 30 min at 4°C. After isolation of supernatant 0.1% Triton 
pulldown buffer (25 mM HEPES, 150 mM NaCl, 2 mM Sodium orthovanadate, 2 mM 
NaF, plus a cocktail of protease inhibitors) was added. Total protein was taken and the 
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samples were processed for protein concentration determination using Bio-Rad‘s protein 
assay and spectrometry at 595 nm Biotinylated proteins were then isolated using 
ImmunoPure immobilized streptavidin beads (Pierce/ThermoScientific) overnight at 4°C 
with agitation. Beads were washed three times with 0.1% Triton pulldown buffer and 
biotinylated proteins were then eluted in 50 µL of 2X SDS-PAGE sample loading buffer 
at 95°C and then room temperature. Total slice lysates and the biotinylated (slice surface) 
fraction underwent immunodetection for NET, pAkt473, total Akt, Na
+
/K
+
 ATPase, and 
TH as described previously.  
 
Immunostaining 
SCG neurons were either serum starved for one hour (insulin treatment) or non-
starved (Akt inhibitor treatment) in DMEM:F12 and treated with vehicle, insulin, Akt1, 
or Akt2 inhibitor for 20 or 60 minutes respectively. Slices were obtained as previously 
described (cell and slice biotinylation methods). Slices and neurons were subsequently 
fixed with PBS Ca
2+
/Mg
2+
/4% paraformaldehyde, washed three times with PBS 
Ca
2+
/Mg
2+
, permeabilized and blocked with PBS/4% bovine serum albumin 
(BSA)/0.15% Tween-20, and immunostained with the appropriate antibody dissolved in 
PBS plus 4% BSA and 0.05% Tween-20. Primary antibodies were visualized with the 
appropriate covalently Alexa-labeled secondary antibody from Molecular Probes. 
Immunofluorescence was imaged using a Perkin Elmer UltraView confocal with a Nikon 
Eclipse 2000-U microscope equipped with a 60X lens with N.A.=1.49, or an Olympus 
FV 1000 using a 60X lens of N.A.=1.45 (VUMC Cell Imaging Shared Resource). Image 
processing was performed using Image J and Adobe Photoshop.  
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Analysis of NET internalization 
The quantitation of NET intracellular accumulation was achieved using pixel 
intensity plots of a single confocal section along a line through the center of each bouton 
using ImageJ. The line intersects the brightest spot on one side of the widest portion of 
the bouton perimeter. The line was extended beyond the limits of the bouton to generate a 
background value, and then divided into 20 bins (bin # 10 is approximately at the center 
of the bouton) for the pixels spanning the bouton. NET fluorescence intensity of each bin 
was normalized to the fluorescence intensity of the brightest spot on the bouton perimeter 
(100%) and the mean ± SEM pixel intensity of each bin plotted. 
 
Colocalization analysis 
Only images in which there was no pixel saturation were analyzed. Background 
fluorescence was first subtracted in ImageJ by selecting an unstained area of each image 
and running the background subtraction plugin available at UHN research facilities (CA). 
The intensity correlation quotient (ICQ) was then determined by running the intensity 
correlation analysis (ICA) plugin for ImageJ developed by Tony Collins and Elise 
Stanley (Toronto Western Research Institute), also available at the above link. The ICQ 
indicates whether the intensity of staining for two proteins varies in synchrony over 
space. An ICQ value of +0.5 means that in any pixel with a certain intensity of staining 
for one protein, the intensity of staining for the other protein studied will be exactly the 
same, while an ICQ value of 0 signifies no relation between the two staining patterns. 
Consistently, an ICQ value of –0.5 indicates an inverse relationship for colocalization. 
87 
       
This method is based on the synchrony around which two signals vary in space (Li et al. 
2004). 
 
Uptake assay 
hNET cells were seeded into 6-well plates 24-48 h prior to the experiment and 
grown to confluency. After 30 minutes of serum starvation, the cells were incubated with 
10 nM insulin for 1 min (Sigma, St Louis, MO, USA) in KRH/glucose buffer at 37°C. 
The cells were then placed into 37°C KRH/glucose uptake buffer for 10 min (130 mM 
NaCl, 1.3 mM KCl, 10 mM Hepes, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.2 mM CaCl2, 
10mM glucose, pH 7.4) containing, 100 µM ascorbic acid, 100 µm pargyline, and 
[
3
H]DA (50 nM) for uptake and depending on the treatment group the uptake buffer also 
had vehicle, 10 nM insulin, or cocaine to measure non-specific uptake. Immediately 
following uptake, cells were washed in cold 4°C KRH/glucose buffer 3 times. All 
solution was removed and plates were allowed to dry on the 37°C plate. Once dry, cells 
were lysed with 1 mL of 0.01% SDS. Radioactivity was measured in a Beckman 
scintillation counter with UniverSol cocktail. Specific uptake was defined as total uptake 
minus non-specific uptake in the presence of 10 µM cocaine. 
 
STZ treatment 
All procedures were approved by the Vanderbilt University Medical Center and 
the University of Texas Health Science Center at San Antonio Institutional Animal Care 
and Use Committees and were conducted according to the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. For all experiments, male C57BL/6J 
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15 to 20-week-old mice from Jackson Laboratories served as experimental subjects. STZ 
is an antibiotic that destroys the insulin-secreting beta cells of the pancreas and has 
previously been used to induce chronic hypoinsulinemia in rats by our laboratories 
(Galici et al. 2003; Owens et al. 2005). STZ (Sigma- Aldrich;) was freshly dissolved in 
ice-cold 100 mM citrate saline (pH 4.5) for all studies. Mice received STZ (200 mg/kg, 
i.p. for biochemical and high-speed chronoamperometry (HSCA) studies) and were 
returned to their home cages for 7-10 days. Weight and blood glucose were measured 
prior to injection and post injection. Blood glucose was measured with a glucometer 
(Advantage Accu-Chek, Roche Diagnostics;) before STZ, at 48 hours after injection and 
at animal sacrifice. Animals were considered hypoinsulinemic when their blood glucose 
levels exceeded 300 mg/dl. 
 
Tissue extraction for neurochemistry 
The brain sections were homogenized in 100-750 ul of 0.1M TCA, containing 10-
2 M sodium acetate, 10-4 M EDTA, 5ng/ml isoproterenol (as internal standard) and 10.5 
% methanol (pH 3.8). Samples were spun in a microcentrifuge at 10000 g for 20 minutes. 
The supernatant was removed and stored at –80 degrees (3). The pellet was saved for 
protein analysis. Supernatant was then thawed and spun for 20 minutes. Samples of the 
supernatant were then analyzed for biogenic monoamines and/or amino acids. Biogenic 
amines were determined by a specific HPLC assay utilizing an Antec Decade II 
(oxidation: 0.5) electrochemical detector operated at 33° C. Samples of the supernatant 
were injected using a Water 717+ autosampler, twenty onto a Phenomenex Nucleosil (5u, 
100A) C18 HPLC column (150 x 4.60 mm). Biogenic amines were eluted with a mobile 
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phase consisting of 89.5% 0.1M TCA, 10-2 M sodium acetate, 10-4 M EDTA and 10.5 % 
methanol (pH 3.8). Solvent was delivered at 0.6 ml/min using a Waters 515 HPLC pump. 
Using this HPLC solvent the following biogenic amines elute in the following order: 
noradrenaline, MHPG, adrenaline, DOPAC, dopamine, 5-HIAA, HVA, 5-HT, and 3-MT 
(2). HPLC control and data acquisition are managed by Millennium 32 software. 
 
High-speed chronoamperometry (HSCA) 
HSCA is an electrochemical recording technique, which affords the kinetics of 
NE clearance to be measured in vivo. Detailed methods are published elsewhere (Daws & 
Toney, 2007; Daws et al. 2005). Mice were anaesthetized by intraperitoneal injection (2 
ml/kg body weight) of a mixture of chloralose (25 mg/kg) and urethane (250 mg/kg) 
followed by tracheal intubation and placement into a stereotaxic frame. Body temperature 
was maintained at 36-37°C and blood oxygen levels monitored (MouseOximeter, 
StarrLifeSciences, USA) and maintained above 90%. A Nafion-coated carbon fiber 
electrode was attached to a glass micropipette containing NE. The assembly was lowered 
into the brain region of interest (stereotaxic coordinates in mm: DG region of 
hippocampus AP -1.6 to -1.7; ML 0.5; DV -1.8 to -2.0) and NE pressure ejected to 
achieve concentrations at the recording electrode ranging from about 0.2–4.0 μM. High-
speed chronoamperometric recordings were made using the FAST-12 and FAST-16 
systems (Quanteon, USA). Oxidation potentials consisted of 100-ms pulses of +0.55 V. 
Each pulse was separated by a 900-ms interval during which the electrode potential was 
maintained at 0.0 V. Voltage at the active electrode was applied with respect to a 
Ag/AgCl reference electrode positioned in the extracellular fluid of the ipsilateral 
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superficial cortex. Electrode placement was confirmed by making an electrolytic lesion at 
the recording site at the conclusion of the experiment. 
 
Statistical analysis 
All data are expressed as the mean ± s.e.m. Mean differences between groups 
were determined using t-tests or one and two-way ANOVAs followed by post hoc tests 
when the main effect or interaction was significant at P < 0.05. Statistical analyses were 
conducted using software from Graph-Pad Prism. The number of animals and specific 
statistical analyses used in each experiment are indicated in the figure legends and/or text. 
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CHAPTER III 
 
DYSREGULATION OF THE NOREPINEPHRINE TRANSPORTER SUSTAINS 
CORTICAL HYPODOPAMINERGIA AND SCHIZOPHRENIA-LIKE BEHAVIORS 
IN NEURONAL RICTOR NULL MICE* 
 
Abstract 
Background: The mammalian target of rapamycin (mTOR) complex 2 (mTORC2) is a 
multimeric signaling unit that phosphorylates protein kinase B/Akt following hormonal 
and growth factor stimulation. Defective Akt phosphorylation at the mTORC2-catalyzed 
Ser473 site has been linked to schizophrenia. Although human imaging and animal 
studies implicate a fundamental role for Akt signaling in prefrontal dopaminergic 
networks, the molecular mechanisms linking Akt phosphorylation to specific 
schizophrenia-related neurotransmission abnormalities have not yet been described. 
Importantly, current understanding of schizophrenia suggests that cortical decreases in 
DA neurotransmission and content, defined here as cortical hypodopaminergia, 
contribute to both the cognitive deficits and the negative symptoms characteristic of this 
disorder. We sought to identify a mechanism linking aberrant Akt signaling to these 
hallmarks of schizophrenia.  
Methodology/Findings: We used conditional gene targeting in mice to eliminate the 
mTORC2 regulatory protein rictor in neurons, leading to impairments in neuronal Akt  
* The work presented in this chapter is in press as Michael A. Siuta
‡
, Sabrina D. Robertson
‡
, Heidi Kocalis, 
Christine Saunders, Paul J. Gresch, Vivek Khatri, Chiyo Shiota, J. Philip Kennedy, Craig W. Lindsley, 
Lynette C. Daws, Daniel B. Polley, Jeremy Veenstra-Vanderweele, Gregg D. Stanwood, Mark A. 
Magnuson, Kevin D. Niswender, Aurelio Galli (PLoS Biology) 2010. (
‡
 designates co-authorship) 
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Ser473 phosphorylation. Rictor-null (KO) mice exhibit prepulse inhibition (PPI) 
deficits,a schizophrenia-associated behavior. In addition, they show reduced prefrontal 
dopamine (DA) content, elevated cortical norepinephrine (NE), unaltered cortical 
serotonin (5-HT), and enhanced expression of the NE transporter (NET). In the cortex, 
NET takes up both extracellular NE and DA. Thus, we propose that amplified NET 
function in rictor KO mice enhances accumulation of both NE and DA within the 
noradrenergic neuron. This phenomenon leads to conversion of DA to NE and ultimately 
supports both increased NE tissue content as well as a decrease in DA.  In support of this 
hypothesis, NET blockade in rictor KO mice reversed cortical deficits in DA content and 
PPI, suggesting that dysregulation of DA homeostasis is driven by alteration in NET 
expression which we show is ultimately influenced by Akt phosphorylation status.  
Conclusions/Significance: These data illuminate a molecular link, Akt regulation of 
NET, between the recognized association of Akt signaling deficits in schizophrenia with 
a specific mechanism for cortical hypodopaminergia and hypofunction. Additionally, our 
findings identify Akt as a novel modulator of monoamine homeostasis in the cortex. 
 
Introduction 
Mammalian target of rapamycin (mTOR) complex 2 (mTORC2) is one of two 
highly conserved protein kinases that are critical regulators of cell growth and 
metabolism. mTOR complex 1 (mTORC1) and mTORC2 are functionally distinct 
multiprotein complexes that are defined by their subunit composition, rapamycin 
sensitivity, and substrate selectivity. Raptor, mLST8, PRAS40, and mTOR comprise the 
rapamycin sensitive mTORC1 whereas the rapamycin insensitive mTORC2 contains 
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rictor, mSIN1, mLST8, and mTOR. Two key substrates of mTORC1 are S6K and 4E-BP, 
which are important regulators of translation, whereas protein kinase B, also known as 
Akt, is the primary substrate of mTORC2 (Sarbassov et al. 2005). Specifically, mTORC2 
is the kinase responsible for phosphorylation of Akt at serine residue 473, one of two key 
phosphorylation sites (Sarbassov et al. 2005). Akt is an extensively studied kinase that 
has been implicated in numerous disorders such as diabetes, obesity, cancer, and mental 
disorders such as schizophrenia(Beaulieu et al. 2009). Post-mortem, imaging and genetic 
association studies in humans (Emamian et al. 2004; Dawn et al. 2008; Tan et al. 2008) 
reveal that Akt deficiencies are associated with schizophrenia. Genetic studies in rodents 
further corroborate the relationship between dysregulation in Akt signaling and 
disruptions in dopamine (DA)-associated behaviors linked to schizophrenia (Emamian et 
al. 2004; Lai et al. 2006).  
Putative evidence for a role of defects in mTORC2 signaling in mental illnesses 
preceded the discovery of the mTORC2 complex itself. Indeed, lithium, used to treat 
bipolar disorder, stimulates phosphorylation of Akt at Ser473, the mTORC2 
phosphorylation site (Chalecka-Franaszek et al. 1999). The link between mTORC2 
signaling deficits and mental illness has been strengthened by work demonstrating that 
certain antidepressants (Krishnan et al. 2008), along with both typical (Emamian et al. 
2004) and atypical antipsychotics (Lu et al. 2005) increase Akt Ser473 phosphorylation. 
Furthermore, findings of diminished Ser473 phosphorylation and/or activity in post-
mortem brains of patients with schizophrenia (Zhao et al. 2006) and depression (Karege 
et al. 2007) potentially fortify the association between dysregulation of mTORC2-Akt 
signaling and development of psychiatric illnesses, although these findings may be 
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confounded by perimortem artifacts (Ide et al. 2006). Recent observations that blunted 
Ser473 phosphorylation occurs in lymphocytes derived from patients with schizophrenia 
and psychosis-prone normal individuals (Keri et al. 2009) also support the plausibility 
that mTORC2-Akt deficits are involved in schizophrenia.  
 While human imaging and animal studies implicate a fundamental role for Akt 
signaling in prefrontal DA networks, the molecular mechanisms linking mTORC2/Akt to 
schizophrenia-related neurotransmission abnormalities have been elusive (Lai et al. 2006; 
Tan et al. 2008). Importantly, models of schizophrenia suggest that cortical deficits in DA 
neurotransmission and content, defined here as cortical hypodopaminergia, contribute to 
both the cognitive deficits and the negative symptoms characteristic of this disorder 
(Davis et al. 1991). Consistent with this hypothesis, imaging studies reveal that genetic 
variation associated with low activity Akt alleles interact epistatically with catechol-O-
methyltransferase (COMT), a gene responsible for degradation of prefrontal synaptic DA. 
Together, these interactions ultimately affect the fidelity of prefrontal networks in 
humans (Tan et al. 2008) by decreasing DA availability at prefrontal synapses (Lotta et 
al. 2002). Thus, a compelling hypothesis in schizophrenia is that impaired mTORC2/Akt 
signaling triggers aberrant regulation of DA homeostasis.  
Termination of DA signaling at prefrontal synapses involves two mechanisms: 
degradation via enzymes including COMT, and clearance via the norepinephrine (NE) 
transporter (NET) (Gresch et al. 1995; Moron et al. 2002; Miner et al. 2003), which takes 
up both major brain catecholamines, DA and NE (Yamamoto et al. 1998; Moron et al. 
2002). Interestingly, insulin administration, which stimulates mTORC2/Akt signaling, 
decreases NET transcription in brain, while hypoinsulinemia and decreased 
95 
       
mTORC2/Akt signaling increases NET transcription (Figlewicz et al. 1996). Therefore, 
we hypothesized that dysregulation of mTORC2/Akt signaling may provide a 
mechanistic link to cortical hypodopaminergia. Specifically, we propose that reduced Akt 
activity mediates increased NET expression and increased DA clearance by 
noradrenergic neurons in cortex; a novel molecular mechanism that explains how Akt 
dysfunction contributes to a reduction in prefrontal dopamine.  
To test this hypothesis, we have generated an animal model in which 
mTORC2/Akt signaling down-regulation is achieved by neuronal deletion of a key 
mTORC2 regulatory subunit, rictor. We used a Cre-lox strategy to restrict the genetic 
deletion to neurons and bypass embryonic lethality associated with whole body deletion 
(Shiota et al. 2006). The goal of the present study is to test how alteration in Akt 
signaling affects dopamine homeostasis in the prefrontal cortex. 
 
Results 
Rictor deletion attenuates Akt Ser473 phosphorylation  
Akt deficiency is mechanistically linked to prefrontal cortex abnormalities and 
schizophrenia-linked phenotypes in several mouse models (Lai et al. 2006), although a 
clear molecular mechanism for how Akt regulates cortical function remains elusive. 
Here, we investigate the dopaminergic consequences of abolishing Akt phosphorylation 
at Ser473 in neurons by utilizing the Cre/LoxP system to delete rictor specifically in 
neurons. Mice were engineered with a floxed rictor allele, as previously described (Shiota 
et al. 2006), and crossed with neuron-specific nestin gene (NES mice) Cre driver line. 
Validating our approach, rictor knockout mice (KO) lack rictor mRNA expression and 
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rictor protein expression in a gene-dosage dependent manner within the brain and cortex 
(Appendix Fig. B1; P < 0.01 and P < 0.05 respectively, by one-way ANOVA followed by 
Dunnett‘s test). Importantly for the current hypothesis, neuronal rictor deletion abolishes 
Akt phosphorylation at Ser473 within the cortex of rictor KO mice (Fig. 15a; ***P < 
0.001 by one-way ANOVA Dunnett‘s test) compared to FLOX (floxed allele(s) in the 
absence of Cre), NES (Cre allele in the absence of a FLOX allele), and heterozygous 
rictor neuronal knockout mice (HET). Phosphorylation of Akt at Thr308 (Fig. 15b) and 
total levels of Akt (Fig. 15c) within the cortex are not different among the genotypes, 
allowing a direct evaluation of the effects of Ser473 phosphorylation. Similarly, rictor 
deletion also abolishes Akt phosphorylation at Ser473 in other brain regions, such as the 
substantia nigra (SN)/ventral tegmental area (VTA) of rictor KO mice, while Thr308 
phosphorylation and total levels of Akt are unaltered (data were normalized to control 
(FLOX) and reported as mean ± s.e.m., P values by Student‘s t-test; pAkt Ser473 
FLOX=100 ± 13%, KO=6 ± 1%, P < 0.001; pAkt Thr308 FLOX=100 ± 13%, KO=89 ± 
8%, P = 0.49; total Akt FLOX=100 ± 13%, KO=101 ± 10%, P = 0.96). Furthermore, total 
protein levels of mTOR in the cortex are not altered by neuron-specific rictor knockout 
(data were normalized to control (FLOX) and reported as mean ± s.e.m.; FLOX=100 ± 
9%, NES=130 ± 12%, HET=118 ±12%, KO=116 ± 12%; P = 0.32 by one-way ANOVA 
followed by Dunnett‘s test).  
Neuronal rictor KO mice display sensorimotor gating deficits  
Pre-pulse inhibition (PPI) behavior has long been identified as a promising 
phenotype for translational studies of schizophrenia owing to the direct parallels in 
expression between rodent and human subjects. While PPI deficits are present in 
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Figure 15.  Neuronal rictor deletion specifically abolishes Akt phosphorylation at Ser473 
in the cortex.  (a)  Phosphorylation of Akt on residue Ser473 in the cortex.  (b) 
Phosphorylation of Akt at Thr308 and (c) total Akt in the cortex are similar for all 
genotypes.  Shown are mean ± s.e.m of optical densities as a percentage of FLOX control 
mice.  Genotypes shown include animals expressing only nestin-CRE (NES), mice 
expressing two copies of the ‗floxed‘ rictor allele (FLOX) only, heterozygous mice which 
express nestin-CRE and a single copy of the ‗floxed‘ rictor allele (HET), and knock-out 
mice expressing both nestin-CRE and two copies of the ‗floxed‘ rictor allele (KO).  Total 
cortical protein extract was loaded in each lane.  Representative immunoblots are shown, 
as probed with antibodies to phosphorylated Akt at Ser473 (a) Thr308 (b), total Akt (c), 
and actin to serve as a loading control.  Samples n=9-16.  ***P<0.001 One-way 
ANOVA. 
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psychiatric disorders other than schizophrenia, they have a clear heritable component in 
schizophrenic families and these deficits can be attenuated by antipsychotic drug 
administration. Furthermore, PPI deficits are also linked to the hypofunction of 
corticostriatal forebrain circuits that is characteristic of schizophrenia (Powell et al. 
2009). The PPI behavioral assay measures the degree to which the startle response 
elicited by a loud sound ―pulse‖ sound is attenuated when immediately preceded by a 
non-startling ―prepulse‖ sound. As such, it assays the degree to which a brief sensory 
trace can rapidly modify a subsequent motoric response, thereby representing a 
straightforward approach towards quantifying sensorimotor dysregulation, which is 
generally regarded as an endophenotype of schizophrenia. Since evidence suggests a role 
for Akt in schizophrenia, and rictor KO mice demonstrate profound deficits in Akt 
phosphorylation, we tested whether rictor KO mice display impaired PPI relative to 
FLOX control mice. No differences in startle responses elicited by a 94 dB sound 
pressure level (SPL) noise burst were observed, suggesting that hearing and gross motor 
function were similar between groups (Fig. 16a; Student‘s t-test; P = 0.44). By contrast, 
analysis of PPI behavior revealed clear differences between genotypes; startle reflex 
amplitude was inhibited at all prepulse intensities in FLOX control mice, with the amount 
of PPI increasing monotonically from 40 to 75 dB SPL (Fig. 16b). In rictor KO mice, 
prepulse sound levels between 40-55 dB did not appreciably attenuate the startle reflex. 
PPI was not observed in rictor KO mice until prepulse levels > 55 dB, albeit at a weaker 
level in comparison to FLOX mice. These differences gave rise to a significant reduction 
of PPI across prepulse sound levels (Fig. 16b; *P < 0.05 by ANOVA). This PPI deficit 
can also be expressed as a significant decrease in average PPI across all sound levels in 
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rictor KO mice (Fig. 16c; Student‘s t-test, *P < 0.05). Thus neuronal rictor deletion, with 
loss of Akt Ser473 phosphorylation, impairs the forebrain circuits critically involved with 
sensorimotor integration. Given the strong evidence for PPI deficits in schizophrenic 
patients, we hypothesize that this mouse model has the potential to lend novel insight into 
the molecular mechanisms by which Akt deficits contribute to the schizophrenic 
phenotype.  
 
Rictor KO mice display hypodopaminergia in rostral cortex  
 For almost fifty years, schizophrenia research has centered on dopaminergic 
signaling as a crucial component of the etiology of the disease (Delay et al. 1952; 
Carlsson et al. 1963; Seeman et al. 1975). In particular, the original ―DA hypothesis‖ 
heavily supported the notion of excessive DA neurotransmission and DA content, defined 
here as hyperdopaminergia, within the brain (Matthysse 1973; Snyder 1976). Subsequent 
revision of the hypothesis, however, has transformed thinking from a global 
hyperdopaminergia to a regional hyperdopaminergia within the striatum and 
dopaminergic hypofunction within the cortex (Weinberger et al. 1988; Davis et al. 1991; 
Howes et al. 2009). While this conceptualization is an oversimplification of a highly 
complex disorder, we utilized this hypothesis to hone in on molecular mechanisms that 
contribute to cortical hypodopaminergia. Furthermore, previous studies have linked pre-
frontal dopamine deficits with PPI deficits in animal models, and perhaps the PPI deficits 
observed in the rictor KO mice could be partially explained by alterations in cortical DA 
content (Koch et al. 1994; Swerdlow et al. 2006). Thus, we investigated steady state 
levels of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) in a region of 
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mouse brain that is roughly analogous to the human prefrontal cortex and contains areas 
such as the intralimbic, prelimbic, and anterior cingulate cortex. Interestingly, HPLC with 
electrochemical detection of DA, NE, and 5-HT in the PFC of rictor KO mice revealed 
striking alterations in the DA and NE tissue content of these animals, while 5-HT levels 
remained unchanged (Fig. 17). Although both DA and NE levels are significantly 
different in rictor KO mice they change in opposite directions; NE tissue content is 
significantly increased (Fig. 17a; **P < 0.01 by one-way ANOVA followed by Dunnett‘s 
test) while DA levels are significantly decreased (Fig. 17b; Student‘s t-test, *P < 0.05). In 
addition, NES mice show similar PFC DA content levels (6.4±0.2 ng/mg protein) as 
FLOX mice. Thus, rictor KO mice display a key feature of the ―dopamine hypothesis‖ of 
schizophrenia, namely hypodopaminergia in the rostral cortex, which may explain the 
sensorimotor gating deficits described earlier. Importantly, 5-HT levels are unaltered in 
the cortex (Fig. 17c; Student‘s t-test, P=0.26) indicating that rictor deletion does not 
simply result in global monoaminergic alterations but rather specific changes in the 
dopaminergic and noradrenergic systems. In addition, extracellular levels of DA were 
determined in the PFC of rictor KO mice by microdialysis. Under basal conditions, 
extracellular DA is not significantly different in rictor KO mice compared to FLOX 
controls (data are reported as pg of DA/µL, mean ± s.e.m.; FLOX=0.54 ± 0.15, KO=0.76 
± 0.18, n=4-5; P = 0.35 by Student‘s t-test). Whereas basal extracellular levels of DA are 
unaltered in rictor KO mice, these animals do display significant deficits in DA tissue 
content suggesting that maintenance of DA homeostasis is perturbed.  
Although prefrontal hypodopaminergia has been linked to PPI deficits, other 
studies 
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clearly demonstrate a link between striatal hyperdopaminergia and PPI deficits (Ralph et 
al. 1999; Ralph et al. 2001). Thus, we sought to determine if rictor deletion increases 
tissue levels of DA in the striatum or in projecting DA neurons from the SN and VTA. 
DA levels in the SN/VTA are not altered in rictor KO mice (data are reported as ng of 
DA/mg protein, mean ± s.e.m.; FLOX=4.4 ± 0.5, KO=4.8 ± 0.4, P = 0.60 by Student‘s t-
test).  Importantly, similar to the cortex, DA tissue content in the striatum of rictor KO 
mice is significantly decreased (data are reported as ng of DA/mg protein, mean ± s.e.m.; 
FLOX=101.2 ± 7.7, KO=80.1 ± 3.4, *P < 0.05 by Student‘s t-test). Thus, our data 
indicate that the PPI deficits observed in rictor KO mice are likely to arise from 
impairments in DA neurotransmission. 
 
Rictor deletion increases NET expression and function 
It is intriguing that DA content is decreased while NE content is increased in 
rictor KO mice. Importantly, decreases in mTORC2/Akt signaling induced by 
hypoinsulinemia have been shown to increase NET transcription (Figlewicz et al. 1996). 
Moreover, early studies and unpublished data from our laboratory implicate deficits in 
Akt signaling with not only increases in NET transcription, but also with acute increases 
in NET cell surface expression (i.e. intact Akt signaling decreases NET availability at the 
plasma membrane) (Boyd et al. 1986; Figlewicz et al. 1993; Figlewicz et al. 1993; 
Figlewicz et al. 1996). Thus, we predict that altered DA homeostasis in rictor KO mice is 
due to changes in NET cell surface expression mediated by impaired Akt 
phosphorylation. Importantly, unlike other brain regions where DAT is the primary 
mechanism for removing DA from the synapse, in cortex DAT contributes relatively little 
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and NET performs the majority of DA clearance. Indeed NET has a higher affinity for 
DA than NE itself, but DA can also be degraded in the synapse by catechol-o-
methyltransferase (COMT) (Moron et al. 2002; Miner et al. 2003). Given the pivotal role 
of rictor in Akt regulation and the role of Akt signaling in determining NET availability, 
we hypothesize that rictor KO mice will display aberrant NET regulation that sustains the 
alterations in NE and DA levels seen in the rostral cortex.  
As hypothesized, total cortical NET protein is increased approximately two-fold 
in rictor KO mice compared to all other genotypes (Fig. 18a; ***P < 0.0001 by one-way 
ANOVA followed by Dunnett‘s test). Furthermore, biotinylation assays reveal that cell 
surface levels of NET are also significantly increased (Fig. 18b; Student‘s t-test, 
***P<0.0001). Tyrosine hydroxylase (TH), a cytosolic protein, was detected exclusively 
in the total protein fraction but not in the surface fraction, indicating that the biotinylated 
fraction represents exclusively cell surface proteins. Finally, the striking enhancement in 
surface NET detected in rictor KO mice results in a significant increase in NET function 
as assayed by cortical synaptosomal NE uptake (Fig. 18c; Student‘s t-test, *P<0.05). The 
nearly two-fold increase in cortical synaptosomal NE uptake was also observed for DA 
(Fig. 18c; Student‘s t-test, *P<0.05) indicating that rictor deletion increases DA clearance 
by NET in noradrenergic neurons and as a consequence reduces cortical DA content. 
Furthermore, DA content is not decreased due to increased degradation since COMT 
levels were not different in cortex compared to FLOX control mice (data were 
normalized to control (FLOX) and reported as mean ± s.e.m.; FLOX=100 ± 8%, NES=78 
± 11%, HET=130 ±24%, KO=80 ± 11%; P = 0.10 by one-way ANOVA followed by 
Dunnett‘s test). Thus, the increase in NET expression and function within the cortex of
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Figure 18.  Neuronal rictor deletion results in increased NET expression and function.  
(a) NET protein levels in the cortex.  Mean ± s.e.m optical densities are shown as a 
percentage of FLOX control mice.  Representative immunoblots are shown, as probed 
with antibodies to NET, and actin (loading control); n=10.  (b) Levels of surface NET as 
measured from the biotinylated fraction of cortical slices.  Mean ± s.e.m optical density is 
shown as a percentage of FLOX control mice. Representative immunoblots are shown, as 
probed with antibodies to NET, Na
+
/K
+
 ATPase to serve as plasma membrane/loading 
control (n=3-5), and TH which is absent in the biotinylated fractions since it is a cytosolic 
protein. (c) [
3
H]NE and [
3
H]DA uptake into cortical synaptosomes of FLOX and KO 
mice.  Mean ± s.e.m uptake is shown as a percentage of uptake in FLOX control mice; 
n=12-18 *P<0.05; ***P<0.001 Student‘s t-test. 
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rictor KO mice has the potential to mechanistically explain both the increased NE tissue 
content and decreased cortical DA tissue content described earlier (Fig. 17). Interestingly, 
we did not find a significant difference in serotonin transporter expression within the PFC 
of the rictor KO mice, as measured by citalopram binding (data not shown).  
While our data indicates that global neuronal mTORC2 dysfunction enhances 
NET function and induces cortical hypodopaminergia, we sought to demonstrate more 
specifically that these alterations could arise from downregulation of cortical Akt activity. 
Thus, we utilized the isoform specific Akt1 inhibitor (DeFeo-Jones et al. 2005; Lindsley 
et al. 2005; She et al. 2008) in cortical slices to show that Akt inhibition is capable of 
directly determining NET surface availability (Appendix Fig. B2). Surface levels of NET 
are significantly enhanced in biotinylated cortical slices treated with the Akt1 inhibitor 
(Appendix Fig. B2a; *P < 0.05 by Student‘s t-test). Importantly, the levels of Akt Ser473 
phosphorylation are substantially diminished in samples of these inhibitor treated slices 
(Appendix Fig. B2b; ***P < 0.0001). Together, these data support the notion that Akt 
stimulated regulation of the transporter occurs not only at the level of transcription, as is 
seen in rictor KO mice, but also at the level of transporter trafficking. Furthermore, the 
ability of Akt inhibition to enhance NET surface expression in cortical slices indicates 
that all the molecular machinery necessary for this rictor/Akt regulation of NET is intact 
within the PFC, and thus is consistent with our hypothesis that altered cortical 
monoamine homeostasis via aberrant NET regulation underlies PPI deficits in rictor KO 
mice. 
We hypothesize that amplified NET function in rictor KO mice enhances the 
accumulation of both NE and DA within the noradrenergic neuron leading to conversion 
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of DA to NE and ultimately supporting both increased NE tissue content and a state of 
hypodopaminergia. Such a mechanism within the prefrontal cortex provides an elegant 
molecular mechanism linking Akt hypophosphorylation to both cortical 
hypodopaminergia and PPI deficits, two key hallmarks of schizophrenia.   
 
Midbrain dopaminergic neurons and cortical monoaminergic projections are unaltered 
in rictor KO mice 
 Considering the widespread function of Akt, and its role in cell growth and 
proliferation, we next sought to demonstrate that the changes in DA and NE levels within 
the cortex were specifically due to increased NET expression rather than global changes 
in the number or projections of dopaminergic and noradrenergic neurons. Although rictor 
KO mice do display a gross reduction in brain size, similar to what is seen for Akt3 
deficient mice (brain weight normalized to body weight; FLOX 2.49 ± 0.18% compared 
to KO 1.63 ± 0.10%; P < 0.0005 by one-way ANOVA followed by Dunnett‘s test), 
coronal brain sections stained for TH revealed no significant alterations in dopaminergic 
cell number within the VTA or SN (Fig 19a and 19c-d; VTA P = 0.82 by one-way 
ANOVA, SN P = 0.53 by one-way ANOVA). Furthermore, TH staining of dopaminergic 
and noradrenergic projections within the cortex do not reveal any gross alterations among 
the groups (Fig. 19b). The immunostaining was confirmed with western blot analysis of 
total cortical TH protein levels (Fig. 19e; P = 0.20 by one-way ANOVA). Other markers 
of dopaminergic neurons in the cortex were not significantly altered in the rictor KO mice 
such as total levels of D2 dopamine receptors (data were normalized to control (FLOX) 
and reported as mean ± s.e.m.; FLOX=100 ± 5%, NES=95 ± 13%, HET=96 ±9%, 
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Figure 19.  TH staining and expression in the midbrain and cortex is similar in NES, 
FLOX, and KO mice. TH immunoreactivity in the (a) midbrain substantia nigra (SN) and 
ventral tegmental area (VTA) and the (b) cortex.  Scale bars = 50 µm. Coronal brain 
sections were stained with TH antibody and cell counts of TH
+
 cells were taken.  Cell 
counts are similar in NES, FLOX, and KO matched mice in both the (c) VTA and the (d) 
SN.  Mean ± s.e.m TH
+
 cells/mm
2
 are shown; n=6.  (e) TH protein levels in the cortex.  
Mean ± s.e.m optical densities are shown as a percentage of FLOX control mice; n=19-
22.  One-way ANOVA analysis reveals no significant difference between genotypes.  
Panels a-d courtesy of Gregg Stanwood.  
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KO=108 ± 18%; P = 0.85 by one-way ANOVA followed by Dunnett‘s test). These data 
demonstrate that the DA and NE systems in the rictor KO mice are not globally altered. 
Therefore, we propose that the changes in cortical NE and DA tissue content can be 
primarily accounted for by the specific enhancement of NET expression in noradrenergic 
neurons. 
 
NET blockade reverses the sensorimotor gating deficits and hypodopaminergia in rictor 
KO mice 
 We hypothesize that aberrant Akt phosphorylation in rictor KO mice results in 
enhancement of NET function within the cortex, resulting in changes in both DA and NE 
homeostasis. If this model is valid, then NET inhibition should reverse both PPI 
behavioral deficits and cortical deficits in DA tissue content. In order to test this 
hypothesis, we treated rictor KO mice with nisoxetine (NET specific blocker) or saline. 
Prior to treatment, both groups of rictor KO mice demonstrated comparable startle reflex 
amplitude similar to Fig. 16b (data not shown). The average PPI across all sound levels 
also were not different between the two rictor KO groups prior to treatment (Fig. 20a; 
Student‘s t-test, P = 0.95). Following the initial PPI trial, the rictor KO mice received i.p. 
injections of either saline or nisoxetine (30 mg/kg) and 30 minutes later began a second 
PPI trial. Nisoxetine reversed rictor KO PPI deficits compared to saline treated animals 
with a ~5 fold increase of average PPI (Fig. 20b Student‘s t-test, ***P<0.0001). Similar 
to FLOX control mice (Fig. 16b), nisoxetine treated rictor KO mice display startle reflex 
amplitudes that are inhibited by all prepulse intensities, with the amount of PPI increasing 
monotonically from 40 – 75 dB SPL (Fig. 20c). Importantly, saline treated animals
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Figure 20.  Nisoxetine restores PPI deficits and DA levels in the rostral cortex of rictor 
KO mice. (a) No differences are observed in the average %PPI across the experimental 
range of dB in KO mice prior to treatment with saline or nisoxetine.  (b) Average %PPI 
30 min after i.p. injection of either saline or nisoxetine (30mg/kg) in KO mice reveals a 
significant increase in %PPI in nisoxetine treated KO mice.  (c) The mean PPI across all 
sound levels in KO mice treated with either saline or nisoxetine for 30 min; n=5-6, 
***P<0.001 Student‘s t-test.  (d) 8 days of nisoxetine treatment restores DA levels in the 
rostral cortex of rictor KO mice; n=4-6. *P<0.05 Student‘s t-test. 
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exhibited PPI at prepulse levels > 55 dB, albeit at a weaker level as compared to 
nisoxetine treated animals, consistent with Fig. 16b. Thus, nisoxetine treatment 
significantly reverses the PPI deficits observed in rictor KO mice (Fig. 20c; P < 0.0001 
by two way ANOVA) providing support for our model of mechanistic linkage between 
Akt, NET, and cortical DA and NE homeostasis.  
In addition to nisoxetine treatment, we sought to determine if traditional 
antipsychotics were capable of reversing the PPI deficits displayed in rictor KO mice. 
Unlike nisoxetine, acute clozapine treatment (i.p. 3 mg/kg for 30 minutes prior to PPI) 
did not rescue PPI deficits in rictor KO mice (data are reported as average percent PPI 
mean ± s.e.m. as in Fig. 16c; saline-KO 24.3 ± 8.6%, clozapine-KO 20.5 ± 6.4%; 
Student‘s t-test, P = 0.73). Interestingly, previous studies have shown that antipsychotic 
treatment enhances activity and phosphorylation of Akt at Ser473, and this increase is 
hypothesized to be important for the efficacy of such drugs (Emamian et al. 2004; Kang 
et al. 2004; Roh et al. 2007). Consistently, FLOX mice subjected to the same clozapine 
treatment as described above show significantly enhanced cortical phosphorylation of 
Akt at Ser473 (data are normalized to total levels of Akt and expressed as percent of 
control mean ± s.e.m.; saline-FLOX 100 ± 20%, clozapine-FLOX 215 ± 50%; *P < 0.05 
by one way ANOVA). Importantly, the same treatment does not alter Ser473 
phosphorylation of Akt in rictor KO mice (data are normalized to total levels of Akt and 
expressed as percent of control (saline treated FLOX) mean ± s.e.m.; saline-KO 5 ± 1%, 
clozapine-KO 5 ± 2%; P > 0.05 by one way ANOVA). Thus, the inability of clozapine to 
rescue PPI deficits in rictor KO mice may be partially due to the genetic neuronal 
deletion of rictor, which abolishes the ability of clozapine to enhance Akt Ser473 
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phosphorylation in these animals. These data are consistent with the hypothesis that Akt 
deficits play an important role in the etiology of schizophrenia, and that perhaps some 
degree of antipsychotic efficacy is due to their ability to enhance Akt function. 
The success of nisoxetine treatment in rescuing the PPI deficits in rictor KO mice 
was consistent with our model and led us next to determine if NET inhibition could 
normalize prefrontal cortex DA tissue content. In this experiment, rictor KO and FLOX 
control mice received either nisoxetine (30 mg/kg) or saline injections i.p. daily for eight 
consecutive days and were euthanized 30 min following their last i.p. injection. DA levels 
were measured in the rostral cortex by electrochemical detection. Similar to the results 
seen in Fig. 17, saline treated rictor KO mice had reduced DA tissue content levels in 
comparison to saline treated controls (Fig. 20d; Student‘s t-test, *P<0.04) and 8 days of 
nisoxetine treatment significantly enhanced DA content (Fig. 20d; Student‘s t-test, 
*P<0.03) while the same treatment in FLOX control mice did not have a significant 
impact on DA levels (Fig. 20d; Student‘s t-test, P = 0.21). Moreover, chronic nisoxetine 
treatment does not significantly alter cortical NE tissue content in either FLOX control or 
rictor KO mice (data are reported as ng of NE/mg protein, mean ± s.e.m.; FLOX-
saline=5.7 ± 0.4, FLOX-nisoxetine=6.5 ± 0.5, Student‘s t-test, P = 0.29; KO-saline=8.3 ± 
0.7, KO-nisoxetine=8.6 ± 0.4, Student‘s t-test, P = 0.74). These data further support the 
model that enhanced NET expression alters DA content in the rictor KO mice, and 
indicate that hypodopaminergia (and PPI deficits) can be rectified with NET specific 
inhibition via nisoxetine. The observations that chronic nisoxetine administration rescues 
DA content and acute treatment reverses impaired PPI are consistent with a model 
whereby impairment of PPI is due to decreased intra-synaptic DA in rictor KO mice. Our 
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data suggest that reduced intra-synaptic DA content could arise from enhanced clearance 
of DA via NET. 
NET specific inhibition with nisoxetine has been utilized to rectify PPI deficits in 
some animal models of schizophrenia (Yamashita et al. 2006). Only a small number of 
studies, however, have investigated the utility of NET specific inhibition in schizophrenic 
patients with a particular focus on symptoms related to cortical hypofunction, and the 
efficacy of such treatment is still controversial (Kelly et al. 2009). Currently, a number of 
additional clinical trials with substantial sample sizes are ongoing and promise to reveal 
if NET specific inhibition is therapeutic in schizophrenia, especially for cognitive 
symptoms such as poor concentration and memory (clinicaltrials.gov). 
 
Discussion 
The ―dopamine hypothesis‖ for schizophrenia has enjoyed a resurgence of 
interest, and increasing evidence links Akt to DA related behaviors, yet key molecular 
mechanisms linking Akt to DA homeostasis have been elusive. Given evidence for a role 
of Akt in the regulation of NET expression and function in cortex and evidence that NET 
transports DA in this brain area, it has been our priority to develop a compelling 
experimental model to uncover a molecular link between Akt and cortical DA 
homeostasis. Here, we conducted the first studies, to our knowledge, in an animal model 
where a genetic deletion that disrupts Akt phosphorylation enhances expression of NET 
and leads to a cortical hypodopaminergic phenotype with schizophrenia-linked 
behavioral consequences.  
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Our data are consistent with pathophysiological models of schizophrenia that 
emphasize ―hypofrontality‖ of DA systems. Given the role of NET in DA clearance in 
prefrontal synapses (Carvelli et al. 2002; Moron et al. 2002; Miner et al. 2003), Akt-
linked changes in NET expression may thereby translate to cognitive deficits and 
negative symptoms (Davis et al. 1991). These data, as well as our proof-of-principle 
results in mice, lead to the compelling hypothesis that NET inhibition would have 
therapeutic potential to selectively enhance DA tone in the prefrontal cortex and perhaps 
alleviate negative symptoms. Consistent with this reasoning, several clinical trials are 
currently investigating NET blockers for cognitive deficits in patients with schizophrenia.  
Our data demonstrate that neuronal mTORC2 dysfunction is sufficient to generate 
cortical hypodopaminergia and schizophrenia-linked behaviors. In particular, we show 
that genetic mTORC2 disruption impairs PPI, a schizophrenia-linked phenotype, which 
has been validated in genetic mouse models of the disorder (Powell et al. 2009). An 
emerging body of evidence associates Akt phosphorylation deficits with mental illness in 
humans, giving our findings of impaired Akt phosphorylation in mice more translational 
viability (Emamian et al. 2004; Keri et al. 2009). For example, studies show diminished 
Akt1 protein content in lymphocytes of patients with schizophrenia (Emamian et al. 
2004; Keri et al. 2009). In concert with our findings, candidate gene approaches aimed at 
identifying genetic variation in proteins associated with mTORC2/Akt signaling 
pathways, including rictor and other mTORC2 subunit proteins like mSin1 (Jacinto et al. 
2006) may yield new insights into the genetic basis of mental illness.  
Although DA is classically implicated in the pathogenesis of schizophrenia, 
concepts of neurotransmitter dysfunction in this disease process are constantly evolving. 
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This is reflected by popular glutamatergic and recently proposed revisions to 
dopaminergic hypotheses of schizophrenia (Howes et al. 2009). However, the role of 
elevated cortical NE, while not typically emphasized, should not be overlooked. Indeed, 
findings of elevated NE in CSF of patients with schizophrenia, which led to 
noradrenergic hypotheses of schizophrenia in the early 1980‘s (Lake et al. 1980), support 
our model by which increased cortical NET expression leads to increased NE content but 
decreased DA content. Although the sensitivity of these measurements to acute stressors 
made the reproducibility and reliability of these methods in the aforementioned studies 
questionable, a role for elevated NE in the development of schizophrenia-like phenotypes 
in humans cannot be completely ruled out. Indeed, our current findings, as well as others, 
intimately and mechanistically link DA alterations together with NE changes (Ventura et 
al. 2003). As a recent revision to the DA hypothesis of schizophrenia suggests, 
schizophrenia could be conceptualized as a disease where DA dysfunction is a ―final 
common pathway‖ that can be elicited by a number of more proximal causes, including 
both genetic and epigenetic factors and disruption in other neurotransmitter systems 
(Howes et al. 2009), and including, as we propose here, increased NET function. 
Schizophrenia is thought to arise from rather complex gene-environment 
interactions, and, therefore, acquired (rather than monogenetic) dysfunction in 
mTORC2/Akt signaling is a particularly intriguing mechanism. For example, acquired 
Akt defects are associated with impaired regulation of blood glucose and diabetes, which 
is over-represented in first episode, medication-naive patients with schizophrenia (Ryan 
et al. 2003). mTORC2/Akt signaling also provides a promising portal into ―multiple hit‖ 
models of schizophrenia, as Akt is positioned to interact with other candidate genes such 
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as neuregulin-1 and COMT (Kanakry et al. 2007; Tan et al. 2008) as well as 
environmental risk factors for schizophrenia including obstetric complications and early 
life stressors (Krishnan et al. 2008; Nicodemus et al. 2008). The effects of neuronal 
mTORC2 dysfunction on NET expression observed in our study ultimately illustrates a 
potential molecular mechanism to link disparate genetic and environmental factors (i.e. 
obesity/diabetes/insulin resistance) to dysfunction in a putative ―final common pathway‖ 
of schizophrenia, namely alterations in DA signaling (Howes et al. 2009). Indeed, while 
more remains to be learned about mTORC2, deficiencies in Akt signaling even in 
―healthy‖ individuals are associated with impaired prefrontal cortex activation on 
working memory tasks (Tan et al. 2008) and risk for psychosis, suggesting a subtle 
influence on brain function and behavior that may require other genetic and 
environmental hits to result in clinical disease. Thus, our data provide one molecular 
mechanism, NET regulation, towards a framework linking environmental stressors and/or 
lifestyle factors to mTORC2/Akt signaling and ultimately to DA dependent behaviors. 
Our studies provide a potential molecular mechanism linking Akt dysfunction to a 
schizophrenia-like phenotype and suggest the viability of targeting both Akt 
phosphorylation and NET as pharmacotherapies for schizophrenia. 
 
Materials and Methods 
Generation of mice 
All mice were fully backcrossed to C57Bl6 background. Mice homozygous for an 
allele containing LoxP sites flanking exon 3 of the rictor gene (rictor f/f Nes-/-; FLOX) 
were crossed with neuron specific Nestin cre transgenic mice (rictorw/w Nes+/+; NES) 
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obtained from Jackson Laboratories to create double heterozygous (rictorf/w NesCre+/-; 
HET) offspring (w is the wildtype allele). HET mice were then crossed to produce neuron 
specific rictor knockout mice (rictor f/f Nes+/+ or +/-; KO) and HET KO mice. Control 
animals were of the following genotypes (rictorf/f Nes-/- FLOX, rictorf/w Nes-/- and 
rictorw/w Nes+/+, Nes+/- or Nes-/-). Subsequent crossings between FLOX and HET 
mice were used to generate additional study animals. Genotyping was performed by PCR 
using DNA obtained from tail clippings with primers for the floxed, nestin and 
recombined alleles as described (Shiota et al. 2006).  
 
mRNA expression 
Total brain RNA was extracted from with Trizol reagent (Invitrogen). cDNA was 
synthesized with a High Capacity cDNA reverse transcription kit (Applied Biosystems). 
rictor mRNA was quantified with real time RT PCR on a Bio-Rad iCycler using iQ 
SYBR green Supermix reagent (Bio-Rad) and primer pairs as reported in (Shiota et al. 
2006). Expression was normalized to levels of the housekeeping gene RPL13.  
 
Immunoblot analysis 
Mice were anesthetized with volatile isoflurane after which rapid decapitation 
allowed brain removal. Brains were chilled on ice and dissected under a microscope for 
either total cortex, rostral cortex, or caudal cortex. Tissue was homogenized and lysed in 
a Triton based buffer that contained a cocktail of protease inhibitors plus NaF (2mM) and 
sodium orthovanadate (2mM). After homogenization samples were centrifuged at 
17,000Xg for 30 min, and the supernatant was collected and processed for protein 
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concentration determination. For western blotting, ≈30µg of protein per sample was run 
on a 10-12% acrylamide gel, transferred to a PVDF membrane blocked with 5% milk and 
incubated with primary antibodies to a variety of proteins. Akt, rictor, and mTOR 
antibodies were obtained from Cell Signaling. We also used actin (Sigma), Na+/K+ 
ATPase (DBH), NET (Mab Technologies Inc. NET05-2), and tyrosine hydroxylase 
(Chemicon/Millipore) antibodies. Secondary antibodies were obtained from Santa Cruz 
Biotechnology. After chemiluminescent visualization on Hyper-film ECL film, protein 
band densities were quantified and analyzed (Scion Image; http://www.scioncorp.com). 
 
Pre-pulse inhibition 
Startle responses were elicited with a 94 dB SPL broadband noise burst (2-75 
kHz, 50 ms duration, 0 ms rise/fall time) and measured through a floor plate mounted on 
piezo force transducers (PCB Piezotronics). In two-thirds of the trials, the noise burst 
(pulse) was preceded by a prepulse (2.4-78.2 kHz frequency-modulated sweep, 40 
octaves/s, 0.14 ms stimulus onset asynchrony) ranging from 40-75 dB SPL. Startle 
responses were measured across 297 trials (20 ± 6.4 sec intertrial interval, initial 27 trials 
discarded to minimize within-session habituation), as max – min of the force signal 
within 400 ms following onset of the noise burst.  Presence of a normal startle response 
(significant difference between force plate amplitude -600 to -200 ms (baseline) vs. 0-400 
ms (startle) from noise burst onset) was a prerequisite for subsequent analysis to 
minimize possible contributions of gross sensorimotor deficits in either genotype. This 
criterion excluded 2/8 WT and 0/7 rictor KO mice from further analysis. Inhibition of the 
122 
       
startle reflex was quantified for each prepulse intensity as PPI = 100 x ((pulse-alone) – 
(prepulse + pulse) / pulse alone). 
 
Tissue extraction for neurochemistry 
Brain sections were homogenized in 100-750 ul of 0.1M TCA, which contains 10-
2 M sodium acetate, 10-4 M EDTA, 5ng/ml isoproterenol (as internal standard) and 10.5 
% methanol (pH 3.8). Samples were spun in a microcentrifuge at 10000 g for 20 minutes, 
the supernatant removed and stored at –80 ºC. The pellet was saved for protein analysis. 
Supernatant was then thawed and spun for 20 minutes and then analyzed for biogenic 
monoamines and/or amino acids by a specific HPLC assay (Vanderbilt Neurochemistry 
Core). Biogenic amines were eluted in the following order: NE, MHPG, epinephrine, 
DOPAC, DA, 5-HIAA, HVA, 5-HT, and 3-MT (2).  
 
In vivo microdialysis 
Mice were anesthetized with isoflurane and placed in a stereotaxic frame using 
mouse-specific ear bars (Kopf Instruments, Tujunga, CA). A guide cannula (CMA7 
microdialysis, USA) was placed above the medial prefrontal cortex (+2.0 AP, ± 0.7 ML 
from Bregma and -1.0 DV from skull for FLOX or NES mice and (+1.9 AP, ± 0.6 ML 
from Bregma and -1.0 DV from skull for rictor KO mice and secured to the skull with 
epoxy adhesive (Plastics one). Animals were allowed to recover from the surgery (1-3 
days). The day before the experiment, animals were placed in individual dialysis 
chambers and the microdialysis probe (CMA7 microdialysis, USA) with the active length 
of 2 mm was inserted into the guide cannula. One end of a tether (Plastics One) is 
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attached to a harness and the other end attached to a swivel (Instech) that is mounted on a 
counterbalanced arm above the dialysis chamber. The probe was perfused overnight at a 
flow rate of 0.5 μL/min with artificial cerebral spinal fluid containing 149 mM NaCl, 2.8 
mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 5.4 mM d-glucose, pH 7.2. On the day of the 
experiment the flow rate was changed to 1.0 μL/min and after equilibration dialysis 
fractions (20 min each) were collected to establish baseline concentrations of 
neurotransmitter efflux. Dialysate samples were stored at -80°C and analyzed by HPLC-
EC for DA levels. Probe placement was verified after collection of slices by Nissl 
staining of coronal slices.  
 
Brain slice preparation and biotinylation 
Brain slices were prepared from 6- to 10-week-old mice that were anesthetized 
with isoflurane and rapidly decapitated. Following, brain removal the brain was chilled in 
oxygenated ≈4°C sucrose solution (sucrose 210mM; NaCl 20mM; KCl 2.5mM; MgCl2 
1mM; NaH2PO4•H2O 1.2mM), and then while in sucrose solution 300µm coronal slices 
were made using a vibratome. Slices were then collected in oxygenated artificial cerebral 
spinal fluid (ACSF) (NaCl 125mM, KCl 2.5mM,  NaH2PO4•H2O 1.2mM, MgCl2 1mM, 
CaCl2•2H2O 2mM). For in vitro drug treatments slices were then allowed to recover for 
1 hour at 37°C in oxygenated ACSF (NaCl 125mM, KCl 2.5mM, 1nM insulin, 
NaH2PO4•H2O 1.2mM, MgCl2 1mM, CaCl2•2H2O 2mM)with either vehicle or Akt1 
inhibitor and following recovery slices were then biotinylated. For non-treated slices, 
slices were immediately washed twice with oxygenated 4°C ACSF following collection, 
and then incubated with 4°C ACSF solution containing 1mg/mL of EZ-Link Sulfo-NHS-
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SS-Biotin (Pierce/ThermoScientific; Rockford, IL.) for 45 min. Slices were then washed 
twice with oxygenated 4°C ACSF, and then incubated with 4°C ACSF solution 
containing 1mg/mL of EZ-Link Sulfo-NHS-SS-Biotin (Pierce Chemical; Rockford, IL) 
for 45min. After biotin incubation, the slices were rinsed twice quickly and for two 10 
min washes in oxygenated 4°C ACSF. The reaction was quenched by washing twice for 
20 min each with oxygenated 4°C ACSF containing glycine. Following quenching, slices 
were frozen on dry ice and the cortex was cut out and frozen at -80°C until used. Slices 
were lysed in 1% Triton buffer (25mM Hepes, 150mM NaCl, 2mM sodium 
orthovanadate, 2mM NaF, plus a cocktail of protease inhibitors) and centrifuged at 
17,000g for 30min at 4°C. After isolation of supernatant 0.1% Triton pulldown buffer 
(25mM HEPES, 150mM NaCl, 2mM sodium orthovanadate, 2mM NaF, plus a cocktail 
of protease inhibitors) was added. Protein concentration was determined using Bio-Rad‘s 
protein concentration kit. Biotinylated proteins were then isolated using ImmunoPure 
immobilized streptavidin beads (Pierce) overnight at 4°C with agitation. Beads were 
washed three times with 0.1% Triton pulldown buffer and biotinylated proteins were then 
eluted in 50µL of 2X SDS-PAGE sample loading buffer at 95°C and then cooled to room 
temperature. Total slice lysates and the biotinylated (slice surface) fraction underwent 
immunodetection for NET (MabTechnoligies Inc. Stone Mountain, GA) as described 
previously.  
 
Synaptosomal uptake 
Mice were sacrificed by rapid decapitation and cortex dissected using an ice cold 
metal block and then homogenized at 400 rpm in at least 10 volumes (w/v) of ice-cold 
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0.32 M glucose with a Teflon-glass homogenizer (Wheaton Science Products, Millville, 
NJ). After centrifugation of the homogenate at 800g for 10 min at 4°C, the supernatant 
was again centrifuged at 10,000g for 15 min. The final pellet was gently resuspended in 
Krebs-Ringer HEPES (KRH) medium containing 118 mM NaCl, 4.8 mM KCl, 25 mM 
NaHCO3, 1 mM NaH2PO4, 1.3 mM CaCl2, 1.4 mM MgSO4, 10 mM glucose, 1 mM 
tropolone, 0.1 mM pargyline, and 0.1 mM ascorbic acid, pH 7.4 and protein 
concentration assayed. Aliquots (0.2 ml) of synaptosomal preparations (50 ng of protein) 
were prepared on ice. DA and NE transport assays (5 min at 37°C) were initiated by the 
addition of [3H]DA or [3H]NE (~100 Ci/mmol, Amersham) and were terminated by 
immediate filtration over 0.3% polyethylenimine-coated glass fiber filters using a cell 
harvester (Brandel Inc., Gaithersburg, MD). The filters were washed three times with 1.5 
ml of ice-cold phosphate-buffered saline (PBS) and incubated overnight in Ecoscint H 
(National Diagnostics, Atlanta, GA). Radioactivity bound to filters was counted using a 
Beckman LS 6000 liquid scintillation counter. Nonspecific uptake, defined as the 
accumulation of [3H]DA or [3H]NE in the presence of 1 µM desipramine, was subtracted 
from total uptake values to obtain specific uptake values.  
 
TH immunohistochemistry 
Mice (n = 6/genotype) were anesthetized and transcardially perfused with 4% 
paraformaldehyde. Brains were removed and cryopreserved, and coronal sections were 
cut on a microtome at 40 µm and stained using minor modifications of published 
protocols. Sections were blocked in 4% Blotto (Nestlé Carnation dried milk), 0.2% 
Triton-X 100 in PBS and incubated at 4°C for 3 days with a monoclonal anti-tyrosine 
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hydroxylase antibody (Sigma, 1:4000). Sections were thoroughly washed and then 
incubated in biotinylated anti-mouse IgG (Jackson Immunoresearch, 1:1000) for 60 min. 
Avidin-biotin amplification (Vectastain ABC Standard, Vector Labs) and 3-3‘-
diaminobenzidine reactions were used to visualize labeled proteins. Sections from all 
genotypes were processed in parallel to minimize variability between groups. Negative 
controls in which primary antibody was omitted revealed no specific labeling.  Slides 
were coded so that the investigator was blinded to the genotype and sections were imaged 
using a Zeiss Axioskop microscope and Axiocam HR. TH-immunoreactive (IR) cells 
were counted in images obtained with a 40X objective in two fields per hemisphere 
derived from 2-3 sections per animal. Values were corrected for cell diameter, but no 
differences in cell diameter were found across genotypes.  
 
Statistical analysis 
All data are expressed as the mean ± s.e.m. Statistical significance between 
groups was determined using t-tests or one and two-way ANOVAs followed by post hoc 
tests when the main effect or interaction was significant at P < 0.05. Statistical analyses 
were conducted using software from Graph-Pad Prism. The number of animals and 
specific statistical analyses used in each experiment are indicated in the results and figure 
legends. 
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CHAPTER IV 
 
DISCUSSION 
 Diseases characterized by peripheral insulin and Akt dysfunction such as diabetes 
and obesity are reaching epic proportions in the United States.  Indeed, recent national 
health surveys reveal that approximately two-thirds of adults in the United States are 
overweight, and almost one-third of the adult population is obese which translates into 
63.6 million people (www.niddk.nih.gov).  This alarming increase in the waistline of the 
average American is reflected by similarly increasing numbers of obesity related 
disorders such as diabetes which is currently estimated to affect 7.8 percent of the 
population.  On a more global level, these same trends are spreading rampantly as 
developing countries continue to adopt the ‗Western lifestyle‘ of diminished exercise and 
overconsumption of high calorie, high fat food.  As such, the already staggering 171 
million people afflicted worldwide with diabetes in 2000 is projected to increase to 366 
million by 2030 (Wild et al. 2004).  This barrage of data on a growing global problem 
highlights the necessity for understanding how insulin related disorders impact our 
health.   
In particular, a largely overlooked statistic is the substantial number of diabetic 
patients that suffer from monoamine related mental health disorders such as depression 
and schizophrenia.  In fact, depression affects more than one quarter of the diabetic 
population, a level that is nearly 5 times higher than that in the general population 
(Gavard et al. 1993; Anderson et al. 2001; Lustman et al. 2005).  While affliction with a 
life altering disorder such as diabetes may be a trigger for brain disorders, it is interesting 
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that a significant proportion of these individuals actually present with depressive 
symptoms several years prior to the onset of diabetes.  The high co-morbidity between 
schizophrenia and diabetes is equally surprising.  For example, a family history of type II 
diabetes is three times more likely in schizophrenic patients (Mukherjee et al. 1989; 
Mukherjee et al. 1996).  Consistently, studies of glucose tolerance in first episode, drug 
naive (these individuals have never received antipsychotics) schizophrenics, have 
revealed significant impaired fasting glucose tolerance implying diabetes-linked 
metabolic disruptions prior to the onset of mental illness (Ryan et al. 2003).  Thus, the 
increased prevalence of monoamine related mood disorders in the diabetic and obese 
populations insinuates a link between peripheral insulin signaling and brain function.  In 
addition, studies revealing altered levels of monoamines in various animal models of 
diabetes and in humans with diabetes also support this notion (Chu et al. 1986; Lucas et 
al. 1989; Lackovic et al. 1990; Shimizu 1991; Barber et al. 2003).   
Importantly, the primary source of brain insulin is from actively transported 
peripheral insulin across the blood brain barrier, thus aberrant alterations in peripheral 
insulin have the potential to significantly impact brain insulin signaling (Banks 2004).  
Insulin signaling in the brain has been shown to influence a variety of brain functions 
such as neurodevelopment, neurogenesis, neurotransmitter release, and importantly 
neurotransmitter reuptake (van der Heide et al. 2006).  Of particular interest here, was to 
understand the role of insulin signaling in the regulation of monoamine reuptake, 
specifically via its regulation of NET.  As such, the specific aims of this project were to: 
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I. Determine the role of insulin signaling in the regulation of NET in both 
the central nervous system (CNS) and the peripheral nervous system 
(PNS). 
II. Identify components of the insulin signaling pathway that are required 
for the regulation of NET. 
III. Study the physiological and behavioral consequences of manipulating 
this regulation in vivo.  
 
Collectively, our studies from heterologous systems, the CNS, and the PNS 
demonstrate that acute insulin exposure diminishes NET mediated NE uptake by 
decreasing the surface availability of the transporter.  These results were further extended 
by illustrations that severe chronic manipulations of peripheral insulin, as in the case of 
STZ-induced diabetes, significantly disrupt NET function and noradrenergic homeostasis. 
Support for functional consequences of these changes in monoamine homeostasis, comes 
from studies demonstrating behavioral deficits in STZ-induced hypoinsulinemic mice 
(Massol et al. 1989; Hilakivi-Clarke et al. 1990; Hirano et al. 2007; Alvarez et al. 2009).  
For example, these diabetic mice exhibit behavioral deficits particularly within the realm 
of monoamine related behaviors such as Porsolt‘s swim test, which is also held as an 
indicator of depressive symptoms in mice.  Thus, our studies provide proof of principle 
that aberrant peripheral insulin can directly impact brain insulin signaling, subsequent 
monoamine homeostasis, and perhaps ultimately behavior.  Correspondingly, this work 
provides implications for the high co-morbidity of insulin related disorders such as 
diabetes and obesity with noradrenergic related mood disorders such as depression.   
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While the data reported here supports a role for peripheral insulin in the 
regulation of brain monoamine homeostasis, STZ initiated depletion of insulin is a  
manipulation of body insulin that most closely resembles the untreated type I diabetic 
state in humans.  Today, as noted previously, the staggering worldwide increases in 
diabetes is primarily of the type II state which is almost always secondary to substantial 
weight gain or obesity and is characterized by a state of excessive insulin and insulin 
resistance rather than insulin depletion.  Thus, the consequences of this more subtle and 
slower in onset change in peripheral insulin on NET function and subsequent 
noradrenergic homeostasis remains to be determined.  Indeed, studies in the lab are 
currently underway to determine if a model of high fat, diet-induced obesity in rats, that 
more closely resembles the growing obesity epidemic, can contribute to changes in 
monoaminergic signaling and behavior.  
In addition to exploring the nature of insulin‘s regulation of NET, we also sought 
to identify specific components of the insulin signaling pathway that are critical for this 
regulation.  Our data, utilizing both pharmacological inhibitors and overexpression of a 
dominant negative form of Akt, supports a requirement for Akt in the insulin regulation 
of NET.  In addition, our studies demonstrate that Akt stimulation or inhibition, 
independent of insulin, also dynamically modulates NET surface levels thereby 
identifying Akt as a key regulator of the transporter.  Indeed, the phosphorylation status 
of Akt at residue ser473 correlates remarkably well with the surface availability of the 
transporter.  This identification of Akt as a potent regulator of NET function is 
particularly interesting when one considers the accumulating evidence for Akt 
dysfunction in various psychiatric disorders such as depression and schizophrenia.  The 
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newfound interest in Akt as a potential candidate gene for these monoamine related mood 
disorders is a rather recent development.  In fact, the first study that provided substantial 
converging evidence for Akt dysfunction in schizophrenia did not appear until 2004 
(Emamian et al. 2004).  Here, the authors demonstrated a significant decrease in Akt1 
protein levels in the peripheral lymphocytes and post-mortem brain tissue from 
individuals with schizophrenia.  In addition, they also illustrated the ability of 
antipsychotics to increase Akt phosphorylation as well as provided evidence for a 
significant association between schizophrenia and an Akt haplotype associated with 
diminished protein levels.  Since these original observations, numerous studies have 
followed suit and provided additional evidence for an association of Akt gene variants 
with schizophrenia (Ikeda et al. 2004; Schwab et al. 2005; Bajestan et al. 2006; Norton et 
al. 2007; Xu et al. 2007; Dawn et al. 2008).  In addition to these reports, other patient 
studies have investigated the phosphorylation of Akt in response to activation of 
upstream signaling pathways.  Indeed, Neuregulin 1-stimulated phosphorylation of Akt 
has been shown to be deficient in schizophrenics and other patients with psychosis (Keri 
et al. 2009; Keri et al. 2009).  Similarly, substantial deficits in the insulin receptor (IR) 
signaling pathway have also been reported (Zhao et al. 2006).  In this particular study, 12 
schizophrenic patients had significant deficits in IR levels, IR phosphorylation, Akt 
levels, and phosphorylation of Akt at ser473 in the dorsolateral PFC.  These findings are 
of particular interest when one considers our demonstration of correlations between Akt 
ser473 phosphorylation and NET surface levels.  Perhaps, these individuals, with 
substantial IR signaling deficits may also have significantly enhanced NET function.   
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In conjunction with the substantial number of post-mortem human studies 
supporting a link between Akt dysfunction and schizophrenia, Akt deficient animal 
models as well as functional imaging studies on humans with low expressing Akt variants 
also support a role for this pathway in the pathology of the disorder.  Indeed, work from 
the Weinberger lab connects Akt variation with disruption of schizophrenia-linked 
prefrontal-striatal monoamine related brain functions (Tan et al. 2008).  While studies on 
Akt1 deficient mice also reveal deficits in PFC development and structure which the 
authors propose predisposes these mice to deficits in PFC related tasks (Lai et al. 2006).  
Importantly, while these studies link Akt dysfunction with specific aspects of 
schizophrenia pathology they fail to provide plausible molecular mechanisms by which 
this dysfunction may actually contribute to the disorder.   
 Given the role of Akt in the regulation of NET and the importance of the 
transporter in maintaining the fidelity of cortical dopaminergic and global noradrenergic 
signaling, we hypothesized that disruptions in Akt signaling in vivo may disrupt 
monoamine homeostasis and lead to subsequent behavioral deficits.  Indeed, neuronal 
deletion of rictor, a vital component of the mTORC2 complex responsible for Akt ser473 
phosphorylation, results in schizophrenia-linked behavioral deficits (i.e. abnormal PPI) as 
well as alterations in cortical monoamine homeostasis.  In particular, these mice exhibit a 
pronounced increase in cortical NE tissue content as well as a significant diminishment of 
cortical DA tissue content.  Interestingly, current conceptualizations of schizophrenia 
support a role for such cortical hypofunction and hypodopaminergia as is seen in these 
rictor KO mice.  In addition, we provide evidence that these deficits arise due to aberrant 
increases in NET surface expression and function, given pharmacological inhibition of 
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the transporter restores both deficits.  Thus, these data provide one plausible molecular 
mechanism, the anomalous Akt regulation of NET, by which Akt dysfunction may lead 
to specific impairments (i.e. PPI deficits and cortical hypodopaminergia) associated with 
schizophrenia.   
 Indications of Akt dysfunction in neuropsychiatric disorders, however, are not 
limited to the pathology of schizophrenia.  In fact, a few, rather recent studies have 
implicated Akt dysfunction in depression, a disorder that is already heavily associated 
with noradrenergic dysfunction and in some instances specifically with abnormally 
functioning NET variants (Hahn et al. 2005; Haenisch et al. 2008; Hahn et al. 2008).  For 
instance, significant reductions in Akt activity were found in the ventral PFC of both 
depressed non-suicide and depressed suicide victims but not in non-depressed suicide 
victims (Karege et al. 2007).  Similarly, reductions in cortical PI3K and Akt activity were 
also reported by an independent group (Hsiung et al. 2003).  Furthermore, the disrupted-
in-schizophrenia 1 (DISC1) gene has been associated with major depressive disorder, and 
signaling through this pathway ultimately converges on and stimulates Akt activity 
(Hashimoto et al. 2006).  Finally, studies in stress induced animal models of depression 
also reveal significant reductions in the levels of Akt activity and phosphorylation 
(Krishnan et al. 2008).  Also, the authors demonstrate that these reductions in Akt activity 
are both necessary and sufficient to initiate depressive behaviors.  To extend their studies 
further, the authors show that, like antipsychotics, chronic antidepressant treatment 
significantly increases Akt phosphorylation not only in their animal model but also in 
postmortem brain tissue from chronically treated depressed patients.  Altogether, these 
studies supporting a link between Akt dysregulation and depression encourage further 
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investigation into the subject.  For instance, are Akt1 variants associated with lower 
protein levels which have been linked to schizophrenia also associated with depressive 
disorders?  Or, perhaps, depressive or anxiety related behaviors stand out in individuals 
possessing such Akt alleles.  Similarly, do depressive/anxiety phenotypes express in Akt 
defective animal models such as the rictor KO mice?  Answers to questions such as these, 
promise to offer new insight into the role Akt may play in depression.   
 Cumulatively, our data indicates that deficits in Akt signaling sustain abnormally 
elevated levels of NET surface expression and function.  Given the recent identification 
of schizophrenic patients with Akt variants associated with low levels of protein, it would 
be interesting to determine if these specific individuals have altered NET levels via post 
mortem and PET imaging studies.  Considering the heterogeneous nature of 
schizophrenia, such studies in general schizophrenic populations may yield little insight.  
However, narrowing the criterion for inclusion (i.e. only Akt1 variant possessing 
schizophrenics) in studies searching for changes in transporter levels/function may 
increase the chances of seeing through correlates from rictor KO mice to human studies.  
Similarly, examining these individuals for deficits in specific NE related functions such 
as attention, working memory, and anxiety may be advantageous.  Another important 
consideration for Akt1 variant possessing individuals is the use of NET specific inhibitors 
for treatment especially for cognitive related symptoms.  Although studies of NET 
specific inhibition for the alleviation of negative symptoms in schizophrenia are currently 
underway (www.clinicaltrials.gov), such studies may be aided by again narrowing the 
criterion for inclusion to only those individuals with Akt1 variation.  Perhaps, this 
alternative treatment will prove more efficacious in individuals whom we would 
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hypothesize to have aberrant transporter regulation.  A similar rationale could be applied 
for the antipsychotic clozapine, which targets numerous receptors beyond the D2DR and 
in particular impacts noradrenergic receptor signaling, and as we show here actually 
increases Akt activity and subsequently reduces NET surface levels.  Interestingly, some, 
still debated, reports indicate that clozapine is especially effective at treating the hard to 
alleviate cognitive symptoms of schizophrenia.  Perhaps, this increased efficacy may in 
part be due to this drug‘s ability to manipulate NET levels and thus presumably alter NE 
within the cortex which is crucial for optimal attention/cognition.  Clozapine however, is 
not the only antipsychotic that increases Akt phosphorylation and activity (Kang et al. 
2004; Lu et al. 2004; Lu et al. 2005; Roh et al. 2007), although whether these other 
antipsychotics are capable of impacting NET function/availability remains to be 
determined.  Despite our focus on NET here, given the general implication of Akt 
dysfunction in schizophrenia and the fact that antipsychotics appear to combat these 
deficits, we ought not to forget evidence for Akt regulation of the DAT.  Perhaps 
antipsychotics further impact the dopaminergic system beyond D2DR signaling by 
stimulating Akt regulation of the DAT. 
 As mentioned previously, our studies reveal a significant divergence in the Akt 
regulation of two fairly homologous transporters, the DAT and the NET.  Indeed, for the 
DAT insulin appears to be crucial for transporter function by maintaining DAT levels at 
the surface while insulin/Akt stimulation decreases NET function and surface expression.  
The obvious question then becomes, how does this divergent regulation occur for two 
very similar transporters.  Interestingly, similar paradoxical scenarios exist for the insulin 
regulation of other important CNS proteins, such as AMPA receptors.  Indeed, for AMPA 
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receptors, depending on the developmental context, insulin will stimulate AMPA receptor 
internalization under one condition and exocytosis in another (Man et al. 2000; Plitzko et 
al. 2001; Zhao et al. 2004).  As in our case, however, the reason for such divergent 
regulation is unknown.  One plausible explanation for the differential regulation of NET 
versus DAT lies in the structural differences between the two transporters.  Whereas the 
majority of NET and DAT is fairly homologous, the intracellular N- and C- termini of 
these transporters are not very well conserved (Gu et al. 2001).  In addition, these regions 
are also the most heavily targeted areas of the transporter by intracellular signaling 
pathways for trafficking regulation.  Thus, creating and examining insulin induced 
trafficking in a NET construct with the DAT‘s N-terminus rather than its own (or vice 
versa) may offer unique insight about the structural determinants which dictate the 
direction of insulin regulation.  Another plausible explanation for the divergent Akt 
regulation of the monoamine transporters is the cellular context in which the signaling is 
initiated.  In other words, insulin/Akt signaling in noradrenergic neurons may impact 
differential downstream targets in comparison to the Akt initiated signaling in 
dopaminergic neurons.  Exogenous expression of NET in DAT KO dopaminergic 
neurons (or vice versa) could determine if indeed neuronal environment dictates the 
direction of transporter regulation.  Along a similar rationale, insulin/Akt-induced NET 
trafficking correlates very well with phosphorylation status of Akt at ser473.  
Alternatively, ongoing studies in the lab indicate that insulin induced changes in DAT 
function correspond more so with the phosphorylation of Akt at residue thr308.  
Importantly, studies support the notion that Akt phosphorylation status dictates 
differential substrate specificity and thus activation of unique signaling pathways 
137 
       
(Guertin et al. 2006; Jacinto et al. 2006).  Consistent with this notion, ser473 
phosphorylation of Akt is absolutely required for phosphorylation of the Akt substrate 
FoxO1/3a but not for GSK3 targeting.  Interestingly, in support of this hypothesis, so far, 
changes in DAT expression in Akt ser473 deficient rictor KO mice are not nearly as 
striking as changes in NET expression and function in these animals.  Thus, perhaps 
phosphorylated ser473 Akt initiated signaling pathways impact NET function more 
significantly than DAT.  This hypothesis raises the question, of whether PDK1 KO mice, 
which would be deficient in thr308 Akt phosphorylation, would show substantial changes 
in NET expression. Such studies promise to uncover how seemingly similar monoamine 
transporters are so differentially regulated by insulin and Akt signaling. 
 Another interesting, yet overlooked aspect of this research is the evidence for a 
role of Akt  in the regulation of NET transcription.  Indeed, several early investigations 
into the insulin regulation of the transporter supported its ability to downregulate NET 
mRNA (Figlewicz et al. 1993; Figlewicz et al. 1996).  In addition, our data involving 
chronic manipulation of insulin/Akt signaling also supports this notion.  Both STZ 
induced hypoinsulinemic mice and Akt signaling deficient rictor KO mice exhibit 
significantly increased levels of total NET protein.  This ability of Akt to initiate both 
trafficking and transcription renders the question, what downstream components instigate 
these two distinct aspects of transporter regulation? Although Akt is known to target 
several transcription factors, none of these known factors have been shown to impact 
NET transcription.  Indeed, relatively few transcription factors for NET have been 
identified (i.e. Phox2, MeCP2, Slug) (Kim et al. 2006; Fan et al. 2009; Harikrishnan et al. 
2010).  Thus, investigations of Akt related changes in NET transcription would be a very 
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new and exciting avenue of research.  Similarly, the number of potential downstream 
targets for the Akt regulation of NET trafficking is staggering.  Although insulin 
signaling regulates the availability of other membrane targeted proteins beyond the 
monoamine transporters, such as the glucose transporter, the epithelial Na+ channel 
(ENaC), the insulin receptor itself, and AMPA receptors, the majority of these examples 
are instances of insulin stimulated increases in protein surface levels.  Those of which are 
examples of insulin initiated decreases in surface expression offer few parallels from our 
current knowledge of NET trafficking regulation.  Thus, here to, an entirely new avenue 
of research is open ground to develop a complete understanding of how Akt initiates 
decreases in NET surface expression.  As noted before, one potential starting point for 
both of these avenues of research is the striking correlation between Akt ser473 
phosphorylation and NET regulation.  Since phosphorylation status dictates differential 
substrate specificity, starting the search off with Akt ser473 specific substrates may 
narrow the vast pool of potential downstream components.       
 In conclusion, the data presented here demonstrates that peripheral changes in 
insulin and Akt signaling are capable of impacting transporter function, subsequent 
monoamine homeostasis, and ultimately behavior.  Given the unprecedented rise in 
insulin related disorders worldwide, these data further necessitate our continued study of 
how disruptions in brain insulin signaling may impact mental health.  Furthermore, 
independent of peripheral insulin disorders, Akt dysfunction in its own right has been 
implicated in a number of neuropsychiatric disorders associated with monoamine 
dysfunction.  Here, we provide evidence that Akt dysfunction directly impacts 
monoamine homeostasis via its aberrant regulation of NET.  Thus, providing one small 
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molecular insight into how Akt dysfunction may contribute to the pathology of mood 
disorders.  More importantly, when trying to understand the pathological underpinnings 
of these monoamine related mental diseases, these studies remind us not to forget the 
neglected noradrenergic system and in particular the beloved NET.  Indeed, prior 
experience has demonstrated that single mutations in the transporter are capable of 
instigating complex and devastating disease states (i.e. orthostatic intolerance).  Thus, 
understanding transporter function and importantly transporter regulation at an intricate 
level promises only new insight and unique therapeutic opportunities in the realm of 
mental health research.   
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APPENDIX 
 
 
Appendix Figure A1. SCGN express the insulin receptor at NET enriched boutons.  
Mouse SCGNs were cultured and processed for immunocytochemistry as described in 
Material and Methods.  Shown is a confocal image of a SCGN bouton co-stained for 
NET (green) and the insulin receptor β subunit (IRβ) (red).  The images depict a single 
bouton with associated axons (linear structures).  The bouton is marked by NET 
immunoreactivity as well as IRβ immunoreactivity. 
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Appendix Figure A2.  STZ treatment induces a significant increase in blood glucose 
levels.  Male C57BL/6J 15 to 20-week-old mice from Jackson Laboratories receive either 
vehicle (CTR) or STZ (200 mg/kg, i.p.) injections and then are returned to their home 
cages for 7-10 days.  Blood glucose levels are measured prior to injection and post 
injection.  Blood glucose measurements of CTR versus STZ mice pre and post injection 
are represented. (mean ± s.e.m, ***P<0.001 by Student‘s t-test;  N=8-7).   
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Appendix Figure A3.  Both Akt1 and Akt2 isoforms are found at boutons of SCGN 
cultures.  Mouse SCGNs were cultured and processed for immunocytochemistry as 
described in Material and Methods.  SCGN boutons co-stained for NET (green) and Akt1 
(red top panel) or Akt2 (red bottom panel).  Images depict single boutons with associated 
axons (linear structures).  The perimeter of the boutons is marked by NET 
immunoreactivity as well as intra-bouton Akt1 and Akt2 immunoreactivity. 
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Appendix Figure B1.  Rictor mRNA levels and protein expression in the brain are 
reduced in a gene-dosage dependent manner.  (a) qRT-PCR confirms down regulation of 
the rictor gene in HET and KO mice.  Mean ± s.e.m relative expression shown as a 
percentage of FLOX control mice; n=4-5 animals.  Panel A courtesy of Kevin 
Niswender. (b) Rictor protein levels in the cerebral cortex.  Mean ± s.e.m optical 
densities are shown as a percentage of FLOX control mice; n=5, *P<0.05; **P<0.01 
One-way ANOVA.  
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Appendix Figure B2.  Akt1 inhibition enhances NET surface availability in cortical 
slices.  (a) Levels of NET as measured from the different fractions (surface, total) of 
cortical slices from NES control mice.  Slices were treated with either vehicle-DMSO 
(CTR) or 12 µM of the Akt1 inhibitor.  Mean ± s.e.m optical density were normalized to 
total NET and are shown as a percentage of CTR. Representative immunoblots are 
shown, as probed with antibodies to NET, Na
+
/K
+
 ATPase to serve as plasma 
membrane/loading control; n=4, *P<0.05 Student‘s t-test. (b) Phosphorylation of Akt on 
residue Ser473 measured from the same samples as panel A.  Mean ± s.e.m of optical 
densities normalized to total Akt and shown as a percentage of CTR; n=4, ***P<0.001 
Student‘s t-test.   
 
145 
       
REFERENCES 
 
Abercrombie, E. D., R. W. Keller, Jr. and M. J. Zigmond (1988). "Characterization of 
hippocampal norepinephrine release as measured by microdialysis perfusion: 
pharmacological and behavioral studies." Neuroscience 27(3): 897-904. 
 
Alvarez, E. O., J. Beauquis, Y. Revsin, A. M. Banzan, P. Roig, A. F. De Nicola and F. 
Saravia (2009). "Cognitive dysfunction and hippocampal changes in experimental 
type 1 diabetes." Behav Brain Res 198(1): 224-30. 
 
Anderson, I. M. (1998). "SSRIS versus tricyclic antidepressants in depressed inpatients: a 
meta-analysis of efficacy and tolerability." Depress Anxiety 7 Suppl 1: 11-7. 
 
Anderson, I. M. (2000). "Selective serotonin reuptake inhibitors versus tricyclic 
antidepressants: a meta-analysis of efficacy and tolerability." J Affect Disord 
58(1): 19-36. 
 
Anderson, R. J., K. E. Freedland, R. E. Clouse and P. J. Lustman (2001). "The prevalence 
of comorbid depression in adults with diabetes: a meta-analysis." Diabetes Care 
24(6): 1069-78. 
 
Androutsellis-Theotokis, A. and G. Rudnick (2002). "Accessibility and conformational 
coupling in serotonin transporter predicted internal domains." J Neurosci 22(19): 
8370-8. 
 
Apparsundaram, S., A. Galli, L. J. DeFelice, H. C. Hartzell and R. D. Blakely (1998). 
"Acute regulation of norepinephrine transport: I. protein kinase C-linked 
muscarinic receptors influence transport capacity and transporter density in SK-
N-SH cells." Journal of Pharmacology & Experimental Therapeutics 287(2): 733-
43. 
 
Apparsundaram, S., S. Schroeter, E. Giovanetti and R. D. Blakely (1998). "Acute 
regulation of norepinephrine transport: II. PKC-modulated surface expression of 
human norepinephrine transporter proteins." J Pharmacol Exp Ther 287(2): 744-
51. 
 
Apparsundaram, S., U. H. Sung, R. D. Price and R. D. Blakely (2001). "Trafficking-
dependent and -independent pathways of neurotransmitter transporter regulation 
differentially involving p38 mitogen-activated protein kinase revealed in studies 
of insulin modulation of norepinephrine transport in SK-N-SH cells." Journal of 
Pharmacology & Experimental Therapeutics 299(2): 666-677. 
 
Arguello, P. A. and J. A. Gogos (2008). "A signaling pathway AKTing up in 
schizophrenia." J Clin Invest 118(6): 2018-21. 
 
146 
       
Arnsten, A. F. (2007). Norepinephrine and Cognitive Disorders. Brain Norepinephrine: 
Neurobiology and Therapeutics, G. A. S. Ordway, M.A.; Frazer, A. New York, 
Cambridge University Press. 
 
Ashby, C. R., Jr. and R. Y. Wang (1996). "Pharmacological actions of the atypical 
antipsychotic drug clozapine: a review." Synapse 24(4): 349-94. 
 
Aston-Jones, G. and F. E. Bloom (1981). "Activity of norepinephrine-containing locus 
coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking 
cycle." J Neurosci 1(8): 876-86. 
 
Aston-Jones, G. and J. D. Cohen (2005). "Adaptive gain and the role of the locus 
coeruleus-norepinephrine system in optimal performance." J Comp Neurol 
493(1): 99-110. 
 
Aston-Jones, G., J. Rajkowski and J. Cohen (1999). "Role of locus coeruleus in attention 
and behavioral flexibility." Biol Psychiatry 46(9): 1309-20. 
 
Aston-Jones, G. G., Monica; Doran, Scott (2007). Role of the locus coeruleus-
norepinephrine system in arousal and circadian regulation of the sleep-wake 
cycle. Brain Norepinephrine: Neurobiology and Therapeutics. G. A. S. Ordway, 
M.A.; Frazer, A. New York, Cambridge University Press: 157. 
 
Aston-Jones, G. I., M.; Clayton, E.; Rajkowski, J.; Cohen, J. (2007). The locus coeruleus 
and regulation of behvioral flexibility and atention: clinical implications. Brain 
Norepinephrine: Neurobiology and Therapeutics, G. A. S. Ordway, M.A.; Frazer, 
A. New York, Cambridge University Press. 
 
Axelrod, J. (1965). "The Metabolism, Storage, and Release of Catecholamines." Recent 
Prog Horm Res 21: 597-622. 
 
Axelrod, J. (1971). "Noradrenaline: fate and control of its biosynthesis." Science 
173(997): 598-606. 
 
Axelrod, J. and I. J. Kopin (1969). "The uptake, storage, release and metabolism of 
noradrenaline in sympathetic nerves." Prog Brain Res 31: 21-32. 
 
Axelrod, J. and R. Tomchick (1958). "Enzymatic O-methylation of epinephrine and other 
catechols." J Biol Chem 233(3): 702-5. 
 
Bajestan, S. N., A. H. Sabouri, M. Nakamura, H. Takashima, M. R. Keikhaee, F. 
Behdani, M. R. Fayyazi, M. R. Sargolzaee, M. N. Bajestan, Z. Sabouri, E. 
Khayami, S. Haghighi, S. B. Hashemi, N. Eiraku, H. Tufani, H. Najmabadi, K. 
Arimura, A. Sano and M. Osame (2006). "Association of AKT1 haplotype with 
the risk of schizophrenia in Iranian population." Am J Med Genet B 
Neuropsychiatr Genet 141B(4): 383-6. 
147 
       
Baker, K. G., I. Tork, J. P. Hornung and P. Halasz (1989). "The human locus coeruleus 
complex: an immunohistochemical and three dimensional reconstruction study." 
Exp Brain Res 77(2): 257-70. 
 
Baldessarini, R. J., D. Huston-Lyons, A. Campbell, E. Marsh and B. M. Cohen (1992). 
"Do central antiadrenergic actions contribute to the atypical properties of 
clozapine?" Br J Psychiatry Suppl(17): 12-6. 
 
Banks, W. A. (2004). "The source of cerebral insulin." Eur J Pharmacol 490(1-3): 5-12. 
 
Barber, M., B. S. Kasturi, M. E. Austin, K. P. Patel, S. M. MohanKumar and P. S. 
MohanKumar (2003). "Diabetes-induced neuroendocrine changes in rats: role of 
brain monoamines, insulin and leptin." Brain Res 964(1): 128-35. 
 
Beaulieu, J. M., R. R. Gainetdinov and M. G. Caron (2009). "Akt/GSK3 signaling in the 
action of psychotropic drugs." Annu Rev Pharmacol Toxicol 49: 327-47. 
 
Bell, R. H., Jr. and R. J. Hye (1983). "Animal models of diabetes mellitus: physiology 
and pathology." J Surg Res 35(5): 433-60. 
 
Bennett, M. R. (2000). "The concept of transmitter receptors: 100 years on." 
Neuropharmacology 39(4): 523-46. 
 
Berman, R. M., M. Narasimhan, H. L. Miller, A. Anand, A. Cappiello, D. A. Oren, G. R. 
Heninger and D. S. Charney (1999). "Transient depressive relapse induced by 
catecholamine depletion: potential phenotypic vulnerability marker?" Arch Gen 
Psychiatry 56(5): 395-403. 
 
Biegon, A. and S. Fieldust (1992). "Reduced tyrosine hydroxylase immunoreactivity in 
locus coeruleus of suicide victims." Synapse 10(1): 79-82. 
 
Binda, F., C. Dipace, E. Bowton, S. D. Robertson, B. J. Lute, J. U. Fog, M. Zhang, N. 
Sen, R. J. Colbran, M. E. Gnegy, U. Gether, J. A. Javitch, K. Erreger and A. Galli 
(2008). "Syntaxin1A Interaction with the Dopamine Transporter Promotes 
Amphetamine-Induced Dopamine Efflux." Mol Pharmacol. 
 
Blakely, R. D. and L. J. DeFelice (2007). "All aglow about presynaptic receptor 
regulation of neurotransmitter transporters." Mol Pharmacol 71(5): 1206-8. 
 
Blakely, R. D., S. Ramamoorthy, S. Schroeter, Y. Qian, S. Apparsundaram, A. Galli and 
L. J. DeFelice (1998). "Regulated phosphorylation and trafficking of 
antidepressant-sensitive serotonin transporter proteins." Biological Psychiatry 
44(3): 169-78. 
 
Bonisch, H. and M. Bruss (2006). "The norepinephrine transporter in physiology and 
disease." Handb Exp Pharmacol(175): 485-524. 
148 
       
Boudanova, E., D. M. Navaroli and H. E. Melikian (2008). "Amphetamine-induced 
decreases in dopamine transporter surface expression are protein kinase C-
independent." Neuropharmacology 54(3): 605-12. 
 
Boudanova, E., D. M. Navaroli, Z. Stevens and H. E. Melikian (2008). "Dopamine 
transporter endocytic determinants: Carboxy terminal residues critical for basal 
and PKC-stimulated internalization." Mol Cell Neurosci. 
 
Boyd, F. T., Jr., D. W. Clarke, T. F. Muther and M. K. Raizada (1985). "Insulin receptors 
and insulin modulation of norepinephrine uptake in neuronal cultures from rat 
brain." J Biol Chem 260(29): 15880-4. 
Boyd, F. T., Jr., D. W. Clarke and M. K. Raizada (1986). "Insulin inhibits specific 
norepinephrine uptake in neuronal cultures from rat brain." Brain Research 
398(1): 1-5. 
 
Breier, A., O. M. Wolkowitz, A. Roy, W. Z. Potter and D. Pickar (1990). "Plasma 
norepinephrine in chronic schizophrenia." Am J Psychiatry 147(11): 1467-70. 
 
Bridge, T. P., J. E. Kleinman, F. Karoum and R. J. Wyatt (1985). "Postmortem central 
catecholamines and antemortem cognitive impairment in elderly schizophrenics 
and controls." Neuropsychobiology 14(2): 57-61. 
 
Bridge, T. P., J. E. Kleinman, B. J. Soldo and F. Karoum (1987). "Central 
catecholamines, cognitive impairment, and affective state in elderly 
schizophrenics and controls." Biol Psychiatry 22(2): 139-47. 
 
Bruning, J. C., D. Gautam, D. J. Burks, J. Gillette, M. Schubert, P. C. Orban, R. Klein, 
W. Krone, D. Muller-Wieland and C. R. Kahn (2000). "Role of brain insulin 
receptor in control of body weight and reproduction." Science 289(5487): 2122-5. 
 
Bruss, M., R. Hammermann, S. Brimijoin and H. Bonisch (1995). "Antipeptide 
antibodies confirm the topology of the human norepinephrine transporter." J Biol 
Chem 270(16): 9197-201. 
 
Burn, J. H. and M. J. Rand (1958). "The action of sympathomimetic amines in animals 
treated with reserpine." J Physiol 144(2): 314-36. 
 
Burnette, W. B., M. D. Bailey, S. Kukoyi, R. D. Blakely, C. G. Trowbridge and J. B. 
Justice, Jr. (1996). "Human norepinephrine transporter kinetics using rotating disk 
electrode voltammetry." Analytical Chemistry 68(17): 2932-8. 
 
Callado, L. F., J. J. Meana, B. Grijalba, A. Pazos, M. Sastre and J. A. Garcia-Sevilla 
(1998). "Selective increase of alpha2A-adrenoceptor agonist binding sites in 
brains of depressed suicide victims." J Neurochem 70(3): 1114-23. 
 
149 
       
Carlsson, A., N. A. Hillarp and B. Waldeck (1962). "A Mg-ATP dependent storage 
mechanism in the amine granules of the adrenal medulla." Med Exp Int J Exp 
Med 6: 47-53. 
 
Carlsson, A. and M. Lindqvist (1963). "Effect of Chlorpromazine or Haloperidol on 
Formation of 3methoxytyramine and Normetanephrine in Mouse Brain." Acta 
Pharmacol Toxicol (Copenh) 20: 140-4. 
 
Carlsson, A., M. Lindqvist, T. Magnusson and B. Waldeck (1958). "On the presence of 
3-hydroxytyramine in brain." Science 127(3296): 471. 
Carvelli, L., R. D. Blakely and L. J. DeFelice (2008). "Dopamine transporter/syntaxin 1A 
interactions regulate transporter channel activity and dopaminergic synaptic 
transmission." Proc Natl Acad Sci U S A 105(37): 14192-7. 
 
Carvelli, L., J. A. Moron, K. M. Kahlig, J. V. Ferrer, N. Sen, J. D. Lechleiter, L. M. 
Leeb-Lundberg, G. Merrill, E. M. Lafer, L. M. Ballou, T. S. Shippenberg, J. A. 
Javitch, R. Z. Lin and A. Galli (2002). "PI 3-kinase regulation of dopamine 
uptake." J Neurochem 81(4): 859-69. 
 
Cervinski, M. A., J. D. Foster and R. A. Vaughan (2005). "Psychoactive substrates 
stimulate dopamine transporter phosphorylation and down regulation by cocaine 
sensitive and protein kinase C dependent mechanisms." J Biol Chem. 
 
Chalecka-Franaszek, E. and D. M. Chuang (1999). "Lithium activates the 
serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of 
Akt-1 activity in neurons." Proceedings of the National Academy of Sciences of 
the United States of America 96(15): 8745-50. 
 
Chan-Palay, V. and E. Asan (1989). "Alterations in catecholamine neurons of the locus 
coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease 
with and without dementia and depression." J Comp Neurol 287(3): 373-92. 
 
Chan-Palay, V. and E. Asan (1989). "Quantitation of catecholamine neurons in the locus 
coeruleus in human brains of normal young and older adults and in depression." J 
Comp Neurol 287(3): 357-72. 
 
Charney, D. S. (1998). "Monoamine dysfunction and the pathophysiology and treatment 
of depression." J Clin Psychiatry 59 Suppl 14: 11-4. 
 
Chen, J. G., S. Liu-Chen and G. Rudnick (1998). "Determination of external loop 
topology in the serotonin transporter by site-directed chemical labeling." J Biol 
Chem 273(20): 12675-81. 
 
Chi, L. and M. E. Reith (2003). "Substrate-induced trafficking of the dopamine 
transporter in heterologously expressing cells and in rat striatal synaptosomal 
preparations." J Pharmacol Exp Ther 307(2): 729-36. 
150 
       
Chu, P. C., M. T. Lin, L. R. Shian and S. Y. Leu (1986). "Alterations in physiologic 
functions and in brain monoamine content in streptozocin-diabetic rats." Diabetes 
35(4): 481-5. 
 
Cohen, B. M. and J. F. Lipinski (1986). "In vivo potencies of antipsychotic drugs in 
blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug 
mechanisms of action." Life Sci 39(26): 2571-80. 
Corman, S. L., B. A. Fedutes and C. M. Culley (2004). "Atomoxetine: the first 
nonstimulant for the management of attention-deficit/hyperactivity disorder." Am 
J Health Syst Pharm 61(22): 2391-9. 
 
Cowell, R. M., L. Kantor, G. H. Hewlett, K. A. Frey and M. E. Gnegy (2000). 
"Dopamine transporter antagonists block phorbol ester-induced dopamine release 
and dopamine transporter phosphorylation in striatal synaptosomes." European 
Journal of Pharmacology 389(1): 59-65. 
 
Coyle, J. T. and S. H. Snyder (1969). "Catecholamine uptake by synaptosomes in 
homogenates of rat brain: stereospecificity in different areas." J Pharmacol Exp 
Ther 170(2): 221-31. 
 
Daniels, G. M. and S. G. Amara (1999). "Regulated trafficking of the human dopamine 
transporter. Clathrin-mediated internalization and lysosomal degradation in 
response to phorbol esters." Journal of Biological Chemistry 274(50): 35794-801. 
 
Davis, K. L., R. S. Kahn, G. Ko and M. Davidson (1991). "Dopamine in schizophrenia: a 
review and reconceptualization." Am J Psychiatry 148(11): 1474-86. 
 
Dawn, L. T., I. V. Vladimir, K. Po-Hsiu, M. Joseph, W. Brandon, F. Ayman, A. O. N. 
Francis, W. Dermot, J. C. G. V. d. O. Edwin, S. K. Kenneth and P. R. Brien 
(2008). "AKT1 Is Associated with Schizophrenia Across Multiple Symptom 
Dimensions in the Irish Study of High Density Schizophrenia Families." 
Biological psychiatry 63(5): 449-457. 
 
DeFelice, L. J. and T. Goswami (2007). "Transporters as channels." Annu Rev Physiol 
69: 87-112. 
 
DeFeo-Jones, D., S. F. Barnett, S. Fu, P. J. Hancock, K. M. Haskell, K. R. Leander, E. 
McAvoy, R. G. Robinson, M. E. Duggan, C. W. Lindsley, Z. Zhao, H. E. Huber 
and R. E. Jones (2005). "Tumor cell sensitization to apoptotic stimuli by selective 
inhibition of specific Akt/PKB family members." Mol Cancer Ther 4(2): 271-9. 
 
Delay, J., P. Deniker and J. M. Harl (1952). "[Therapeutic use in psychiatry of 
phenothiazine of central elective action (4560 RP).]." Ann Med Psychol (Paris) 
110(2:1): 112-7. 
 
151 
       
Dipace, C., U. Sung, F. Binda, R. D. Blakely and A. Galli (2007). "Amphetamine induces 
a calcium/calmodulin-dependent protein kinase II-dependent reduction in 
norepinephrine transporter surface expression linked to changes in syntaxin 
1A/transporter complexes." Mol Pharmacol 71(1): 230-9. 
 
Doolen, S. and N. R. Zahniser (2001). "Protein tyrosine kinase inhibitors alter human 
dopamine transporter activity in Xenopus oocytes." Journal of Pharmacology & 
Experimental Therapeutics 296(3): 931-8. 
Dummler, B. and B. A. Hemmings (2007). "Physiological roles of PKB/Akt isoforms in 
development and disease." Biochem Soc Trans 35(Pt 2): 231-5. 
 
Easton, R. M., H. Cho, K. Roovers, D. W. Shineman, M. Mizrahi, M. S. Forman, V. M. 
Lee, M. Szabolcs, R. de Jong, T. Oltersdorf, T. Ludwig, A. Efstratiadis and M. J. 
Birnbaum (2005). "Role for Akt3/protein kinase Bgamma in attainment of normal 
brain size." Mol Cell Biol 25(5): 1869-78. 
 
Emamian, E. S., D. Hall, M. J. Birnbaum, M. Karayiorgou and J. A. Gogos (2004). 
"Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia." 
Nat Genet 36(2): 131-7. 
 
Erreger, K., C. Grewer, J. A. Javitch and A. Galli (2008). "Currents in response to rapid 
concentration jumps of amphetamine uncover novel aspects of human dopamine 
transporter function." J Neurosci 28(4): 976-89. 
 
Fan, Y., J. Huang, N. Kieran and M. Y. Zhu (2009). "Effects of transcription factors 
Phox2 on expression of norepinephrine transporter and dopamine beta-
hydroxylase in SK-N-BE(2)C cells." J Neurochem 110(5): 1502-13. 
 
Farley, I. J., K. S. Price, E. McCullough, J. H. Deck, W. Hordynski and O. Hornykiewicz 
(1978). "Norepinephrine in chronic paranoid schizophrenia: above-normal levels 
in limbic forebrain." Science 200(4340): 456-8. 
 
Figlewicz, D. P., K. Bentson and I. Ocrant (1993). "The effect of insulin on 
norepinephrine uptake by PC12 cells." Brain Research Bulletin 32(4): 425-31. 
 
Figlewicz, D. P., M. D. Brot, A. L. McCall and P. Szot (1996). "Diabetes causes 
differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a 
molecular study." Brain Research 736(1-2): 54-60. 
 
Figlewicz, D. P., P. Szot, P. A. Israel, C. Payne and D. M. Dorsa (1993). "Insulin reduces 
norepinephrine transporter mRNA in vivo in rat locus coeruleus." Brain Research 
602(1): 161-4. 
 
Finlay, J. M., M. J. Zigmond and E. D. Abercrombie (1995). "Increased dopamine and 
norepinephrine release in medial prefrontal cortex induced by acute and chronic 
stress: effects of diazepam." Neuroscience 64(3): 619-28. 
152 
       
Fischer, J. F. and A. K. Cho (1979). "Chemical release of dopamine from striatal 
homogenates: evidence for an exchange diffusion model." Journal of 
Pharmacology & Experimental Therapeutics 208(2): 203-9. 
 
Fleckenstein, A. E., R. R. Metzger, D. G. Wilkins, J. W. Gibb and G. R. Hanson (1997). 
"Rapid and reversible effects of methamphetamine on dopamine transporters." 
Journal of Pharmacology & Experimental Therapeutics 282(2): 834-8. 
Fleckenstein, A. E., T. J. Volz, E. L. Riddle, J. W. Gibb and G. R. Hanson (2007). "New 
insights into the mechanism of action of amphetamines." Annu Rev Pharmacol 
Toxicol 47: 681-98. 
 
Fog, J. U., H. Khoshbouei, M. Holy, W. A. Owens, C. B. Vaegter, N. Sen, Y. 
Nikandrova, E. Bowton, D. G. McMahon, R. J. Colbran, L. C. Daws, H. H. Sitte, 
J. A. Javitch, A. Galli and U. Gether (2006). "Calmodulin Kinase II Interacts with 
the Dopamine Transporter C Terminus to Regulate Amphetamine-Induced 
Reverse Transport." Neuron 51(4): 417-29. 
 
Fon, E. A., E. N. Pothos, B. C. Sun, N. Killeen, D. Sulzer and R. H. Edwards (1997). 
"Vesicular transport regulates monoamine storage and release but is not essential 
for amphetamine action." Neuron 19(6): 1271-83. 
 
Forrest, L. R., Y. W. Zhang, M. T. Jacobs, J. Gesmonde, L. Xie, B. H. Honig and G. 
Rudnick (2008). "Mechanism for alternating access in neurotransmitter 
transporters." Proc Natl Acad Sci U S A 105(30): 10338-43. 
 
Foster, J. D., S. D. Adkins, J. R. Lever and R. A. Vaughan (2008). "Phorbol ester induced 
trafficking-independent regulation and enhanced phosphorylation of the dopamine 
transporter associated with membrane rafts and cholesterol." J Neurochem 105(5): 
1683-99. 
 
Foster, J. D., B. Pananusorn and R. A. Vaughan (2002). "Dopamine transporters are 
phosphorylated on N-terminal serines in rat striatum." J Biol Chem 277(28): 
25178-86. 
 
Fu, C. H., L. J. Reed, J. H. Meyer, S. Kennedy, S. Houle, B. S. Eisfeld and G. M. Brown 
(2001). "Noradrenergic dysfunction in the prefrontal cortex in depression: an 
[15O] H2O PET study of the neuromodulatory effects of clonidine." Biol 
Psychiatry 49(4): 317-25. 
 
Galici, R., A. Galli, D. J. Jones, T. A. Sanchez, C. Saunders, A. Frazer, G. G. Gould, R. 
Z. Lin and C. P. France (2003). "Selective decreases in amphetamine self-
administration and regulation of dopamine transporter function in diabetic rats." 
Neuroendocrinology 77(2): 132-40. 
 
153 
       
Galli, A., R. D. Blakely and L. J. DeFelice (1996). "Norepinephrine transporters have 
channel modes of conduction." Proceedings of the National Academy of Sciences 
of the United States of America 93(16): 8671-6. 
 
Galli, A., R. D. Blakely and L. J. DeFelice (1998). "Patch-clamp and amperometric 
recordings from norepinephrine transporters: channel activity and voltage-
dependent uptake [see comments]." Proceedings of the National Academy of 
Sciences of the United States of America 95(22): 13260-5. 
 
Galli, A., L. J. DeFelice, B. J. Duke, K. R. Moore and R. D. Blakely (1995). "Sodium-
dependent norepinephrine-induced currents in norepinephrine-transporter-
transfected HEK-293 cells blocked by cocaine and antidepressants." Journal of 
Experimental Biology 198(Pt 10): 2197-212. 
 
Ganguly, P. K., K. S. Dhalla, I. R. Innes, R. E. Beamish and N. S. Dhalla (1986). 
"Altered norepinephrine turnover and metabolism in diabetic cardiomyopathy." 
Circ Res 59(6): 684-93. 
 
Garcia, B. G., Y. Wei, J. A. Moron, R. Z. Lin, J. A. Javitch and A. Galli (2005). "Akt is 
essential for insulin modulation of amphetamine-induced human dopamine 
transporter cell-surface redistribution." Mol Pharmacol 68(1): 102-9. 
 
Gavard, J. A., P. J. Lustman and R. E. Clouse (1993). "Prevalence of depression in adults 
with diabetes. An epidemiological evaluation." Diabetes Care 16(8): 1167-78. 
 
Giambalvo, C. T. (1992). "Protein kinase C and dopamine transport--2. Effects of 
amphetamine in vitro." Neuropharmacology 31(12): 1211-22. 
 
Gnegy, M. E., H. Khoshbouei, K. A. Berg, J. A. Javitch, W. P. Clarke, M. Zhang and A. 
Galli (2004). "Intracellular Ca2+ regulates amphetamine-induced dopamine efflux 
and currents mediated by the human dopamine transporter." Mol Pharmacol 
66(1): 137-43. 
 
Gonzalez, A. M., J. Pascual, J. J. Meana, F. Barturen, C. del Arco, A. Pazos and J. A. 
Garcia-Sevilla (1994). "Autoradiographic demonstration of increased alpha 2-
adrenoceptor agonist binding sites in the hippocampus and frontal cortex of 
depressed suicide victims." J Neurochem 63(1): 256-65. 
 
Granas, C., J. Ferrer, C. J. Loland, J. A. Javitch and U. Gether (2003). "N-terminal 
truncation of the dopamine transporter abolishes phorbol ester- and substance P 
receptor-stimulated phosphorylation without impairing transporter 
internalization." J Biol Chem 278(7): 4990-5000. 
 
Gresch, P. J., A. F. Sved, M. J. Zigmond and J. M. Finlay (1995). "Local influence of 
endogenous norepinephrine on extracellular dopamine in rat medial prefrontal 
cortex." J Neurochem 65(1): 111-6. 
154 
       
Gu H. H., X.Wu, B. Giros, M. G. Caron, M. J. Caplan, G. Rudnick. (2001) "The NH(2)-
terminus of norepinephrine transporter contains a basolateral localization signal 
for epithelial cells." Mol Biol Cell 12(12):3797-807. 
 
Guertin, D. A., D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. 
Brown, K. J. Fitzgerald and D. M. Sabatini (2006). "Ablation in Mice of the 
mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required 
for Signaling to Akt-FOXO and PKC[alpha], but Not S6K1." Developmental Cell 
11(6): 859-871. 
 
Gulley, J. M., S. Doolen and N. R. Zahniser (2002). "Brief, repeated exposure to 
substrates down-regulates dopamine transporter function in Xenopus oocytes in 
vitro and rat dorsal striatum in vivo." J Neurochem 83(2): 400-11. 
 
Haenisch, B., K. Linsel, M. Bruss, R. Gilsbach, P. Propping, M. M. Nothen, M. 
Rietschel, R. Fimmers, W. Maier, A. Zobel, S. Hofels, V. Guttenthaler, M. 
Gothert and H. Bonisch (2008). "Association of major depression with rare 
functional variants in norepinephrine transporter and serotonin(1A) receptor 
genes." Am J Med Genet B Neuropsychiatr Genet. 
 
Hahn, M. K., J. U. Blackford, K. Haman, M. Mazei-Robison, B. A. English, H. C. 
Prasad, A. Steele, L. Hazelwood, H. M. Fentress, R. Myers, R. D. Blakely, E. 
Sanders-Bush and R. Shelton (2008). "Multivariate permutation analysis 
associates multiple polymorphisms with subphenotypes of major depression." 
Genes Brain Behav 7(4): 487-95. 
 
Hahn, M. K., M. S. Mazei-Robison and R. D. Blakely (2005). "Single nucleotide 
polymorphisms in the human norepinephrine transporter gene affect expression, 
trafficking, antidepressant interaction, and protein kinase C regulation." Mol 
Pharmacol 68(2): 457-66. 
 
Hahn, M. K., D. Robertson and R. D. Blakely (2003). "A mutation in the human 
norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance 
disrupts surface expression of mutant and wild-type transporters." J Neurosci 
23(11): 4470-8. 
 
Hahn, M. K., A. Steele, R. S. Couch, M. A. Stein and J. J. Krueger (2009). "Novel and 
functional norepinephrine transporter protein variants identified in attention-
deficit hyperactivity disorder." Neuropharmacology. 
 
Halushka, M. K., J. B. Fan, K. Bentley, L. Hsie, N. Shen, A. Weder, R. Cooper, R. 
Lipshutz and A. Chakravarti (1999). "Patterns of single-nucleotide 
polymorphisms in candidate genes for blood-pressure homeostasis." Nat Genet 
22(3): 239-47. 
 
155 
       
Harikrishnan, K. N., R. Bayles, G. D. Ciccotosto, S. Maxwell, R. Cappai, G. J. Pelka, P. 
P. Tam, J. Christodoulou and A. El-Osta (2010). "Alleviating transcriptional 
inhibition of the norepinephrine slc6a2 transporter gene in depolarized neurons." J 
Neurosci 30(4): 1494-501. 
 
Hashimoto, R., T. Numakawa, T. Ohnishi, E. Kumamaru, Y. Yagasaki, T. Ishimoto, T. 
Mori, K. Nemoto, N. Adachi, A. Izumi, S. Chiba, H. Noguchi, T. Suzuki, N. 
Iwata, N. Ozaki, T. Taguchi, A. Kamiya, A. Kosuga, M. Tatsumi, K. Kamijima, 
D. R. Weinberger, A. Sawa and H. Kunugi (2006). "Impact of the DISC1 
Ser704Cys polymorphism on risk for major depression, brain morphology and 
ERK signaling." Hum Mol Genet 15(20): 3024-33. 
 
He, A., X. Liu, L. Liu, Y. Chang and F. Fang (2007). "How many signals impinge on 
GLUT4 activation by insulin?" Cell Signal 19(1): 1-7. 
 
Heikkila, R. E., H. Orlansky, C. Mytilineou and G. Cohen (1975). "Amphetamine: 
evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-
dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex." 
J Pharmacol Exp Ther 194(1): 47-56. 
 
Henry, L. K., J. Meiler and R. D. Blakely (2007). "Bound to be different: 
neurotransmitter transporters meet their bacterial cousins." Mol Interv 7(6): 306-
9. 
 
Hernandez, L. and E. Briese (1972). "Analysis of diabetic hyperphagia and polydipsia." 
Physiol Behav 9(5): 741-6. 
 
Hersch, S. M., H. Yi, C. J. Heilman, R. H. Edwards and A. I. Levey (1997). "Subcellular 
localization and molecular topology of the dopamine transporter in the striatum 
and substantia nigra." J Comp Neurol 388(2): 211-27. 
 
Hilakivi-Clarke, L. A., K. M. Wozniak, M. J. Durcan and M. Linnoila (1990). "Behavior 
of streptozotocin-diabetic mice in tests of exploration, locomotion, anxiety, 
depression and aggression." Physiol Behav 48(3): 429-33. 
 
Hirano, S., S. Miyata and J. Kamei (2007). "Antidepressant-like effect of leptin in 
streptozotocin-induced diabetic mice." Pharmacol Biochem Behav 86(1): 27-31. 
 
Howes, O. D. and S. Kapur (2009). "The dopamine hypothesis of schizophrenia: version 
III--the final common pathway." Schizophr Bull 35(3): 549-62. 
 
Hsiung, S. C., M. Adlersberg, V. Arango, J. J. Mann, H. Tamir and K. P. Liu (2003). 
"Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement 
of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated 
protein kinase." J Neurochem 87(1): 182-94. 
 
156 
       
Ide, M., T. Ohnishi, M. Murayama, I. Matsumoto, K. Yamada, Y. Iwayama, I. Dedova, 
T. Toyota, T. Asada, A. Takashima and T. Yoshikawa (2006). "Failure to support 
a genetic contribution of AKT1 polymorphisms and altered AKT signaling in 
schizophrenia." J Neurochem 99(1): 277-87. 
 
Ikeda, M., N. Iwata, T. Suzuki, T. Kitajima, Y. Yamanouchi, Y. Kinoshita, T. Inada and 
N. Ozaki (2004). "Association of AKT1 with schizophrenia confirmed in a 
Japanese population." Biol Psychiatry 56(9): 698-700. 
 
Iversen, L. L. (1963). "The Uptake of Noradrenaline by the Isolated Perfused Rat Heart." 
Br J Pharmacol Chemother 21: 523-37. 
Iversen, L. L. (1971). "Role of transmitter uptake mechanisms in synaptic 
neurotransmission." British Journal of Pharmacology 41(4): 571-91. 
 
Iversen, L. L., M. N. Rossor, G. P. Reynolds, R. Hills, M. Roth, C. Q. Mountjoy, S. L. 
Foote, J. H. Morrison and F. E. Bloom (1983). "Loss of pigmented dopamine-
beta-hydroxylase positive cells from locus coeruleus in senile dementia of 
Alzheimer's type." Neurosci Lett 39(1): 95-100. 
 
Jacinto, E., V. Facchinetti, D. Liu, N. Soto, S. Wei, S. Y. Jung, Q. Huang, J. Qin and B. 
Su (2006). "SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates 
Akt Phosphorylation and Substrate Specificity."  127(1): 125-137. 
 
Jardetzky, O. (1966). "Simple allosteric model for membrane pumps." Nature 211(52): 
969-70. 
 
Jayanthi, L. D., B. Annamalai, D. J. Samuvel, U. Gether and S. Ramamoorthy (2006). 
"Phosphorylation of the norepinephrine transporter at threonine 258 and serine 
259 is linked to protein kinase C-mediated transporter internalization." J Biol 
Chem 281(33): 23326-40. 
 
Jayanthi, L. D., D. J. Samuvel and S. Ramamoorthy (2004). "Regulated internalization 
and phosphorylation of the native norepinephrine transporter in response to 
phorbol esters. Evidence for localization in lipid rafts and lipid raft-mediated 
internalization." J Biol Chem 279(18): 19315-26. 
 
Jayanthi, L. D., D. J. Samuvel and S. Ramamoorthy (2004). "Regulated internalization 
and phosphorylation of the native norepinephrine transporter in response to 
phorbol esters: Evidence for localization in lipid rafts and lipid raft mediated 
internalization." J Biol Chem. 
 
Jeannotte, A. M., J. G. McCarthy, E. E. Redei and A. Sidhu (2009). "Desipramine 
modulation of alpha-, gamma-synuclein, and the norepinephrine transporter in an 
animal model of depression." Neuropsychopharmacology 34(4): 987-98. 
 
157 
       
Jeannotte, A. M., J. G. McCarthy and A. Sidhu (2009). "Desipramine induced changes in 
the norepinephrine transporter, alpha- and gamma-synuclein in the hippocampus, 
amygdala and striatum." Neurosci Lett. 
 
Johnson, L. A., C. A. Furman, M. Zhang, B. Guptaroy and M. E. Gnegy (2005). "Rapid 
delivery of the dopamine transporter to the plasmalemmal membrane upon 
amphetamine stimulation." Neuropharmacology 49(6): 750-8. 
 
Johnson, L. A., B. Guptaroy, D. Lund, S. Shamban and M. E. Gnegy (2005). "Regulation 
of amphetamine-stimulated dopamine efflux by protein kinase C beta." J Biol 
Chem 280(12): 10914-9. 
 
Jones, S. R., R. R. Gainetdinov, M. Jaber, B. Giros, R. M. Wightman and M. G. Caron 
(1998). "Profound neuronal plasticity in response to inactivation of the dopamine 
transporter." Proceedings of the National Academy of Sciences of the United 
States of America 95(7): 4029-34. 
 
Jones, S. R., R. R. Gainetdinov, R. M. Wightman and M. G. Caron (1998). "Mechanisms 
of amphetamine action revealed in mice lacking the dopamine transporter." 
Journal of Neuroscience 18(6): 1979-86. 
 
Kahlig, K. M., F. Binda, H. Khoshbouei, R. D. Blakely, D. G. McMahon, J. A. Javitch 
and A. Galli (2005). "Amphetamine induces dopamine efflux through a dopamine 
transporter channel." Proc Natl Acad Sci U S A 102(9): 3495-500. 
 
Kahlig, K. M. and A. Galli (2003). "Regulation of dopamine transporter function and 
plasma membrane expression by dopamine, amphetamine, and cocaine." Eur J 
Pharmacol 479(1-3): 153-8. 
 
Kahlig, K. M., J. A. Javitch and A. Galli (2004). "Amphetamine regulation of dopamine 
transport. Combined measurements of transporter currents and transporter 
imaging support the endocytosis of an active carrier." J Biol Chem 279(10): 8966-
75. 
 
Kahlig, K. M., B. J. Lute, Y. Wei, C. J. Loland, U. Gether, J. A. Javitch and A. Galli 
(2006). "Regulation of dopamine transporter trafficking by intracellular 
amphetamine." Mol Pharmacol 70(2): 542-8. 
 
Kanakry, C. G., Z. Li, Y. Nakai, Y. Sei and D. R. Weinberger (2007). "Neuregulin-1 
regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent 
pathway: potential implications for schizophrenia and cancer." PLoS ONE 2(12): 
e1369. 
 
Kang, U. G., M. S. Seo, M.-S. Roh, Y. Kim, S. C. Yoon and Y. S. Kim (2004). "The 
effects of clozapine on the GSK-3-mediated signaling pathway." FEBS Letters 
560(1-3): 115-119. 
158 
       
Kantor, L. and M. E. Gnegy (1998). "Protein kinase C inhibitors block amphetamine-
mediated dopamine release in rat striatal slices." Journal of Pharmacology & 
Experimental Therapeutics 284(2): 592-8. 
 
Kantor, L., G. H. Hewlett and M. E. Gnegy (1999). "Enhanced amphetamine- and K+-
mediated dopamine release in rat striatum after repeated amphetamine: 
differential requirements for Ca2+- and calmodulin-dependent phosphorylation 
and synaptic vesicles." Journal of Neuroscience 19(10): 3801-8. 
 
Kantor, L., G. H. Hewlett, Y. H. Park, S. M. Richardson-Burns, M. J. Mellon and M. E. 
Gnegy (2001). "Protein kinase C and intracellular calcium are required for 
amphetamine- mediated dopamine release via the norepinephrine transporter in 
undifferentiated PC12 cells." J Pharmacol Exp Ther 297(3): 1016-24. 
 
Kantor, L., M. Zhang, B. Guptaroy, Y. H. Park and M. E. Gnegy (2004). "Repeated 
amphetamine couples norepinephrine transporter and calcium channel activities in 
PC12 cells." J Pharmacol Exp Ther 311(3): 1044-51. 
 
Karege, F., N. Perroud, S. Burkhardt, M. Schwald, E. Ballmann, R. La Harpe and A. 
Malafosse (2007). "Alteration in Kinase Activity But Not in Protein Levels of 
Protein Kinase B and Glycogen Synthase Kinase-3[beta] in Ventral Prefrontal 
Cortex of Depressed Suicide Victims." Biological Psychiatry 61(2): 240-245. 
 
Karkanias, G. B., J. C. Morales and C. S. Li (1997). "Deficits in reproductive behavior in 
diabetic female rats are due to hypoinsulinemia rather than hyperglycemia." Horm 
Behav 32(1): 19-29. 
 
Karkoulias, G., O. Mastrogianni, A. Lymperopoulos, H. Paris and C. Flordellis (2006). 
"alpha(2)-Adrenergic receptors activate MAPK and Akt through a pathway 
involving arachidonic acid metabolism by cytochrome P450-dependent 
epoxygenase, matrix metalloproteinase activation and subtype-specific 
transactivation of EGFR." Cell Signal 18(5): 729-39. 
 
Keller, N. R., A. Diedrich, M. Appalsamy, L. C. Miller, M. G. Caron, M. P. McDonald, 
R. C. Shelton, R. D. Blakely and D. Robertson (2006). "Norepinephrine 
transporter-deficient mice respond to anxiety producing and fearful environments 
with bradycardia and hypotension." Neuroscience 139(3): 931-46. 
 
Kelly, C. B. and S. J. Cooper (1998). "Differences and variability in plasma 
noradrenaline between depressive and anxiety disorders." J Psychopharmacol 
12(2): 161-7. 
 
Kelly, D. L., R. W. Buchanan, D. L. Boggs, R. P. McMahon, D. Dickinson, M. Nelson, J. 
M. Gold, M. P. Ball, S. Feldman, F. Liu and R. R. Conley (2009). "A randomized 
double-blind trial of atomoxetine for cognitive impairments in 32 people with 
schizophrenia." J Clin Psychiatry 70(4): 518-25. 
159 
       
Keri, S., I. Seres, O. Kelemen and G. Benedek (2009). "Neuregulin 1-stimulated 
phosphorylation of AKT in psychotic disorders and its relationship with 
neurocognitive functions." Neurochem Int. 
 
Keri, S., I. Seres, O. Kelemen and G. Benedek (2009). "The Relationship Among 
Neuregulin 1-Stimulated Phosphorylation of AKT, Psychosis Proneness, and 
Habituation of Arousal in Nonclinical Individuals." Schizophr Bull: sbp063. 
 
Khoshbouei, H., N. Sen, B. Guptaroy, L. Johnson, D. Lund, M. E. Gnegy, A. Galli and J. 
A. Javitch (2004). "N-terminal phosphorylation of the dopamine transporter is 
required for amphetamine-induced efflux." PLoS Biol 2(3): E78. 
 
Khoshbouei, H., H. Wang, J. D. Lechleiter, J. A. Javitch and A. Galli (2003). 
"Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular 
Na+-dependent mechanism." J Biol Chem 278(14): 12070-7. 
 
Kim, C. H., M. K. Hahn, Y. Joung, S. L. Anderson, A. H. Steele, M. S. Mazei-Robinson, 
I. Gizer, M. H. Teicher, B. M. Cohen, D. Robertson, I. D. Waldman, R. D. 
Blakely and K. S. Kim (2006). "A polymorphism in the norepinephrine 
transporter gene alters promoter activity and is associated with attention-deficit 
hyperactivity disorder." Proc Natl Acad Sci U S A 103(50): 19164-9. 
 
Kim, J. W., J. Biederman, C. L. McGrath, A. E. Doyle, E. Mick, J. Fagerness, S. Purcell, 
J. W. Smoller, P. Sklar and S. V. Faraone (2008). "Further evidence of association 
between two NET single-nucleotide polymorphisms with ADHD." Mol 
Psychiatry 13(6): 624-30. 
 
Kirshner, N. (1962). "Uptake of catecholamines by a particulate fraction of the adrenal 
medulla." J Biol Chem 237: 2311-7. 
 
Kitayama, T., L. Song, K. Morita, N. Morioka and T. Dohi (2006). "Down-regulation of 
norepinephrine transporter function induced by chronic administration of 
desipramine linking to the alteration of sensitivity of local-anesthetics-induced 
convulsions and the counteraction by co-administration with local anesthetics." 
Brain Res 1096(1): 97-103. 
 
Klimek, V., C. Stockmeier, J. Overholser, H. Y. Meltzer, S. Kalka, G. Dilley and G. A. 
Ordway (1997). "Reduced levels of norepinephrine transporters in the locus 
coeruleus in major depression." Journal of Neuroscience 17(21): 8451-8. 
 
Knutson, B., J. M. Bjork, G. W. Fong, D. Hommer, V. S. Mattay and D. R. Weinberger 
(2004). "Amphetamine modulates human incentive processing." Neuron 43(2): 
261-9. 
 
160 
       
Koch, M. and M. Bubser (1994). "Deficient sensorimotor gating after 6-
hydroxydopamine lesion of the rat medial prefrontal cortex is reversed by 
haloperidol." Eur J Neurosci 6(12): 1837-45. 
 
Krishnan, V., M.-H. Han, M. Mazei-Robison, S. D. Iñiguez, J. L. Ables, V. Vialou, O. 
Berton, S. Ghose, H. E. Covington Iii, M. D. Wiley, R. P. Henderson, R. L. Neve, 
A. J. Eisch, C. A. Tamminga, S. J. Russo, C. A. Bolaños and E. J. Nestler (2008). 
"AKT Signaling within the Ventral Tegmental Area Regulates Cellular and 
Behavioral Responses to Stressful Stimuli." Biological Psychiatry 64(8): 691-700. 
 
Lackovic, Z., M. Salkovic, Z. Kuci and M. Relja (1990). "Effect of long-lasting diabetes 
mellitus on rat and human brain monoamines." J Neurochem 54(1): 143-7. 
 
Lai, W. S., B. Xu, K. G. Westphal, M. Paterlini, B. Olivier, P. Pavlidis, M. Karayiorgou 
and J. A. Gogos (2006). "Akt1 deficiency affects neuronal morphology and 
predisposes to abnormalities in prefrontal cortex functioning." Proc Natl Acad Sci 
U S A 103(45): 16906-11. 
 
Lake, C. R., D. E. Sternberg, D. P. V. Kammen, J. C. Ballenger, M. G. Ziegler, R. M. 
Post, I. J. Kopin and W. E. Bunney (1980). "Schizophrenia: Elevated 
Cerebrospinal Fluid Norepinephrine." Science 207(4428): 331-333. 
 
Lapierre, L. A., R. Kumar, C. M. Hales, J. Navarre, S. G. Bhartur, J. O. Burnette, D. W. 
Provance, Jr., J. A. Mercer, M. Bahler and J. R. Goldenring (2001). "Myosin vb is 
associated with plasma membrane recycling systems." Mol Biol Cell 12(6): 1843-
57. 
 
Lenzen, S. (2008). "The mechanisms of alloxan- and streptozotocin-induced diabetes." 
Diabetologia 51(2): 216-26. 
 
Li, L. B., N. Chen, S. Ramamoorthy, L. Chi, X. N. Cui, L. C. Wang and M. E. Reith 
(2004). "The role of N-glycosylation in function and surface trafficking of the 
human dopamine transporter." J Biol Chem 279(20): 21012-20. 
 
Li, Q., A. Lau, T. J. Morris, L. Guo, C. B. Fordyce and E. F. Stanley (2004). "A syntaxin 
1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve 
terminal: analysis by quantitative immunocolocalization." J Neurosci 24(16): 
4070-81. 
 
Lindsley, C. W., Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Jones, 
R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber and M. E. Duggan (2005). 
"Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective 
inhibitors." Bioorg Med Chem Lett 15(3): 761-4. 
 
Liprando, L. A., L. H. Miner, R. D. Blakely, D. A. Lewis and S. R. Sesack (2004). 
"Ultrastructural interactions between terminals expressing the norepinephrine 
161 
       
transporter and dopamine neurons in the rat and monkey ventral tegmental area." 
Synapse 52(4): 233-44. 
 
Loder, M. K. and H. E. Melikian (2003). "The Dopamine Transporter Constitutively 
Internalizes and Recycles in a Protein Kinase C-regulated Manner in Stably 
Transfected PC12 Cell Lines." J Biol Chem 278(24): 22168-74. 
 
Lorang, D., S. G. Amara and R. B. Simerly (1994). "Cell-type-specific expression of 
catecholamine transporters in the rat brain." J Neurosci 14(8): 4903-14. 
 
Lotta, T., J. Vidgren, C. Tilgmann, I. Ulmanen, K. Melen, I. Julkunen and J. Taskinen 
(2002). "Kinetics of Human Soluble and Membrane-Bound Catechol O-
Methyltransferase: A Revised Mechanism and Description of the Thermolabile 
Variant of the Enzyme." Biochemistry 34(13): 4202-4210. 
 
Lu, X. H., R. J. Bradley and D. S. Dwyer (2004). "Olanzapine produces trophic effects in 
vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-
activated protein kinase p38." Brain Res 1011(1): 58-68. 
 
Lu, X. H. and D. S. Dwyer (2005). "Second-generation antipsychotic drugs, olanzapine, 
quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via 
PI3K/AKT, ERK, and pertussis toxin-sensitive pathways." J Mol Neurosci 27(1): 
43-64. 
 
Lucas, P. D. and A. Qirbi (1989). "Tissue noradrenaline and the polyol pathway in 
experimentally diabetic rats." Br J Pharmacol 97(2): 347-52. 
 
Lustman, P. J. and R. E. Clouse (2005). "Depression in diabetic patients: the relationship 
between mood and glycemic control." J Diabetes Complications 19(2): 113-22. 
 
Lute, B. J., H. Khoshbouei, C. Saunders, N. Sen, R. Z. Lin, J. A. Javitch and A. Galli 
(2008). "PI3K signaling supports amphetamine-induced dopamine efflux." 
Biochem Biophys Res Commun 372(4): 656-61. 
 
Maas, J. W., S. A. Contreras, A. L. Miller, N. Berman, C. L. Bowden, M. A. Javors, E. 
Seleshi and S. Weintraub (1993). "Studies of catecholamine metabolism in 
schizophrenia/psychosis--I." Neuropsychopharmacology 8(2): 97-109. 
 
Man, H. Y., J. W. Lin, W. H. Ju, G. Ahmadian, L. Liu, L. E. Becker, M. Sheng and Y. T. 
Wang (2000). "Regulation of AMPA receptor-mediated synaptic transmission by 
clathrin-dependent receptor internalization." Neuron 25(3): 649-62. 
 
Man in 't Veld, A. J., F. Boomsma, P. Moleman and M. A. Schalekamp (1987). 
"Congenital dopamine-beta-hydroxylase deficiency. A novel orthostatic 
syndrome." Lancet 1(8526): 183-8. 
 
162 
       
Manning, B. D. and L. C. Cantley (2007). "AKT/PKB signaling: navigating 
downstream." Cell 129(7): 1261-74. 
 
Martinsson, L. and S. Eksborg (2004). "Drugs for stroke recovery: the example of 
amphetamines." Drugs Aging 21(2): 67-79. 
 
Massol, J., P. Martin, J. P. Belon, A. J. Puech and P. Soubrie (1989). "Helpless behavior 
(escape deficits) in streptozotocin-diabetic rats: resistance to antidepressant 
drugs." Psychoneuroendocrinology 14(1-2): 145-53. 
Masters, B. A., J. Shemer, J. H. Judkins, D. W. Clarke, D. Le Roith and M. K. Raizada 
(1987). "Insulin receptors and insulin action in dissociated brain cells." Brain Res 
417(2): 247-56. 
 
Matthies, H. J., Q. Han, A. Shields, J. Wright, J. L. Moore, D. G. Winder, A. Galli and R. 
D. Blakely (2009). "Subcellular localization of the antidepressant-sensitive 
norepinephrine transporter." BMC Neurosci 10: 65. 
 
Matthies, H. J., J. L. Moore, C. Saunders, D. S. Matthies, L. A. Lapierre, J. R. 
Goldenring, R. D. Blakely, A. Galli. (2010) " Rab11 supports amphetamine-
stimulated norepinephrine transporter trafficking." J Neurosci 30(23):7863-77. 
 
Matthysse, S. (1973). "Antipsychotic drug actions: a clue to the neuropathology of 
schizophrenia?" Fed Proc 32(2): 200-5. 
 
Mazei-Robison, M. S., E. Bowton, M. Holy, M. Schmudermaier, M. Freissmuth, H. H. 
Sitte, A. Galli and R. D. Blakely (2008). "Anomalous dopamine release 
associated with a human dopamine transporter coding variant." J Neurosci 28(28): 
7040-6. 
 
Meana, J. J., F. Barturen and J. A. Garcia-Sevilla (1992). "Alpha 2-adrenoceptors in the 
brain of suicide victims: increased receptor density associated with major 
depression." Biol Psychiatry 31(5): 471-90. 
 
Meana, J. J. and J. A. Garcia-Sevilla (1987). "Increased alpha 2-adrenoceptor density in 
the frontal cortex of depressed suicide victims." J Neural Transm 70(3-4): 377-81. 
 
Melikian, H. E. and K. M. Buckley (1999). "Membrane trafficking regulates the activity 
of the human dopamine transporter." Journal of Neuroscience 19(18): 7699-710. 
 
Miner, L. H., S. Schroeter, R. D. Blakely and S. R. Sesack (2003). "Ultrastructural 
localization of the norepinephrine transporter in superficial and deep layers of the 
rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine 
terminals." J Comp Neurol 466(4): 478-94. 
 
163 
       
Moore, R. Y. and F. E. Bloom (1979). "Central catecholamine neuron systems: anatomy 
and physiology of the norepinephrine and epinephrine systems." Annu Rev 
Neurosci 2: 113-68. 
 
Moron, J. A., A. Brockington, R. A. Wise, B. A. Rocha and B. T. Hope (2002). 
"Dopamine uptake through the norepinephrine transporter in brain regions with 
low levels of the dopamine transporter: evidence from knock-out mouse lines." J 
Neurosci 22(2): 389-95. 
 
Mukherjee, S., P. Decina, V. Bocola, F. Saraceni and P. L. Scapicchio (1996). "Diabetes 
mellitus in schizophrenic patients." Compr Psychiatry 37(1): 68-73. 
 
Mukherjee, S., D. B. Schnur and R. Reddy (1989). "Family history of type 2 diabetes in 
schizophrenic patients." Lancet 1(8636): 495. 
 
Nakane, H., N. Shimizu and T. Hori (1994). "Stress-induced norepinephrine release in 
the rat prefrontal cortex measured by microdialysis." Am J Physiol 267(6 Pt 2): 
R1559-66. 
 
Nicodemus, K. K., S. Marenco, A. J. Batten, R. Vakkalanka, M. F. Egan, R. E. Straub 
and D. R. Weinberger (2008). "Serious obstetric complications interact with 
hypoxia-regulated/vascular-expression genes to influence schizophrenia risk." 
Mol Psychiatry 13(9): 873-7. 
 
Nonen, S., H. Okamoto, Y. Fujio, Y. Takemoto, M. Yoshiyama, T. Hamaguchi, Y. 
Matsui, J. Yoshikawa, A. Kitabatake and J. Azuma (2008). "Polymorphisms of 
norepinephrine transporter and adrenergic receptor alpha1D are associated with 
the response to beta-blockers in dilated cardiomyopathy." Pharmacogenomics J 
8(1): 78-84. 
 
Norton, N., H. J. Williams, S. Dwyer, L. Carroll, T. Peirce, V. Moskvina, R. Segurado, I. 
Nikolov, N. M. Williams, M. Ikeda, N. Iwata, M. J. Owen and M. C. O'Donovan 
(2007). "Association analysis of AKT1 and schizophrenia in a UK case control 
sample." Schizophr Res 93(1-3): 58-65. 
 
Olfson, M., S. C. Marcus, M. M. Weissman and P. S. Jensen (2002). "National trends in 
the use of psychotropic medications by children." J Am Acad Child Adolesc 
Psychiatry 41(5): 514-21. 
 
Ono, K., Y. Iwanaga, T. Mannami, Y. Kokubo, H. Tomoike, K. Komamura, K. Shioji, N. 
Yasui, N. Tago and N. Iwai (2003). "Epidemiological evidence of an association 
between SLC6A2 gene polymorphism and hypertension." Hypertens Res 26(9): 
685-9. 
 
Ordway, G. A., M. A. Schwartz and A. Frazer (2007). Brain Norepinephrine. New York, 
Cambridge University Press. 
164 
       
Ordway, G. A., P. S. Widdowson, K. S. Smith and A. Halaris (1994). "Agonist binding to 
alpha 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide." 
J Neurochem 63(2): 617-24. 
 
Owens, M. J., W. N. Morgan, S. J. Plott and C. B. Nemeroff (1997). "Neurotransmitter 
receptor and transporter binding profile of antidepressants and their metabolites." 
J Pharmacol Exp Ther 283(3): 1305-22. 
 
Owens, W. A., R. J. Sevak, R. Galici, X. Chang, M. A. Javors, A. Galli, C. P. France and 
L. C. Daws (2005). "Deficits in dopamine clearance and locomotion in 
hypoinsulinemic rats unmask novel modulation of dopamine transporters by 
amphetamine." J Neurochem. 
 
Pacholczyk, T., R. D. Blakely and S. G. Amara (1991). "Expression cloning of a cocaine- 
and antidepressant-sensitive human noradrenaline transporter." Nature 350(6316): 
350-4. 
 
Parker, E. M. and L. X. Cubeddu (1988). "Comparative effects of amphetamine, 
phenylethylamine and related drugs on dopamine efflux, dopamine uptake and 
mazindol binding." J Pharmacol Exp Ther 245(1): 199-210. 
 
Patterson, T. A., M. D. Brot, A. Zavosh, J. O. Schenk, P. Szot and D. P. Figlewicz 
(1998). "Food deprivation decreases mRNA and activity of the rat dopamine 
transporter." Neuroendocrinology 68(1): 11-20. 
 
Pearson, J., M. Goldstein, K. Markey and L. Brandeis (1983). "Human brainstem 
catecholamine neuronal anatomy as indicated by immunocytochemistry with 
antibodies to tyrosine hydroxylase." Neuroscience 8(1): 3-32. 
 
Pierce, R. C. and P. W. Kalivas (1997). "Repeated cocaine modifies the mechanism by 
which amphetamine releases dopamine." Journal of Neuroscience 17(9): 3254-61. 
 
Pifl, C., E. Agneter, H. Drobny, H. Reither and E. A. Singer (1997). "Induction by low 
Na+ or Cl- of cocaine sensitive carrier-mediated efflux of amines from cells 
transfected with the cloned human catecholamine transporters." British Journal of 
Pharmacology 121(2): 205-12. 
 
Pifl, C., H. Drobny, H. Reither, O. Hornykiewicz and E. A. Singer (1995). "Mechanism 
of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal 
dopamine transporter versus vesicular monoamine transporter." Molecular 
Pharmacology 47(2): 368-73. 
 
Pifl, C., P. Rebernik, A. Kattinger and H. Reither (2004). "Zn(2+) modulates currents 
generated by the dopamine transporter: parallel effects on amphetamine-induced 
charge transfer and release." Neuropharmacology 46(2): 223-31. 
 
165 
       
Pifl, C. and E. A. Singer (1999). "Ion dependence of carrier-mediated release in 
dopamine or norepinephrine transporter-transfected cells questions the hypothesis 
of facilitated exchange diffusion." Molecular Pharmacology 56(5): 1047-54. 
 
Piletz, J. E., A. Halaris, A. Saran and M. Marler (1990). "Elevated 3H-para-
aminoclonidine binding to platelet purified plasma membranes from depressed 
patients." Neuropsychopharmacology 3(3): 201-10. 
 
Plitzko, D., S. Rumpel and K. Gottmann (2001). "Insulin promotes functional induction 
of silent synapses in differentiating rat neocortical neurons." Eur J Neurosci 
14(8): 1412-5. 
 
Powell, S. B., X. Zhou and M. A. Geyer (2009). "Prepulse inhibition and genetic mouse 
models of schizophrenia." Behav Brain Res. 
 
Prinzmetal, M., Bloomberg, W. (1935). "Use of benzedrine for the treatment of 
narcolepsy." J. Am. Med. Assoc 105: 2051–2054. 
 
Pristupa, Z. B., F. McConkey, F. Liu, H. Y. Man, F. J. Lee, Y. T. Wang and H. B. Niznik 
(1998). "Protein kinase-mediated bidirectional trafficking and functional 
regulation of the human dopamine transporter." Synapse 30(1): 79-87. 
 
Raiteri, M., F. Cerrito, A. M. Cervoni and G. Levi (1979). "Dopamine can be released by 
two mechanisms differentially affected by the dopamine transport inhibitor 
nomifensine." Journal of Pharmacology & Experimental Therapeutics 208(2): 
195-202. 
 
Raizada, M. K., J. Shemer, J. H. Judkins, D. W. Clarke, B. A. Masters and D. LeRoith 
(1988). "Insulin receptors in the brain: structural and physiological 
characterization." Neurochemical Research 13(4): 297-303. 
 
Ralph, R. J., M. P. Paulus, F. Fumagalli, M. G. Caron and M. A. Geyer (2001). "Prepulse 
inhibition deficits and perseverative motor patterns in dopamine transporter 
knock-out mice: differential effects of D1 and D2 receptor antagonists." J 
Neurosci 21(1): 305-13. 
 
Ralph, R. J., G. B. Varty, M. A. Kelly, Y. M. Wang, M. G. Caron, M. Rubinstein, D. K. 
Grandy, M. J. Low and M. A. Geyer (1999). "The dopamine D2, but not D3 or 
D4, receptor subtype is essential for the disruption of prepulse inhibition produced 
by amphetamine in mice." J Neurosci 19(11): 4627-33. 
 
Ramamoorthy, S., F. H. Leibach, V. B. Mahesh, H. Han, T. Yang-Feng, R. D. Blakely 
and V. Ganapathy (1994). "Functional characterization and chromosomal 
localization of a cloned taurine transporter from human placenta." Biochem J 300 
( Pt 3): 893-900. 
 
166 
       
Ramos, B. P. and A. F. Arnsten (2007). "Adrenergic pharmacology and cognition: focus 
on the prefrontal cortex." Pharmacol Ther 113(3): 523-36. 
 
Reil, J. C. (1809). "Untersuchungen uber den Bau des grossen Gehirns im Menschen." 
Arch. Physiol. 9(Halle): 136-524. 
 
Ressler, K. J. and C. B. Nemeroff (1999). "Role of norepinephrine in the pathophysiology 
and treatment of mood disorders." Biol Psychiatry 46(9): 1219-33. 
 
Richelson, E. (2003). "Interactions of antidepressants with neurotransmitter transporters 
and receptors and their clinical relevance." J Clin Psychiatry 64 Suppl 13: 5-12. 
 
Ritz, M. C., R. J. Lamb, S. R. Goldberg and M. J. Kuhar (1987). "Cocaine receptors on 
dopamine transporters are related to self-administration of cocaine." Science 
237(4819): 1219-23. 
 
Robertson, D., N. Flattem, T. Tellioglu, R. Carson, E. Garland, J. R. Shannon, J. Jordan, 
G. Jacob, R. D. Blakely and I. Biaggioni (2001). "Familial orthostatic tachycardia 
due to norepinephrine transporter deficiency." Ann N Y Acad Sci 940: 527-43. 
 
Roh, M. S., M. S. Seo, Y. Kim, S. H. Kim, W. J. Jeon, Y. M. Ahn, U. G. Kang, Y. S. 
Juhnn and Y. S. Kim (2007). "Haloperidol and clozapine differentially regulate 
signals upstream of glycogen synthase kinase 3 in the rat frontal cortex." Exp Mol 
Med 39(3): 353-60. 
 
Room, P., F. Postema and J. Korf (1981). "Divergent axon collaterals of rat locus 
coeruleus neurons: demonstration by a fluorescent double labeling technique." 
Brain Res 221(2): 219-30. 
 
Roy, A., D. Pickar, J. De Jong, F. Karoum and M. Linnoila (1988). "Norepinephrine and 
its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to 
hypothalamic-pituitary-adrenal axis function in depression." Arch Gen Psychiatry 
45(9): 849-57. 
 
Roy, A., D. Pickar, M. Linnoila and W. Z. Potter (1985). "Plasma norepinephrine level in 
affective disorders. Relationship to melancholia." Arch Gen Psychiatry 42(12): 
1181-5. 
 
Rumantir, M. S., D. M. Kaye, G. L. Jennings, M. Vaz, J. A. Hastings and M. D. Esler 
(2000). "Phenotypic evidence of faulty neuronal norepinephrine reuptake in 
essential hypertension." Hypertension 36(5): 824-9. 
 
Ryan, M. C. M., P. Collins and J. H. Thakore (2003). "Impaired Fasting Glucose 
Tolerance in First-Episode, Drug-Naive Patients With Schizophrenia." Am J 
Psychiatry 160(2): 284-289. 
 
167 
       
Saitoh, A., K. Morita, M. Sodeyama and J. Kamei (1998). "Effects of the experimental 
diabetes on dopamine D1 receptor-mediated locomotor-enhancing activity in 
mice." Pharmacology, Biochemistry & Behavior 60(1): 161-6. 
 
Salomon, R. M., H. L. Miller, J. H. Krystal, G. R. Heninger and D. S. Charney (1997). 
"Lack of behavioral effects of monoamine depletion in healthy subjects." Biol 
Psychiatry 41(1): 58-64. 
 
Sarbassov, D. D., D. A. Guertin, S. M. Ali and D. M. Sabatini (2005). "Phosphorylation 
and regulation of Akt/PKB by the rictor-mTOR complex." Science 307(5712): 
1098-101. 
 
Saunders, C., J. V. Ferrer, L. Shi, J. Chen, G. Merrill, M. E. Lamb, L. M. Leeb-Lundberg, 
L. Carvelli, J. A. Javitch and A. Galli (2000). "Amphetamine-induced loss of 
human dopamine transporter activity: an internalization-dependent and cocaine-
sensitive mechanism." Proc Natl Acad Sci U S A 97(12): 6850-5. 
 
Savchenko, V., U. Sung and R. D. Blakely (2003). "Cell surface trafficking of the 
antidepressant-sensitive norepinephrine transporter revealed with an ectodomain 
antibody." Mol Cell Neurosci 24(4): 1131-50. 
 
Schenk, J. O. (2002). "The functioning neuronal transporter for dopamine: kinetic 
mechanisms and effects of amphetamines, cocaine and methylphenidate." Prog 
Drug Res 59: 111-31. 
 
Schomig, E., P. Fischer, C. L. Schonfeld and U. Trendelenburg (1989). "The extent of 
neuronal re-uptake of 3H-noradrenaline in isolated vasa deferentia and atria of the 
rat." Naunyn Schmiedebergs Arch Pharmacol 340(5): 502-8. 
 
Schroeter, S., S. Apparsundaram, R. G. Wiley, L. H. Miner, S. R. Sesack and R. D. 
Blakely (2000). "Immunolocalization of the cocaine- and antidepressant-sensitive 
l- norepinephrine transporter." J Comp Neurol 420(2): 211-32. 
 
Schulingkamp, R. J., T. C. Pagano, D. Hung and R. B. Raffa (2000). "Insulin receptors 
and insulin action in the brain: review and clinical implications." Neurosci 
Biobehav Rev 24(8): 855-72. 
 
Schwab, S. G., B. Hoefgen, C. Hanses, M. B. Hassenbach, M. Albus, B. Lerer, M. 
Trixler, W. Maier and D. B. Wildenauer (2005). "Further evidence for association 
of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair 
families." Biol Psychiatry 58(6): 446-50. 
 
Schwartz, M. W., D. P. Figlewicz, D. G. Baskin, S. C. Woods and D. Porte, Jr. (1992). 
"Insulin in the brain: a hormonal regulator of energy balance." Endocr Rev 13(3): 
387-414. 
 
168 
       
Schwartz, M. W., A. Sipols, S. E. Kahn, D. F. Lattemann, G. J. Taborsky, Jr., R. N. 
Bergman, S. C. Woods and D. Porte, Jr. (1990). "Kinetics and specificity of 
insulin uptake from plasma into cerebrospinal fluid." Am J Physiol 259(3 Pt 1): 
E378-83. 
 
Seeman, P. and T. Lee (1975). "Antipsychotic drugs: direct correlation between clinical 
potency and presynaptic action on dopamine neurons." Science 188(4194): 1217-
9. 
 
Seidel, S., E. A. Singer, H. Just, H. Farhan, P. Scholze, O. Kudlacek, M. Holy, K. 
Koppatz, P. Krivanek, M. Freissmuth and H. H. Sitte (2005). "Amphetamines 
take two to tango: an oligomer-based counter-transport model of neurotransmitter 
transport explores the amphetamine action." Mol Pharmacol 67(1): 140-51. 
 
Seiden, L. S., K. E. Sabol and G. A. Ricaurte (1993). "Amphetamine: effects on 
catecholamine systems and behavior." Annu Rev Pharmacol Toxicol 33: 639-77. 
 
Senard, J. M. and P. Rouet (2006). "Dopamine beta-hydroxylase deficiency." Orphanet J 
Rare Dis 1: 7. 
 
Sesack, S. R., V. A. Hawrylak, C. Matus, M. A. Guido and A. I. Levey (1998). 
"Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex 
exhibit sparse immunoreactivity for the dopamine transporter." Journal of 
Neuroscience 18(7): 2697-708. 
 
Shannon, J. R., N. L. Flattem, J. Jordan, G. Jacob, B. K. Black, I. Biaggioni, R. D. 
Blakely and D. Robertson (2000). "Orthostatic intolerance and tachycardia 
associated with norepinephrine- transporter deficiency." N Engl J Med 342(8): 
541-9. 
 
She, Q. B., S. Chandarlapaty, Q. Ye, J. Lobo, K. M. Haskell, K. R. Leander, D. DeFeo-
Jones, H. E. Huber and N. Rosen (2008). "Breast tumor cells with PI3K mutation 
or HER2 amplification are selectively addicted to Akt signaling." PLoS One 3(8): 
e3065. 
 
Shi, L., M. Quick, Y. Zhao, H. Weinstein and J. A. Javitch (2008). "The mechanism of a 
neurotransmitter:sodium symporter--inward release of Na+ and substrate is 
triggered by substrate in a second binding site." Mol Cell 30(6): 667-77. 
 
Shimizu, H. (1991). "Alteration in hypothalamic monoamine metabolism of freely 
moving diabetic rat." Neurosci Lett 131(2): 225-7. 
 
Shiota, C., J. T. Woo, J. Lindner, K. D. Shelton and M. A. Magnuson (2006). 
"Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is 
essential for fetal growth and viability." Dev Cell 11(4): 583-9. 
 
169 
       
Simpson, K. L. L., R.C.S. (2007). Neuroanatomical and chemical organization of the 
locus coeruleus. Brain Norepinephrine: Neurobiology and Therapeutics. G. A. S. 
Ordway, M.A.; Frazer, A. New York, Cambridge University Press: 9. 
 
Sitte, H. H., S. Huck, H. Reither, S. Boehm, E. A. Singer and C. Pifl (1998). "Carrier-
mediated release, transport rates, and charge transfer induced by amphetamine, 
tyramine, and dopamine in mammalian cells transfected with the human 
dopamine transporter." Journal of Neurochemistry 71(3): 1289-97. 
 
Snyder, S. H. (1976). "The dopamine hypothesis of schizophrenia: focus on the dopamine 
receptor." Am J Psychiatry 133(2): 197-202. 
 
Sonders, M. S., S. J. Zhu, N. R. Zahniser, M. P. Kavanaugh and S. G. Amara (1997). 
"Multiple ionic conductances of the human dopamine transporter: the actions of 
dopamine and psychostimulants." Journal of Neuroscience 17(3): 960-74. 
 
Song, L., T. Kitayama, K. Morita, N. Morioka and T. Dohi (2008). "Down-regulation of 
norepinephrine transporter expression on membrane surface induced by chronic 
administration of desipramine and the antagonism by co-administration of local 
anesthetics in mice." Neurochem Int 52(4-5): 826-33. 
 
Sorkina, T., S. Doolen, E. Galperin, N. R. Zahniser and A. Sorkin (2003). 
"Oligomerization of dopamine transporters visualized in living cells by 
fluorescence resonance energy transfer microscopy." J Biol Chem 278(30): 
28274-83. 
 
South, T. and X. F. Huang (2008). "High-fat diet exposure increases dopamine D2 
receptor and decreases dopamine transporter receptor binding density in the 
nucleus accumbens and caudate putamen of mice." Neurochem Res 33(3): 598-
605. 
 
Southwick, S. M., M. Davis, B. Horner, L. Cahill, C. A. Morgan, 3rd, P. E. Gold, J. D. 
Bremner and D. C. Charney (2002). "Relationship of enhanced norepinephrine 
activity during memory consolidation to enhanced long-term memory in humans." 
Am J Psychiatry 159(8): 1420-2. 
 
Sulzer, D., T. K. Chen, Y. Y. Lau, H. Kristensen, S. Rayport and A. Ewing (1995). 
"Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and 
promotes reverse transport." Journal of Neuroscience 15(5 Pt 2): 4102-8. 
 
Sulzer, D., M. S. Sonders, N. W. Poulsen and A. Galli (2005). "Mechanisms of 
neurotransmitter release by amphetamines: a review." Prog Neurobiol 75(6): 406-
33. 
 
Sung, U., S. Apparsundaram, A. Galli, K. M. Kahlig, V. Savchenko, S. Schroeter, M. W. 
Quick and R. D. Blakely (2003). "A regulated interaction of syntaxin 1A with the 
170 
       
antidepressant- sensitive norepinephrine transporter establishes catecholamine 
clearance capacity." J Neurosci 23(5): 1697-709. 
 
Swerdlow, N. R., J. M. Shoemaker, R. Kuczenski, M. J. Bongiovanni, A. C. Neary, L. S. 
Tochen and R. L. Saint Marie (2006). "Forebrain D1 function and sensorimotor 
gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation." 
Neurosci Lett 402(1-2): 40-5. 
 
Tan, H. Y., K. K. Nicodemus, Q. Chen, Z. Li, J. K. Brooke, R. Honea, B. S. Kolachana, 
R. E. Straub, A. Meyer-Lindenberg, Y. Sei, V. S. Mattay, J. H. Callicott and D. R. 
Weinberger (2008). "Genetic variation in AKT1 is linked to dopamine-associated 
prefrontal cortical structure and function in humans." J Clin Invest 118(6): 2200-
8. 
 
Thomas, S. A., A. M. Matsumoto and R. D. Palmiter (1995). "Noradrenaline is essential 
for mouse fetal development." Nature 374(6523): 643-6. 
 
Thomas, S. A. and R. D. Palmiter (1997). "Disruption of the dopamine beta-hydroxylase 
gene in mice suggests roles for norepinephrine in motor function, learning, and 
memory." Behav Neurosci 111(3): 579-89. 
 
Thomas, S. A. and R. D. Palmiter (1997). "Impaired maternal behavior in mice lacking 
norepinephrine and epinephrine." Cell 91(5): 583-92. 
 
Thomas, S. A. and R. D. Palmiter (1997). "Thermoregulatory and metabolic phenotypes 
of mice lacking noradrenaline and adrenaline. [see comments]." Nature 
387(6628): 94-7. 
 
Thomas, S. A. and R. D. Palmiter (1998). "Examining adrenergic roles in development, 
physiology, and behavior through targeted disruption of the mouse dopamine 
beta-hydroxylase gene." Adv Pharmacol 42: 57-60. 
 
Torres, G. E. and S. G. Amara (2007). "Glutamate and monoamine transporters: new 
visions of form and function." Curr Opin Neurobiol 17(3): 304-12. 
 
Uchida, J., Y. Kiuchi, M. Ohno, A. Yura and K. Oguchi (1998). "Ca(2+)-dependent 
enhancement of [3H]noradrenaline uptake in PC12 cells through calmodulin-
dependent kinases." Brain Res 809(2): 155-64. 
 
Usera, P. C., S. Vincent and D. Robertson (2004). "Human phenotypes and animal 
knockout models of genetic autonomic disorders." J Biomed Sci 11(1): 4-10. 
 
Usher, M., J. D. Cohen, D. Servan-Schreiber, J. Rajkowski and G. Aston-Jones (1999). 
"The role of locus coeruleus in the regulation of cognitive performance." Science 
283(5401): 549-54. 
 
171 
       
van der Heide, L. P., G. M. Ramakers and M. P. Smidt (2006). "Insulin signaling in the 
central nervous system: learning to survive." Prog Neurobiol 79(4): 205-21. 
 
van Kammen, D. P., H. Agren, J. K. Yao, D. T. O'Connor, J. Gurklis and J. L. Peters 
(1994). "Noradrenergic activity and prediction of psychotic relapse following 
haloperidol withdrawal in schizophrenia." Am J Psychiatry 151(3): 379-84. 
 
Ventura, R., S. Cabib, A. Alcaro, C. Orsini and S. Puglisi-Allegra (2003). 
"Norepinephrine in the prefrontal cortex is critical for amphetamine-induced 
reward and mesoaccumbens dopamine release." J Neurosci 23(5): 1879-85. 
 
Vincent, S. and D. Robertson (2002). "The broader view: catecholamine abnormalities." 
Clin Auton Res 12 Suppl 1: I44-9. 
 
Wei, Y., J. M. Williams, C. Dipace, U. Sung, J. A. Javitch, A. Galli and C. Saunders 
(2007). "Dopamine transporter activity mediates amphetamine-induced inhibition 
of Akt through a Ca2+/calmodulin-dependent kinase II-dependent mechanism." 
Mol Pharmacol 71(3): 835-42. 
 
Weinberger, D. R., K. F. Berman and B. P. Illowsky (1988). "Physiological dysfunction 
of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence 
for a monoaminergic mechanism." Arch Gen Psychiatry 45(7): 609-15. 
 
Weinshenker, D., N. S. Miller, K. Blizinsky, M. L. Laughlin and R. D. Palmiter (2002). 
"Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized 
animals." Proc Natl Acad Sci U S A 99(21): 13873-7. 
 
Wenzel, J. (1812). "De Penitiori Structura cerebri hominis et Brutorum." Tubingen. 
 
Wersinger, C., A. Jeannotte and A. Sidhu (2006). "Attenuation of the norepinephrine 
transporter activity and trafficking via interactions with alpha-synuclein." Eur J 
Neurosci 24(11): 3141-52. 
 
Westwood, N. N., D. L. Scarcella and L. J. Bryan-Lluka (1996). "Evidence for uptake1-
mediated efflux of catecholamines from pulmonary endothelial cells of perfused 
lungs of rats." Naunyn Schmiedebergs Arch Pharmacol 353(5): 528-35. 
 
Wild, S., G. Roglic, A. Green, R. Sicree and H. King (2004). "Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030." Diabetes Care 
27(5): 1047-53. 
 
Williams, J. M., W. A. Owens, G. H. Turner, C. Saunders, C. Dipace, R. D. Blakely, C. 
P. France, J. C. Gore, L. C. Daws, M. J. Avison and A. Galli (2007). 
"Hypoinsulinemia regulates amphetamine-induced reverse transport of 
dopamine." PLoS Biol 5(10): e274. 
 
172 
       
Woods, S. C., M. Chavez, C. R. Park, C. Riedy, K. Kaiyala, R. D. Richardson, D. P. 
Figlewicz, M. W. Schwartz, D. Porte, Jr. and R. J. Seeley (1996). "The evaluation 
of insulin as a metabolic signal influencing behavior via the brain." Neurosci 
Biobehav Rev 20(1): 139-44. 
 
Woodward, N. D., S. E. Purdon, H. Y. Meltzer and D. H. Zald (2005). "A meta-analysis 
of neuropsychological change to clozapine, olanzapine, quetiapine, and 
risperidone in schizophrenia." Int J Neuropsychopharmacol 8(3): 457-72. 
 
Xu, F., R. R. Gainetdinov, W. C. Wetsel, S. R. Jones, L. M. Bohn, G. W. Miller, Y. M. 
Wang and M. G. Caron (2000). "Mice lacking the norepinephrine transporter are 
supersensitive to psychostimulants." Nat Neurosci 3(5): 465-71. 
 
Xu, M. Q., Q. H. Xing, Y. L. Zheng, S. Li, J. J. Gao, G. He, T. W. Guo, G. Y. Feng, F. 
Xu and L. He (2007). "Association of AKT1 gene polymorphisms with risk of 
schizophrenia and with response to antipsychotics in the Chinese population." J 
Clin Psychiatry 68(9): 1358-67. 
 
Yamamoto, B. K. and S. Novotney (1998). "Regulation of extracellular dopamine by the 
norepinephrine transporter." J Neurochem 71(1): 274-80. 
 
Yamashita, A., S. K. Singh, T. Kawate, Y. Jin and E. Gouaux (2005). "Crystal structure 
of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters." 
Nature 437(7056): 215-23. 
 
Yamashita, M., S. Fukushima, H.-w. Shen, F. S. Hall, G. R. Uhl, Y. Numachi, H. 
Kobayashi and I. Sora (2006). "Norepinephrine Transporter Blockade can 
Normalize the Prepulse Inhibition Deficits Found in Dopamine Transporter 
Knockout Mice." Neuropsychopharmacology 31(10): 2132-2139. 
 
Zaczek, R., S. Culp and E. B. De Souza (1991). "Interactions of [3H]amphetamine with 
rat brain synaptosomes. II. Active transport." Journal of Pharmacology & 
Experimental Therapeutics 257(2): 830-5. 
 
Zaid, H., C. N. Antonescu, V. K. Randhawa and A. Klip (2008). "Insulin action on 
glucose transporters through molecular switches, tracks and tethers." Biochem J 
413(2): 201-15. 
 
Zhao, W. Q., H. Chen, M. J. Quon and D. L. Alkon (2004). "Insulin and the insulin 
receptor in experimental models of learning and memory." Eur J Pharmacol 
490(1-3): 71-81. 
 
Zhao, Z., H. Ksiezak-Reding, S. Riggio, V. Haroutunian and G. M. Pasinetti (2006). 
"Insulin receptor deficits in schizophrenia and in cellular and animal models of 
insulin receptor dysfunction." Schizophr Res 84(1): 1-14. 
 
173 
       
Zhen, J., M. E. Reith and K. D. Carr (2006). "Chronic food restriction and dopamine 
transporter function in rat striatum." Brain Res 1082(1): 98-101. 
 
Zhou, Q. Y. and R. D. Palmiter (1995). "Dopamine-deficient mice are severely 
hypoactive, adipsic, and aphagic." Cell 83(7): 1197-209. 
 
Zhou, Q. Y., C. J. Quaife and R. D. Palmiter (1995). "Targeted disruption of the tyrosine 
hydroxylase gene reveals that catecholamines are required for mouse fetal 
development." Nature 374(6523): 640-3. 
 
Zhu, M. Y., V. Klimek, G. E. Dilley, J. W. Haycock, C. Stockmeier, J. C. Overholser, H. 
Y. Meltzer and G. A. Ordway (1999). "Elevated levels of tyrosine hydroxylase in 
the locus coeruleus in major depression." Biol Psychiatry 46(9): 1275-86. 
 
Zhu, M. Y., S. Shamburger, J. Li and G. A. Ordway (2000). "Regulation of the human 
norepinephrine transporter by cocaine and amphetamine." J Pharmacol Exp Ther 
295(3): 951-9. 
 
 
